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Abstract 
Leishmania spp. are protozoan parasites that cause a spectrum of pathologies in 
humans and other vertebrates, ranging symptomatically from cutaneous 
ulceration to visceral dissemination. In order to survive within the host, 
Leishmania are able to evade and modulate the host immune responses through 
the actions of their virulence factors; however, few putative virulence factors 
have been characterised during in vivo infection with Leishmania. The 
Leishmania major genome has revealed the presence of three peptide inhibitors 
of S1A family serine peptidases (ISPs), which are orthologues of a bacterial 
protease inhibitor, ecotin. Serine peptidases of the S1A family are absent in 
Leishmania; therefore, the ISPs have been proposed to inhibit the activity of 
host serine peptidases, such as those expressed by cells of the innate immune 
response. ISP2, which is expressed in the mammalian-infective metacyclic 
promastigote and amastigote stages, has previously been shown to inhibit 
neutrophil elastase (NE), a serine peptidase expressed by neutrophils, 
monocytes, and macrophages. This inhibition prevents the activation of a Toll-
like receptor 4 (TLR4)-NE pathway during Leishmania-macrophage interaction 
promoting Leishmania survival and growth in macrophages in vitro. 
The aims of this project were to assess whether the presence or absence of ISP2 
in L. major affects parasite survival in vivo, and to investigate the effects of 
ISP2 on immune cell dynamics in vivo, specifically with regards to cell 
recruitment and activation, using the C57BL/6 mouse model. Parasite burdens 
were performed in mice infected with L. major wild-type (WT) parasites, a cell 
line deficient in ISP2/3 (Δisp2/3), and a cell line re-expressing ISP2/3 
(Δisp2/3:ISP2/3). L. major Δisp2/3 parasites could not be detected at the site of 
inoculation by 5 wk post-infection compared with WT and Δisp2/3:ISP2/3 
parasites, but parasites of all three cell lines were detected in the draining 
lymph nodes (dLNs) throughout the course of infection. These data were 
corroborated using in vivo bioluminescence imaging (BLI) of luciferase-expressing 
(LUC2) versions of these cell lines, in which only a low bioluminescent signal was 
observed at the site of inoculation with the LUC2-expressing Δisp2/3 cell line 
over the course of infection, compared with the LUC2-expressing L. major and 
Δisp2/3:ISP2/3 cell lines. These results suggest that ISP2 may be important in 
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the establishment and persistence of Leishmania infection by conferring parasite 
survival, particularly at the site of infection. 
Serine peptidases of innate immune cells, such as NE, function in the proteolytic 
cleavage of cytokines, chemokines, and cell receptors, to regulate immune cell 
recruitment and activation. Flow cytometric analysis of innate cell populations 
at the site of inoculation, in response to L. major WT and Δisp2/3 parasites over 
5 wk of infection, was conducted. This line of investigation revealed significantly 
higher numbers of monocytes, monocyte-derived macrophages, and monocyte-
derived dendritic cells (moDCs) at 2 wk in Δisp2/3 infection. MoDCs have crucial 
functions in the induction of antigen-specific T helper 1 responses, which are 
considered to be important for parasite clearance. MoDCs at the site of Δisp2/3 
infection showed an upregulation of the DC co-stimulatory molecule CD80 
compared with those from WT infection suggesting an upregulation of DC 
maturation. MoDCs have also been shown to be the major producers of inducible 
nitric oxide synthase (iNOS) during L. major infection, which catalyses the 
production of nitric oxide that is responsible for the killing of Leishmania. 
Intracellular staining of iNOS through flow cytometric techniques showed that 
iNOS expression in moDCs was not affected by the presence or absence of ISP2; 
there was, however, an increase in iNOS expression in other innate cell types, 
the resident macrophages and DCs, monocytes, and monocyte-derived 
macrophages, at the site of Δisp2/3 infection compared with those from WT and 
Δisp2/3:ISP2/3 infections. At the 2 wk time-point, there was also a significant 
increase in the concentration of IFN-γ, a cytokine that induces iNOS expression, 
in response to Δisp2/3 infection compared with WT and Δisp2/3:ISP2/3 
infections, as determined by ELISA. Quantitative in vivo BLI of myeloperoxidase 
(MPO) activity of activated phagocytes was determined over a period of 7 wk, 
which, also, indicated differences in phagocyte activation at the site of 
inoculation in L. major WT and Δisp2/3 infections. Taken together, these results 
indicate that the immune response is more primed towards Leishmania killing in 
Δisp2/3 infection compared with WT infection, which suggests that ISP2 
modulates these immune responses to facilitate Leishmania survival. 
Infections in transgenic mice deficient in NE, Ela-/-, showed similar monocyte 
recruitment and moDC activation responses in Δisp2/3 infection compared with 
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WT and Δisp2/3:ISP2/3 infections, as those observed in the C57BL/6 mice. This 
indicates that NE may not be the major target for ISP2 in vivo, or that there may 
be compensations for the loss of NE by other serine peptidases in this model. 
Although the exact mechanism by which ISP2 modulates the recruitment and 
activation of the innate immune cells in vivo remains to be determined, this 
study has, for the first time, shown numerous differences in the innate immune 
responses induced following infection with either L. major WT or a mutant 
deficient in a putative virulence factor using in vivo techniques, such as in vivo 
imaging (IVIS) and flow cytometry, to compare the infections. 
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1 Introduction 
1.1 Leishmaniasis and the Leishmania parasite 
Leishmaniasis is a neglected tropical disease that manifests in a spectrum of 
pathologies in humans and other vertebrates, collectively known as the 
leishmaniases; these range from ulcerative cutaneous lesions to systemic visceral 
infection. The leishmaniases are caused by species of the protozoan parasite, 
Leishmania, of the family Trypanosomatidae, Order Kinetoplastida. Leishmania 
parasites are primarily transmitted to humans and other vertebrates through the 
bite of an infected phlebotomine sandfly. 
1.1.1 Leishmaniases: Epidemiology, Pathology, and Treatment 
The leishmaniases are endemic in over 98 countries and territories, principally in 
Africa, Asia, and Latin America, with more than 350 million people at risk of 
infection (Alvar et al., 2012). In the order of 12 million people are currently 
infected with Leishmania, which is commonly associated with poverty and poor 
socioeconomic conditions, as the malnourished and immunosuppressed are the 
most susceptible to infection. There are three major clinical forms of the 
disease; cutaneous, the most common form of the disease of which there are 0.7 
to 1.2 million new cases annually; visceral, the most severe form of which there 
are 200 000 to 400 000 new cases annually; and mucocutaneous (Alvar et al., 
2012). Cutaneous leishmaniasis is widely distributed, with 70 to 75% of cases 
occurring in ten countries: Afghanistan, Algeria, Brazil, Colombia, Costa Rica, 
Ethiopia, Iran, Peru, Sudan, and Syria; whereas more than 90% of visceral 
leishmaniasis cases occur in six countries: Bangladesh, Brazil, Ethiopia, India, 
South Sudan, and Sudan (Figure 1-1) (Alvar et al., 2012). Almost 90% of 
mucocutaneous leishmaniasis cases occur in Bolivia, Brazil, and Peru. 
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Figure 1-1 Geographical distribution of (A) cutaneous leishmaniasis and (B) visceral 
leishmaniasis. Source: World Health Organization (WHO) Global Health Observatory Map Gallery 
(http://gamapserver.who.int/mapLibrary/app/searchResults.aspx). 
As the mortality caused by the leishmaniases, 20 000 to 40 000 deaths each year 
(Alvar et al., 2012), is low in comparison to deaths attributed to other infectious 
diseases in low-income countries, such as HIV, tuberculosis, and malaria, 
leishmaniasis has been neglected as a major public health problem. However, 
morbidity is more common than mortality in parasitic infections, producing long-
lasting chronic infections as the parasites evade the host immune response to 
promote their development and survival within the host. Morbidity is, therefore, 
the principal burden of the leishmaniases, contributing to an estimated 2.4 
B 
A 
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million disability-adjusted life years (DALYs), which are the number of years lost 
due to ill-health, disability, or early death. There is also a life-long social and 
psychological stigma associated with leishmaniasis due to disfiguring scars 
caused during the disease. 
There are over thirty species and subspecies of Leishmania, and around twenty 
of these are pathogenic to humans. The leishmaniases can be grouped into 
either zoonotic disease, in which the reservoir hosts are other mammals such as 
dogs and rodents, or anthroponotic disease, in which humans are the reservoir 
host. 
There are two subgenera of Leishmania, Leishmania and Viannia, which were 
originally classified on the basis of the location of parasite colonisation and 
development in the gut of the sandfly vector (Lainson et al., 1977), and 
subsequently supported by phylogenetic analysis. Human-infective Leishmania 
species are separated into two categories based on their geographic distribution, 
which is dependent on the presence of the appropriate species of phlebotomine 
sandfly, of the family Psychodidae, for transmission. ‘Old World’ species of 
Leishmania are transmitted by sandflies of the genus Phlebotomus, present in 
the Eastern hemisphere, specifically Asia, Africa, and Southern Europe. ‘New 
World’ species of Leishmania, however, are transmitted by sandflies of the 
genus Lutzomyia, and are endemic in the Western hemisphere, which includes 
Mexico, Central America, and South America. 
Humans infected with Leishmania exhibit a range of pathologies, the type and 
severity of which, generally depends on the species of Leishmania, as different 
species of Leishmania often display preferential tropisms, primarily 
dermotropism, mucotropism, and viscerotropism (Table 1-1). The species of 
Leishmania in conjunction with the immunological status of the host, 
particularly with regards to the innate inflammatory response and the balance 
between the cellular and humoral arms of the adaptive immune response, 
determine the outcome of the disease. The three main manifestations of the 
leishmaniases are cutaneous, mucosal, and visceral. 
Localised cutaneous leishmaniasis (LCL) is the most common form of 
leishmaniasis, and is characterised by cutaneous ulceration at the site of the 
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sandfly bite on exposed skin, generally on the face, arms and legs. L. major and 
L. tropica are the species that cause the majority of LCL cases in the Old World. 
The development of multiple non-ulcerative papules, plaques, or nodules that 
resemble leprosy, is an indication of diffuse cutaneous leishmaniasis (DCL), 
which typically occurs in individuals with a defective cell-mediated immune 
response. DCL is usually caused by infection with L. mexicana, L. amazonensis, 
and L. aethiopica. There is a variable tendency for LCL lesions to spontaneously 
self-heal within 2 to 6 months for L. major, 3 to 9 months for L. mexicana, or 6 
to 15 months for L. tropica, which normally results in life-long protection from 
the disease, although disfiguring scars are often left. Spontaneous self-resolving 
is not associated with DCL and relapses are frequent after treatment. 
Mucocutaneous leishmaniasis (MCL) arises when parasites disseminate from the 
inoculation site, from less than 5% of LCL or DCL infections, to mucosal tissue. 
Damage associated with MCL includes the extensive destruction of mucosal 
membranes of the oro-nasal and pharyngeal cavities with disfiguring lesions and 
mutilation of the face, particularly the collapse of the nasal septum. MCL is 
primarily caused by members of the Viannia subspecies, such as L. braziliensis, 
L. peruviana, and L. guyanensis. Secondary bacterial infections, such as 
Staphylococcus aureus, are commonly associated with MCL, further complicating 
the treatment of this disease. Mucosal lesions of the oro-nasal cavities and the 
genital mucosa rarely occur in the Old World; these cases are mostly seen in 
India or Sudan, in patients with visceral leishmaniasis (VL) or post-kala azar 
dermal leishmaniasis (PKDL), and can be caused by L. major, L. tropica, L. 
infantum, and L. donovani. 
VL is the most severe form of leishmaniasis. Parasites disseminate from the 
inoculation site and proliferate in liver, spleen, and bone marrow, causing 
undulating fever, weight loss, hepatomegaly, splenomegaly, and anaemia, 
resulting in host immunosuppression, and ultimately death in the absence of 
treatment. VL is usually caused by infection with L. donovani and L. infantum; 
these parasites have also been implicated as important pathogens in co-
infections with HIV creating a lethal combination, which is especially important 
in the countries where the prevalence of these diseases overlap. The incidence 
of VL and HIV co-infections has been reported to be increasing in some areas of 
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Africa and India (Alvar et al., 2008). There is no spontaneous self-healing 
associated with MCL or VL, and both are difficult to treat. In addition, patients 
that have been treated for VL can develop PKDL within two years after apparent 
clinical cure of VL. PKDL patients exhibit a chronic cutaneous disease, which 
requires long and expensive treatment. 
Table 1-1 Human-infective Leishmania species and their clinical forms. LCL, localised 
cutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis; MCL, mucocutaneous 
leishmaniasis; VL, visceral leishmaniasis. 
 
Clinical forms 
LCL DCL MCL VL 
Old World 
species 
L. (L.) major  L. (L.) major  
L. (L.) tropica  L. (L.) tropica  
L. (L.) 
aethiopica 
L. (L.) 
aethiopica 
  
L. (L.) 
infantum 
 
L. (L.) 
infantum 
L. (L.) 
infantum 
  L. (L.) donovani L. (L.) donovani 
New World 
species 
L. (L.) 
venezuelensis 
   
L. (L.) 
mexicana 
L. (L.) 
mexicana 
  
L. (L.) 
amazonensis 
L. (L.) 
amazonensis 
  
L. (L.) 
infantum (syn. 
L. chagasi) 
  
L. (L.) 
infantum (syn. 
L. chagasi) 
L. (V.) lainsoni    
L. (V.) naïffi    
L. (V.) 
peruviana 
   
L. (V.) shawi    
L. (V.) 
braziliensis 
 
L. (V.) 
braziliensis 
 
L. (V.) 
guyanensis 
 
L. (V.) 
guyanensis 
 
L. (V.) 
panamensis 
 
L. (V.) 
panamensis 
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Pentavalent antimonials, such as sodium stibogluconate (SSG) and meglumine 
antimoniate, have been the standard first-line treatments for VL for over 60 
years. These chemotherapies are administered as daily intravenous or 
intramuscular injections for a period of at least 20 days and have efficacy 
around 90% in most parts of the world (reviewed in Singh and Sundar, 2014). 
However, pentavalent antimonials are highly toxic and have serious side effects 
associated with their use. Where drug resistance has emerged in endemic 
regions or where efficacy is low, notably the state of Bihar in India where 
unresponsiveness is as high as 65%, the second-line drugs, amphotericin B, 
paromomycin, or miltefosine, are used. Amphotericin B deoxycholate, a polyene 
antibiotic administered intravenously, complexes with sterols in the Leishmania 
plasma membrane increasing permeability through the formation of pores, which 
ultimately causes cell lysis (Saha et al., 1986). Amphotericin B is also effective 
against MCL. Several formulations of amphotericin B, including a liposomal 
amphotericin B, AmBisome, are now in use, which have similar efficacy to 
amphotericin B but are significantly less toxic (Sundar et al., 2010). 
Paromomycin, an aminoglycoside antibiotic administered intramuscularly, has a 
broad spectrum of activity against Gram-positive and Gram-negative bacteria, 
and Leishmania. Miltefosine, an alkyl phospholipid given orally for over 28 days, 
interferes with the synthesis of Leishmania phospholipids and sterols 
(Rakotomanga et al., 2007); it is now the first-line treatment for VL in India. 
However, miltefosine is potentially teratogenic and should not be used by 
pregnant women or women with child-bearing potential. Oral antifungals agents, 
such as ketoconazole, itraconazole, and fluconazole, have also shown variable 
efficacy in the treatment of leishmaniasis with minimal adverse effects. The 
incidence of VL and HIV co-infections has further complicated treatment, as the 
cure rate of SSG and miltefosine treatments significantly decreases in HIV 
patients and relapses are more frequent. 
Sitamaquine, an 8-aminoquinoline drug used for the treatment of malaria, is 
currently in development by GlaxoSmithKline as an oral treatment for VL. 
Several combination treatments of available anti-leishmanial drugs have also 
been trialled (Sundar et al., 2011; Musa et al., 2012); these have the potential 
to increase efficacy, reduce the probability of selection of drug-resistant 
parasites, and reduce the duration and overall dose of treatment, thereby 
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reducing the occurrence of adverse effects, and the cost of treatment. As LCL 
caused by species of the Old World tends to resolve spontaneously, and is not a 
life-threatening condition, treatment is not typically recommended unless the 
lesions are disfiguring, painful, or have secondary infections. However, new 
approaches to treating LCL, DCL, and MCL are being explored; one such 
approach, as proposed by the Drugs for Neglected Diseases initiative (DNDi), is to 
combine chemotherapy with a therapeutic vaccine or an adjuvant to modulate 
the immune response in order to enhance recovery. 
As yet, there are no prophylactic drugs or vaccines available for any form of 
leishmaniasis, as the diversity of the Leishmania species and the complexity of 
the immunological responses to the different species has hindered vaccine 
development. However, the feasibility for an effective vaccine remains viable, 
as long-lasting natural immunity to re-infection does occur following recovery 
from a primary infection. Some vaccine candidates utilise genetically-modified 
parasites that are avirulent through the deletion of all alleles of specific genes, 
such as those involved in polyamine or nucleotide metabolism, or proteases that 
have roles in the lifecycle or host-parasite interactions (reviewed in Chhajer & 
Ali, 2014). These live-attenuated parasites can deliver the full range of antigens 
to the antigen-presenting cells (APCs) allowing a robust immune response to be 
generated. Other second generation vaccine candidates exploit recombinant 
proteins, or use DNA cloned into mammalian expression vectors to encode 
leishmanial antigens, which may be species- or stage-specific, or conserved 
among species. These antigens will then be presented in the major 
histocompatibility complexes (MHCs) of APCs to prime an adaptive antigen-
specific T cell response. Current recombinant protein vaccine candidates include 
the surface glycoprotein gp63, Leishmania activated C kinase (LACK), 
promastigote surface antigen 2 (PSA-2), and Leishmania-derived recombinant 
polyprotein (Leish-111f) (reviewed in Duthie et al., 2012; Kumar & Engwerda, 
2014). It is necessary to fully understand the pathogenesis and generation of 
host-protective immunity during Leishmania infection to advance progress in 
vaccine research. 
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1.1.2 Leishmania parasite: Structure and lifecycle 
Trypanosomatid kinetoplastids, such as Leishmania and Trypanosoma, are 
unicellular eukaryotic organisms containing membrane-bound organelles, 
including the nucleus, the Golgi body, and endoplasmic reticulum, as well as a 
cytoskeletal structure and a flagellum. Kinetoplastids also have a unique feature 
known as the kinetoplast, a disc-shaped granule containing many copies of 
circular specialised mitochondrial DNA, which is located within the single 
mitochondrion of Leishmania. 
Leishmania parasites have a digenetic lifecycle with two key morphological 
forms; the flagellated, extracellular promastigote in the digestive tract of the 
sandfly vector, and the non-motile, obligate intracellular amastigote in the 
phagocytes of the mammalian host. Procyclic promastigotes, which are only 
present in the sandfly, are stumpy and only slightly motile, whereas the 
infective metacyclic promastigotes, which are inoculated into the host, are 
slender and highly active with an anterior flagellum at least twice the length of 
the cell body. Intermediate promastigote forms have also been identified in the 
sandfly, including nectomonads, leptomonads, and haptomonads (Rogers et al., 
2002); the intermediate forms are often overlooked due to their subtle 
morphological differences and unknown functions. Promastigote development in 
the digestive tract of the sandfly differs between the two Leishmania subgenera, 
Leishmania, which develop exclusively in the midgut and foregut, and Viannia, 
which also have a phase of development in the hindgut (Lainson et al., 1977). 
1.1.2.1 Development in the sandfly vector 
Leishmaniasis is an example of anthropozoonosis, a vector-borne disease 
transmitted by the female phlebotomine sandfly from infected animals, with 
dogs and rodents as the main reservoirs, or from infected humans, to uninfected 
humans. Recently, a species of biting midge were implicated as the vector in the 
transmission of an L. enriettii complex to red kangaroos in Australia (Dougall et 
al., 2011). However, the development and transmission of Leishmania spp. with 
other potential vectors requires further evaluation (Seblova et al., 2012). 
Phlebotomine sandflies, of the family Psychodidae, have an average body length 
of 2 to 3 mm, which is much smaller in comparison to the adult tsetse fly (5 to 
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15 mm), the vector for trypanosome transmission, or the Anopheles mosquito (6 
to 12 mm), the vector for the transmission of Plasmodium spp. that cause 
malaria. Only sandflies of the genus Phlebotomus, in the Old World, and 
Lutzomyia, in the New World, are involved in the transmission of Leishmania. 
There are more than 400 species in both these genera combined but less than 50 
species actually transmit the parasites. Only the female is described as 
telmophage, an arthropod that severs the skin and superficial blood vessels of 
the host to feed on blood, which is required for egg development. 
Naive sandflies become infected with Leishmania amastigotes during a blood 
meal from an infected mammalian host. The blood meal is encased in a film-like 
structure, composed of chitin and proteins, known as the peritrophic membrane, 
a matrix secreted by the midgut epithelium that separates the blood meal from 
the midgut tissue. Within 12 to 18 hours, the amastigotes undergo a 
morphological transformation into procyclic promastigotes, due to changes in 
environmental conditions, notably the decrease in temperature and increase in 
pH. The procyclic promastigotes attach to the microvillar surface of the midgut, 
through the binding of the abundant Leishmania surface molecule, 
lipophosphoglycan (LPG), and replicate as the blood meal continues to be 
digested (Pimenta et al., 1994). Between 48 to 72 hours, procyclic promastigotes 
also transform into the intermediate forms, the first of which is the non-dividing 
nectomonad (Gossage et al., 2003) (Figure 1-2). Procyclic promastigotes and 
nectomonads cluster in the anterior of the abdominal midgut. After three days, 
the peritrophic membrane, which protects the parasites from the hydrolytic 
enzymes of the gut (Pimenta et al., 1997), ruptures due to the activity of 
Leishmania chitinases (Rogers et al., 2008), allowing passage of the parasites to 
the thoracic midgut and stomodeal valve. At this time, the nectomonads 
transform into leptomonads (Gossage et al., 2003), which are responsible for the 
production of promastigote secretory gel (PSG) consisting of a mucin-like 
glycoprotein unique to Leishmania known as filamentous proteophosphoglycan 
(fPPG) (Rogers et al., 2002). Leptomonads replicate and subsequently 
differentiate into mammalian-infective metacyclic promastigotes in a process 
known as metacyclogenesis. PSG blocks the anterior of the thoracic midgut to 
provide a favourable environment for metacyclogenesis. PSG also plays a role in 
transmission, as the gel-like properties of fPPG cause a physical obstruction that 
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prevents the sandfly from taking an adequate blood meal (Stierhof et al., 1999), 
this forces the sandfly to regurgitate the PSG and the attached metacyclic 
promastigotes into the host (Rogers et al., 2004). The PSG obstruction also 
causes sandflies to increase biting persistence and to feed for longer, thereby 
enhancing parasite transmission (Rogers & Bates, 2007). Another intermediate 
form, the haptomonads, remain within the sandfly, through attachment of an 
anterior parasite structure, known as the hemidesmosome, to the cuticular 
intima of the stomodeal valve (Killick-Kendrick et al., 1974; Walters et al., 
1989), whereas the metacyclic promastigotes migrate to the sandfly proboscis, 
where they are suspended in saliva ready to be transmitted to another potential 
host. 
 
Figure 1-2 The Leishmania lifecycle within the sandfly vector. The Leishmania parasite 
undergoes several differentiation steps between the procyclic promastigote in the abdominal 
midgut and the metacyclic promastigote in the thoracic midgut and stomodeal valve. These 
intermediate forms include the nectomonad, leptomonad, and haptomonad promastigotes, but it 
is the metacyclic promastigote that is transmitted to the mammalian host when the sandfly takes 
a blood meal. Adapted from Kamhawi (2006) and Bates (2007) with permission. 
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1.1.2.2 Development in the mammalian host 
As the Leishmania-infected sandfly uses its proboscis to break the skin of the 
host to gain access to the dermal capillaries during a blood meal, highly active 
and infective metacyclic promastigotes are regurgitated into the host dermis. 
The number of Leishmania parasites transmitted to the host by a sandfly can 
vary from 100 to 100 000 per bite (Kimblin et al., 2008), although both Kimblin 
et al. (2008) and Rogers et al. (2010) report an average inoculation dose of less 
than 600 parasites per bite, the majority of which are metacyclic promastigotes. 
Leishmania are internalised by host innate immune cells, mainly neutrophils, 
macrophages, monocytes, and dendritic cells (DCs). Macrophages are the major 
host cell type for Leishmania, providing an environment in which the parasites 
are able to grow and replicate whilst evading the host immune response. The 
metacyclic promastigotes then differentiate into the ovoid, non-motile 
amastigotes within a compartment in macrophages known as the parasitophorous 
vacuole (PV). After leaving the macrophages, the amastigotes can then infect 
local cells or disseminate to secondary sites in distant tissues resulting in tissue 
damage, and giving rise to the spectrum of clinical manifestations associated 
with the leishmaniases. 
Components of the sandfly saliva can contribute to the successful transmission 
and establishment of Leishmania infection. There are around 50 molecules 
present in sandfly saliva, which have vasodilatory, anti-coagulative, or 
immunomodulatory properties, in order to produce a favourable feeding 
environment. Individual molecules from sandfly saliva have been shown to 
coordinate the host immune response, such as maxadilan, a vasodilatory peptide 
(Morris et al., 2001; Rogers & Titus, 2003), and PpSp44 (Oliveira et al., 2008), 
which have been shown to enhance L. major virulence. Pre-exposure to salivary 
gland extract or uninfected sandflies can protect against Leishmania challenge 
in experimental models (Kamhawi et al., 2000; Carregaro et al., 2013), and 
immunisation with individual sandfly saliva proteins, such as LJM11 (Xu et al., 
2011) and LJM19 (Gomes et al., 2008) from Lu. longipalpis, and PpSP15 from P. 
papatasi (Oliveira et al., 2008), can have the same prophylactic effect. 
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1.2 Mammalian immune response to Leishmania spp. 
At the site of infection there is a complex interplay between the Leishmania 
parasites and the host immune response. Experimental models have been a 
powerful tool in dissecting these interactions in order to generate a description 
of the cellular dynamics at the site of infection, including the activation of 
effector cells, and to provide an explanation of how this leads to the formation 
of an adaptive immune and the range of pathologies caused by the different 
Leishmania species. In this section, a general overview of the innate and 
adaptive immune responses to Leishmania spp. through the use of experimental 
models will be presented, highlighting specific differences discovered between 
the well-studied Leishmania species that cause Old World cutaneous 
leishmaniasis, L. major, New World cutaneous leishmaniasis, L. mexicana, and 
Old World visceral leishmaniasis, L. donovani. 
1.2.1 Innate immune response 
Upon tissue damage to the microvasculature of the epidermis and dermis caused 
by the proboscis of the sandfly during Leishmania inoculation, a strong local 
inflammatory response is initiated, with the coordinated recruitment of innate 
immune cells. Despite differences in the local pathogenesis at the site of 
inoculation during infection with Leishmania spp. that cause LCL and VL, the 
early local inflammatory response during VL is not well characterised. 
1.2.1.1 The complement system 
Extracellular metacyclic promastigotes are first exposed to the non-specific 
humoral defence factors, including soluble serum proteins of the complement 
system, such as the opsonins. C3b, cleaved from C3, is one of the most potent 
opsonins; it binds extracellular microorganisms and the complement receptors, 
CR1 and CR3, on phagocytic cells, such as neutrophils and macrophages, to 
promote their phagocytic uptake and lytic clearance. However, Leishmania have 
evolved mechanisms of resisting lysis whilst exploiting opsonic complement 
factors for receptor-mediated entry into their target host cells. The major 
surface metalloprotease of Leishmania, glycoprotein gp63, enhances C3b 
cleavage to a proteolytically inactive fragment, iC3b, which is still able to 
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opsonise the parasites but cannot activate complement-mediated cytotoxic 
activity, such as the oxidative burst which releases reactive oxygen species 
(ROS) (Brittingham et al., 1995). LPG of metacyclic promastigotes also acts as a 
barrier preventing the insertion of the C5b-C9 membrane attack complex (MAC) 
into the Leishmania surface membrane to prevent pore formation (Späth et al., 
2003). A major feature of Leishmania infection is that the parasites retreat into 
“safe target cells”, such as neutrophils, macrophages, monocytes, and DCs of 
the cellular innate response, by exploiting the phagocytic abilities of these cells, 
thereby providing passive protection against anti-leishmanial products in the 
extracellular environment. 
1.2.1.2 Role of skin-resident cells 
The skin acts as a barrier against infection, and cells in the skin are involved in 
surveillance and serve as an important source of immunomodulatory mediators 
once this barrier is penetrated. The epidermis is principally composed of 
keratinocytes, whilst the underlying dermis is formed of fibroblasts and is 
vascularised with blood and lymphatic vessels. Keratinocytes have been reported 
to contribute to the generation of protective T helper 1 (Th1) responses in L. 
major infection through the upregulation of cytokine expression (Ehrchen et al., 
2010). Langerhans cells (LCs), a DC subset, are present in the skin and draining 
lymph nodes (dLNs); LCs have been reported to have an immunosuppressive 
function during L. major infection by driving the expansion of T regulatory 
(Treg) cells (Kautz-Neu et al., 2011). In addition to keratinocytes and LCs, mast 
cells, which are granulocytes that surround the blood vessels in the dermis, also 
have an indirect role in Leishmania infection through degranulation. 
Degranulation involves the release of granules consisting of heparin, histamine, 
serotonin, cytokines, and serine peptidases (SPs), which can influence innate 
cell recruitment (Maurer et al., 2006; Romão et al., 2009). 
1.2.1.3 Leishmania-neutrophil interactions 
Neutrophils, which are polymorphonuclear granulocytes, are one of the earliest 
innate immune cell types that are recruited to the site of infection, occurring a 
few hours after parasite inoculation (Peters et al., 2008). Neutrophils 
continuously circulate through dermal blood vessels and extravasate upon 
inflammation (Figure 1-3). Neutrophil chemotaxis is induced by the presence of 
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sandfly- and Leishmania-derived factors (Peters et al., 2008; van Zandbergen et 
al., 2002), complement C3 (Jacobs et al., 2005), and the production and 
secretion of chemokines by epithelial cells, keratinocytes, fibroblasts, and 
neutrophils, including CXCL1 (KC) and CXCL2 (MIP-2), which are homologues of 
human IL-8 (Müller et al., 2001). Neutrophils phagocytose metacyclic 
promastigotes to serve as temporary intermediate hosts for Leishmania (Laufs et 
al., 2002). Over the first day of infection, the majority of promastigotes, around 
80 to 90%, are phagocytosed by neutrophils, whereas only 10 to 20% are directly 
phagocytosed by monocytes or macrophages as evidenced by flow cytometry and 
intravital two-photon microscopy (2P-IVM) (Peters et al., 2008; Thalhofer et al., 
2011; Ribeiro-Gomes et al., 2012). Leishmania are able to reside and survive 
within the intracellular environment of the neutrophil (Mollinedo et al., 2010); 
in addition, Leishmania are able to evade the adaptive immune response, as 
other immune cells are unable to detect the parasites whilst inside the 
neutrophils. During this ‘silent’ phase of Leishmania growth, neutrophils are 
persistently recruited to, and maintained at, the infection site through the 
presence of chemokines. 
 
Figure 1-3 Neutrophil migration from the blood vessels to the site of infection. Neutrophils 
move along the endothelium, transiently adhering to selectins displayed on the endothelial 
surface, in a process called rolling. Upon microbial infection, chemokines are released from 
multiple sources at the site of infection. The chemokines become bound to proteoglycans on the 
endothelium, which causes an increase in the avidity of integrins of the chemoattracted 
neutrophils. The neutrophils then firmly adhere to the endothelium through the binding of 
integrin ligands, and are then able to transmigrate through the endothelium to the site of 
infection. Other immune cells, such as monocytes, can be recruited be this process, dependent 
upon the chemokines present on the endothelial surface. Adapted from Kolaczkowska and Kubes 
(2013) with permission.  
Neutrophils generate ROS, such as superoxide, O2
-, hydrogen peroxide, H2O2, and 
hypochlorous acid, HOCl, through the NADPH oxidase system upon activation; 
these microbicidal metabolites oxidise molecules, such as amino acids and 
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nucleotides. Neutrophils also contain azurophilic granules that contain 
myeloperoxidase (MPO), and proteolytic enzymes, such as collagenase, 
gelatinase, and SPs. Human neutrophil azurophilic granules also have defensins, 
which render target cell surface membranes more permeable. Neutrophils have 
recently been shown to release neutrophil extracellular traps (NETs), which are 
filamentous structures composed of chromatin with bound granular and 
cytoplasmic proteins, including histones, antimicrobial peptides, and proteolytic 
enzymes (Brinkmann et al., 2004). NETs are able to capture and kill 
microorganisms; however, although L. major, L. amazonensis, L. donovani, and 
L. infantum have been shown to induce NET formation, they evade the 
antimicrobial activities of the NETs due to their nuclease activity (Gabriel et al., 
2010; Guimarães-Costa et al., 2009, 2014). 
By three days, the numbers of neutrophils at the site of infection are highly 
reduced, as it is at this time, that inflammatory monocytes and macrophages 
become the predominant innate immune cells present (Thalhofer et al., 2011; 
Ribeiro-Gomes et al., 2012). Furthermore, through staining of the apoptotic cell 
marker, annexin V, it was observed that the apoptosis of neutrophils infected 
with live L. major is delayed from the average 6 to 12 hour life span to up to two 
days, through the reduction of caspase 3 activity, which coincides with the 
arrival of monocytes and macrophages to the site of infection (Aga et al., 2002). 
1.2.1.4 Leishmania-macrophage interactions 
Neutrophils may be the first host cell type, but macrophages are considered the 
main host cell type for the productive Leishmania infection. Upon infection with 
Leishmania, neutrophils secrete significantly higher levels of the chemokines 
CCL3 (MIP-1α) and CCL4 (MIP-1β) (van Zandbergen et al., 2004), which cause 
monocytes and macrophages to migrate to the site of infection, arriving at two 
or three days post-infection. Monocytes differentiate into either macrophages or 
DCs at the site of infection based on the presence of local growth factors and 
cytokines. There has been much debate as to how Leishmania infect 
macrophages; whether the parasites are released from the neutrophils and taken 
up directly by macrophages; or that macrophage clearance of apoptotic 
neutrophils harbouring parasites leads to the indirect uptake of Leishmania in a 
process termed the ‘Trojan horse’ (van Zandbergen et al., 2004); or that 
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parasites escape from the apoptotic neutrophils and are taken up directly by 
macrophages together with the apoptotic cells in a process termed the ‘Trojan 
rabbit’ (Peters et al., 2008; Ritter et al., 2009). van Zandbergen et al. (2004) 
used confocal microscopy with fluorescently-labelled parasites, neutrophils, and 
macrophages, to observe in vitro macrophages readily phagocytosing 
Leishmania-infected apoptotic neutrophils and the subsequent survival and 
replication of these parasites within the macrophages. Whereas, Peters et al. 
(2008) used 2P-IVM to observe, in vivo, viable parasites being released from 
apoptotic neutrophils surrounded by macrophages. 
Leishmania reside within a PV inside the macrophage, which is formed by the 
fusion of the phagosome with late endosomes or lysosomes, containing acid 
hydrolases, in a process known as phagolysosomal biogenesis (Courret et al., 
2002; Ndjamen et al., 2010). Leishmania facilitate the formation of a more 
suitable environment for their intracellular survival through the remodelling of 
the phagosomal compartments and the interruption of phagosome-lysosome 
fusion allowing sufficient time for the promastigotes to differentiate into the 
hydrolase-resistant amastigotes (reviewed in Moradin & Descoteaux, 2012). 
The ‘silent entry’ of Leishmania parasites into macrophages is enhanced by the 
modulation of the macrophage intracellular signalling pathways by Leishmania to 
render them unresponsive to activating stimuli, or to downregulate or inhibit the 
antimicrobial effector functions. Macrophages produce toxic metabolites, such 
as ROS and nitric oxide (NO), which function as potent effectors against both 
extra- and intracellular Leishmania. IFN-γ, secreted by NK and Th1 cells 
predominantly, stimulates the expression of the inducible isoform of nitric oxide 
synthase (iNOS, also known as NOS2) of macrophages, which catalyses the 
conversion of L-arginine to L-citrulline and NO. Leishmania can induce the 
expression of immunomodulatory molecules to inhibit macrophage activation and 
suppress iNOS-mediated generation of NO (Cortez et al., 2011). The 
requirements for ROS and NO in the control of Leishmania spp. in experimental 
models may be species-dependent, as L. major and L. donovani can be 
sufficiently cleared by NO, whereas the clearance of L. amazonensis also 
requires ROS (Murray & Nathan, 1999; Mukbel et al., 2007). 
Chapter 1 
17 
 
Surviving the intracellular environment of macrophages, amastigotes replicate to 
further infect host cells in local or distant tissues, producing the spectrum of 
clinical manifestations of the leishmaniases. Again, the mechanism by which this 
occurs is unclear; whether the infected macrophages burst, the PVs are released 
from the macrophages by exocytosis, or other uninfected macrophages engulf 
the infected macrophages (reviewed in Rittig & Bogdan, 2000). 
1.2.1.5 Leishmania-dendritic cell interactions 
The inflammatory monocytes recruited to the site of infection differentiate into 
either macrophages or DCs. Monocyte-derived DCs (moDCs) play an important 
role in the induction of protective antigen-specific Th1 responses during 
Leishmania infection (León et al., 2007; De Trez et al., 2009; Petritus et al., 
2012). DCs migrate from the site of infection to the dLNs, and process antigen 
and present it to T cells of the adaptive immune response (Misslitz et al., 2004; 
Ritter et al., 2004; Ng et al., 2008). DCs are the major cell type harbouring 
Leishmania in the dLN and are also major producers of IL-12 during L. major 
infection (León et al., 2007). IL-12 stimulates T cells to form Th1 cells. However, 
the ability of Leishmania to induce IL-12 production from DCs may be species-
dependent, as L. mexicana and L. donovani have been reported to suppress IL-12 
production from DCs (Bennett et al., 2001; McDowell et al., 2002; Favila et al., 
2014). In addition, moDCs have been shown to be major producers of iNOS during 
L. major infection, which can lead to parasite killing (De Trez et al., 2009; 
Petritus et al., 2012); whereas, it has been reported that in L. mexicana 
infection, moDCs produce less iNOS and migrate less efficiently to the dLN 
(Petritus et al., 2012). 
L. major-activated DCs can also promote lymph node hypertrophy, which 
enables the recruitment of more naive T cells from the blood into the lymph 
node to be primed, enhancing the antigen-specific protective responses 
(Carvalho et al., 2012); L. mexicana infection, however, has been associated 
with minimal expansion of the dLN (Hsu & Scott, 2007). 
Chapter 1 
18 
 
1.2.2 Adaptive immune response 
Antigen presentation via the MHC of DCs to the T cell receptor (TCR) of T cells, 
along with the cytokine response at the early stage of infection is fundamental 
in Leishmania disease progression; this essentially determines the type of 
adaptive immune response that will develop, with particular respect to the T 
helper cell subset that is induced. Leishmania antigens are presented through 
the MHC class I and II pathways leading, respectively, to the stimulation of 
Leishmania-specific CD8+ cytotoxic T cell responses, which have been reported 
to promote pathology (Novais et al., 2013), and CD4+ Th cell responses, which 
are important for resistance against Leishmania. MHC I molecules present 
peptide derived from cytosolic proteins, whereas MHC II molecules derives 
peptide from exogenous sources, such as endocytosed microorganisms that are 
degraded in phagolysosomes. Leishmania reside within phagolysosomal 
compartments; therefore, it is usually MHC II that is loaded with leishmanial 
peptide and thus, interaction and activation of naive CD4+ T cells occurs 
(Muraille et al., 2010). 
There are two well-defined CD4+ T helper cell subsets, known as Th1 and Th2. In 
general, IL-12 from macrophages and DCs activates the STAT4 pathway of 
activated T cells to form Th1 cells, whereas other cellular sources, such as mast 
cells, basophils, and eosinophils, release IL-4, which activates the STAT6 
pathway of activated T cells to form Th2 cells. IFN-γ secreted by Th1 cells 
increases the production of IL-12 from macrophages and DCs, creating a positive 
feedback loop driving the expansion of the Th1 cell subset, as evidenced during 
L. major infection (Park et al., 2000). IL-4 secreted by Th2 cells acts in an 
autocrine manner, causing cell activation and expansion of the Th2 subset, 
whilst inhibiting the differentiation of naive CD4+ T cells into Th1 cells, 
downregulating the expression of the IL-12 receptor on Th1 cells to render them 
unresponsive to IL-12 (Gollob et al., 1997), and limiting the recruitment of Th1 
cells to the site of infection (Lazarski et al., 2013). Th2 cells also secrete IL-10, 
which inhibits the synthesis of IFN-γ and IL-2, which is responsible for the 
growth, proliferation, and differentiation of the effector T cells. 
In Leishmania infection, Th1 cells generally promote cellular immunity by 
stimulating macrophage phagocytic and effector functions, such as the iNOS-
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mediated generation of NO, to eliminate the parasites (Figure 1-4). Th2 cells, 
conversely, promote humoral immunity by helping B cells produce parasite-
specific antibodies, which are usually insufficient to clear the parasites and 
control Leishmania infection (Figure 1-4). However, the adaptive immune 
responses are more complex than the proposed Th1/Th2 dichotomy, in that 
other CD4+ Th cell populations (Figure 1-4), and the plasticity of the T helper 
cell subset functions, have been reported (reviewed in O’Shea & Paul, 2010), as 
well as the pleiotropic activities of IL-4 and IL-13, such as in facilitating Th1 
responses (reviewed in Alexander & Brombacher, 2012; Hurdayal & Brombacher, 
2014). In addition, Leishmania can subvert the development of the Th1 
responses, through the selective inhibition of IL-12 and IL-1 production, a pro-
inflammatory mediator, and encourage the induction and expansion of the 
counter-protective Th2 cells (reviewed in Bhardwaj et al., 2010; Shio et al., 
2012), and the Treg cells (Figure 1-4) (reviewed in Belkaid et al., 2002), which 
regulate the effector T cell subsets. The outcome of disease can be influenced 
by the balance between the Th1 and Th2 responses, which is dependent upon 
the species of Leishmania and host genetic factors; however, L. donovani 
infections in experimental models are associated with the presence of both Th1 
and Th2 cytokines (Miralles et al., 1994), and organ-specific immune responses 
may, in fact, provide more insight into the disease pathology in VL (Bunn et al., 
2014). 
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Figure 1-4 Mechanisms mediating healing versus non-healing in leishmaniasis. In general, 
parasite clearance is achieved through classical macrophage activation and nitric oxide (NO) 
production. Early IL-4 and IL-13 instruct macrophages and dendritic cells to produce IL-12, which 
drives the expansion of protective antigen-specific T helper 1 (Th1) cells that produce IFN-γ. 
IFN-γ stimulates the expression of inducible nitric oxide synthase (iNOS), which catalyses the 
production of NO. Persistent or non-healing infections, however, are associated with the 
presence of IL-10-producing T regulatory cells, such as type 1 regulatory (Tr1) cells and natural T 
regulatory (nTreg) cells, as well as the TGF-β/IL-4-driven Th2 and Th9 cells. IL-4, IL-9, IL-10, and 
IL-13 from Th2 and Th9 cells induce alternative macrophage activation and increase arginase 
expression enabling parasite survival and expansion. In addition, Th17 cells secrete IL-17, which 
stimulates neutrophil influx into lesions that is often associated with increased pathology. T 
follicular helper 2 (Tfh2) cells induce IgG1 production, the uptake of IgG1-opsonised parasites via 
macrophage FcγR stimulates IL-10 release from the host cell, which together with the influence 
of cytokines from the other non-Th1 CD4+ T cell populations promotes progressive disease. 
Reproduced from Alexander & Brombacher (2012) under the terms of the Creative Commons 
Attributions Non-Commercial License. 
1.2.3 Second wave of innate cell infiltration 
Through the use of flow cytometry, a second wave of innate cell infiltration, 
consisting of neutrophils, macrophages, monocytes, and DCs, beginning at 1 or 2 
weeks post-infection has recently been described in experimental mouse models 
(Thalhofer et al., 2011; Ribeiro-Gomes et al., 2012). The role of these cells 
during this second wave of infiltration has not yet been characterised, in terms 
of their effects on the immune response at this later phase of infection, as by 
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this time, intracellular infections have fully transitioned into macrophages and 
DCs. 
 
Figure 1-5 The early immune responses to infection with Leishmania spp. During the first 24 h 
post-infection, neutrophils are the principal innate immune cell at the site of inoculation and are 
the first host cell for Leishmania. In the defence against pathogens, neutrophils generate 
reactive oxygen species (ROS), and have granules consisting of myeloperoxidase (MPO) and serine 
peptidases (SPs), such as neutrophil elastase (NE), cathepsin G (CG), and proteinase 3 (PR3). By 3 
d post-infection, macrophages have arrived at the site of inoculation to become the main host 
cell for intracellular Leishmania. Inflammatory monocytes also arrive which can differentiate 
into macrophages and dendritic cells. Dendritic cells process and present Leishmania antigen, 
and migrate to the draining lymph node (dLN) to induce a T cell response. By 1 wk post-
infection, an antigen-specific T helper cell response has been mounted and innate cell effector 
functions, such as the inducible nitric oxide synthase (iNOS)-mediated generation of nitric oxide 
(NO), are activated through the action of IFN-γ secreted by Th1 cells. Also at this time-point, a 
second wave of innate cells to the site of infection occurs. 
1.2.4 The role of cytokines during Leishmania infection 
Cytokines, such as interferons, interleukins, and chemokines, have roles in cell 
signalling, such as in the activation of cell effector functions, and in the 
migration of cell populations. Leishmania are able to modulate the host cytokine 
responses to favour their survival. Table 1-2 summarises some of the common 
cytokines and growth factors that have important functions during Leishmania 
infections. 
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Table 1-2 Important cytokines and growth factors that mediate the immune response during 
Leishmania infection. The general functions of the cytokines and growth factors in immunity are 
given. 
Name Functions Source 
Interleukins 
IL-1 
Pro-inflammatory 
Induces cytokine production 
Monocytes/Macrophages 
Endothelial cells 
Epithelial cells 
IL-2 
T, B, and NK cell 
proliferation and activation 
Th1 cells 
NK cells 
IL-4 
Induces Th2 cell 
differentiation 
Th2 cells 
IL-8  Neutrophil chemoattractant 
Neutrophils 
Endothelial cells 
Fibroblasts  
IL-10 
Inhibits macrophages and 
DCs 
Macrophages 
Th2 cells 
Treg cells 
IL-12 
Induces  Th1 cell 
differentiation 
Stimulates IFN-γ production 
from cells  
Macrophages 
DCs 
IL-13 
Inhibits macrophage 
activation 
Inhibits cytokine production 
Th2 cells 
IL-17 Neutrophil chemoattractant Th17 cells 
Interferons (IFNs) 
IFN-α and IFN-β  
(type I interferons) 
Increases MHC I expression 
Activates NK cells 
Induces NO and IFN-γ 
expression 
Macrophages 
IFN-γ (type II interferon) 
Activates macrophages 
Induces iNOS expression 
Increases MHC I and II 
expression  
Th1 cells 
NK cells 
Tumour necrosis factors (TNFs) 
TNF-α 
Pro-inflammatory 
Induces cytokine production 
Macrophages 
T cells 
NK cells 
Transforming growth factors (TGFs) 
TGF-β 
Inhibits macrophage 
activation  
Inhibits proliferation and 
activation of T cells 
Monocytes/Macrophages 
Treg cells 
 
1.2.5 Experimental cutaneous leishmaniasis: The mouse models 
Various strains of mice differ in their susceptibility to cutaneous leishmaniasis; 
for example, C57BL/6 mice resolve lesions and recover after L. major challenge, 
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whereas BALB/c mice develop severe lesions. Cytokine profiles of these murine 
models during L. major infection reveal that the resistant C57BL/6 mice have 
high levels of IFN-γ and IL-2, but low levels of IL-4 and IL-10, which is 
characteristic of a Th1 cell-mediated response, whilst the converse is true for 
the susceptible BALB/c mice, indicating a polarisation towards a Th2 humoral 
response involving IL-4, IL-5, IL-10, and IL-13 (Locksley et al., 1991). 
IL-12 is essential for parasite elimination as it drives the expansion of a Th1 
response. Susceptible BALB/c mice produce less and respond poorly to IL-12 due 
to a downregulation of the IL-12 receptor β chain (Güler et al., 1996). Resistant 
C57BL/6 mice treated with monoclonal anti-IL-12 antibodies develop a Th2 
response and are unable to contain the infection (Heinzel et al., 1995), whereas 
susceptible BALB/c mice treated with recombinant IL-12 or monoclonal anti-IL-4 
antibodies develop a Th1 response and eliminate the infection (Heinzel et al., 
1993; Chatelain et al., 1999). 
Human cutaneous leishmaniasis caused by L. major has been extrapolated from 
the analysis of infections in these murine models; however, the human Th 
response is not fully understood and often widely variable Th cytokine profiles 
are reported due to few studies actually conducted, host genetic factors and 
immunological status, and the stage of disease (Louzir et al., 1998; Ajdary et 
al., 2000). Mouse models, therefore, provide a reproducible system to study the 
immune responses during L. major infection, particularly with regards to host-
parasite interactions, which is not possible to investigate with clinical samples. 
1.3 Leishmania virulence factors and mechanisms of 
immune evasion and modulation 
Virulence factors are molecules expressed by the parasite to enable them to 
colonise and replicate within the host, and/or avoid or inhibit the host immune 
responses. Virulence factors contribute to the degree of pathogenicity caused by 
the parasite by facilitating the initiation, propagation, and persistence of 
Leishmania infection. Leishmania possess multiple infection-related molecules 
that are crucial for the parasites to establish successful intracellular infection; 
these invasive or evasive determinants are mostly cell surface-bound or 
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secreted/released molecules, such as gp63, LPG, proteophosphoglycans (PPGs), 
glycosylphospholipid (GIPL), and cysteine peptidases (CPs). 
As mentioned earlier, Leishmania are able to avoid complement-mediated lysis, 
retreat into ‘safe’ target cells, such as the neutrophils, macrophages, and DCs, 
and resist the acidic environment of the PV, through the actions of LPG and 
gp63, in order to facilitate their survival in the host and initiate infection 
(reviewed in Franco et al., 2012). LPG has a lipid backbone coated with a 
polymer of repeating disaccharide-phosphate units with variable side-chain 
modifications attached to a glycan core that is inserted into the membrane via a 
glycophosphatidylinositol (GPI) anchor, and is capped by a neutral 
oligosaccharide. The most abundant surface protein, gp63, is a GPI-anchored 
zinc metalloprotease. To generate a persistent infection, Leishmania can alter 
host signalling pathways in macrophages and DCs to render the macrophages 
unresponsive to activating stimuli, through the Toll-like receptors (TLRs) for 
example, or to suppress the antimicrobial effector functions, such as the 
oxidative burst and iNOS-mediated generation of NO (reviewed in Shio et al., 
2012). Leishmania modulate the expression of cytokines and chemokines to alter 
immune cell activation, IL-12 in particular (Piedrafita et al., 1999), and the 
migration of cell populations to the site of infection. LPG and other 
proteoglycans have been implicated in the inhibition of IL-2, IL-12, and IFN-γ 
production, whilst stimulating the production of IL-4 and IL-10 (Liu et al., 2009). 
Attenuation of T cell-mediated responses by interfering with the loading of 
Leishmania antigens onto MHC II, downregulating the macrophage and DC co-
stimulatory cell surface molecules required to stimulate a T cell response, 
polarisation towards a Th2 phenotype, and induction of Treg cell activity, which 
suppress Th cell responses, are also common mechanisms of Leishmania immune 
evasion and exploitation (reviewed in Bhardwaj et al., 2010; Shio et al., 2012). 
Leishmania cysteine peptidases, designated CPA, CPB, and CPC, have already 
been proven to be important Leishmania virulence factors (Mottram et al., 
2004). When L. mexicana, which are particularly rich in CPs, are genetically-
modified to be deficient in the multicopy CPB gene array, their ability to infect 
macrophages and lesion development in BALB/c mice is much reduced compared 
to infection with L. mexicana wild-type (WT) (Mottram et al., 1996), due to an 
Chapter 1 
25 
 
inability to induce IL-4 production (Pollock et al., 2003). CPB has been shown to 
inhibit IL-12 production in C3H and C57BL/6 mice, and induce IL-4 production in 
BALB/c mice, both of which prevent the host from mounting a protective Th1 
response, and may enhance a counter-protective Th2 cell response (Alexander et 
al., 1998; Buxbaum et al., 2003; Pollock et al., 2003; Cameron et al., 2004). 
Leishmania exosomes have been implicated in the priming of host target cells 
for Leishmania invasion and have been shown to have immunosuppressive effects 
on monocytes and moDCs (Silverman et al., 2010b; Hassani et al., 2011). 
However, the functions of the individual proteins of the exoproteome on 
immune modulation have yet to be elucidated. Despite much being known about 
the immune responses to Leishmania spp., few putative Leishmania virulence 
factors, other than LPG, gp63, and CPs, have been characterised in their 
interactions with host immune cells and the modulation of host immune 
responses, particularly using in vivo infection models. 
1.4 Inhibitors of serine peptidases (ISPs) 
1.4.1 Discovery of Leishmania ISPs 
The haploid genome of L. major Friedlin has been completely sequenced 
showing 32.8 Mb distributed on 36 chromosomes with over 8000 predicted 
protein-coding genes, 36% of which have a putative function (Ivens et al., 2005). 
BLAST analysis of these protein-coding genes has led to the discovery of putative 
Leishmania virulence factors, such as the inhibitors of serine peptidases (ISPs) 
(Eschenlauer et al., 2009). 
One of the major mechanisms used to control the activity of peptidases in 
mammals is through tight interaction with natural peptidase inhibitors, such as 
serpins and cystatins. Orthologues of mammalian peptidase inhibitors have not 
been identified in the Leishmania genome; orthologues of peptidase inhibitors 
from other pathogens, such as bacteria, however, have been detected, including 
ISPs and inhibitors of cysteine peptidases (ICPs) (Sanderson et al., 2003), which 
suggests that these inhibitors may be virulence factors that act upon host 
peptidases during Leishmania infection. Non-healing, progressive lesions were 
observed in BALB/c mice infected with L. mexicana WT parasites, ICP-deficient 
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mutants, and ICP re-expressing mutants, whilst BALB/c mice infected with 
mutants over-expressing ICP have severely reduced virulence and were able to 
significantly control lesion growth, due to reduced IL-4 and enhanced IFN-γ 
production (Besteiro et al., 2004; Bryson et al., 2009). 
Peptidases of immune cells, particularly serine peptidases (SPs), have roles in 
fighting pathogenic infections, as they can have direct microbicidal activity 
against bacteria through the degradation of bacterial membranes (Belaaouaj et 
al., 2000). SPs also have important functions in the modulation of host immune 
responses through the proteolytic modification of cytokines and chemokines, 
which can regulate immune cell activation and recruitment, and the activation 
or inactivation of specific cell receptors (discussed in Chapter 5). Very few 
studies have explored the roles of such peptidases during infection with 
Leishmania; Ribeiro-Gomes et al. (2004) have shown that the host SP, neutrophil 
elastase (NE), released from dying neutrophils, induces the microbicidal activity 
of macrophages infected with L. major. 
Three ISPs have been identified in the L. major genome, designated ISP1, ISP2, 
and ISP3; these have also been identified in L. mexicana, L. infantum, and L. 
braziliensis. ISP1 and ISP2 are present in T. brucei but only ISP2 has been 
identified in T. cruzi. Leishmania ISPs are orthologues of the Escherichia coli 
protein, ecotin. Trypanosomatids are the only known eukaryotes to possess these 
ecotin-like natural peptide inhibitors, which suggests there may have been a 
horizontal gene transfer event between the bacteria and Leishmania, possibly 
during a co-infection in a mutual host (Opperdoes & Michels, 2007). 
Ecotin is a homodimeric protein found in the periplasmic space between the 
inner and outer membranes of bacteria. Ecotin inhibits a wide range of SPs from 
the S1A trypsin-fold peptidase family of clan PA(S), which include trypsin, 
chymotrypsin, NE, cathepsin G (CG), and coagulation factors Xa and XIIa (Chung 
et al., 1983; Eggers et al., 2004). The broad range of peptidases inhibited by 
ecotin can be explained by the fact that ecotin forms a head-to-tail dimer that 
interacts with two enzyme molecules via multiple binding sites (Yang et al., 
1998). No E. coli peptidase has been identified that is sensitive to ecotin and 
there are no reports that ecotin inhibits SPs of other families or catalytic classes 
(Chung et al., 1983). Therefore, ecotin is hypothesised to protect the cell 
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against exogenous S1A peptidases, such as digestive or pancreatic peptidases, or 
SPs produced by the host immune cells during infection. It has been shown that 
E. coli expressing an inactive form of ecotin were more sensitive to NE than WT 
cells (Eggers et al., 2004). Ecotin has well-conserved orthologues in several 
pathogenic genera, including Burkholderia, Pseudomonas, Salmonella, Serratia, 
and Yersinia (Eggers et al., 2004; Clark et al., 2011; Ireland et al., 2014), 
although few studies have investigated the role of ecotin in virulence. Ecotin of 
Burkholderia pseudomallei, the causative agent of melioidosis, has been shown 
to be important for disease persistence in murine macrophages and the in vivo 
mouse model (Ireland et al., 2014). The genome of L. major reveals the 
presence of at least 153 identifiable peptidases, representing approximately 2% 
of the genome, which can be classified into the major catalytic types, aspartic, 
cysteine, metallo-, threonine, and serine peptidases (Ivens et al., 2005). L. 
major has 13 SPs belonging to six families but lacks genes encoding trypsin-fold 
SPs from the S1A family (Ivens et al., 2005); therefore, it is hypothesised that, 
like bacterial ecotin, Leishmania ISPs act against host-derived SPs (Eschenlauer 
et al., 2009). 
L. major ISP1 (LmjF 15.0300), ISP2 (LmjF 15.0510), and ISP3 (LmjF 15.0520) are 
found in a cluster on chromosome 15. ISP3 (41.8 kDa) is not detected in any of 
the Leishmania lifecycle stages and has been suggested to be a pseudogene 
(Eschenlauer et al., 2009). ISP1 is a 16.5 kDa protein that can only be detected 
in procyclic and metacyclic promastigotes, whereas ISP2, a 17.5 kDa protein, is 
expressed in all three lifecycle stages with the levels of expression being greater 
in the infective metacyclic promastigotes and amastigotes (Eschenlauer et al., 
2009). ISP1 and ISP2 share only 36% sequence identity with each other, and 
recombinant ISP2 (rISP2) has been shown to have high peptidase inhibitory 
activity against human NE, trypsin, and chymotrypsin, whereas rISP1 has 
peptidase inhibitory activity at least 10-fold lower than that of rISP2 
(Eschenlauer et al., 2009; Morrison et al., 2012). This indicates that ISP2 may 
play a role in the inhibition of host SPs during mammalian infection. 
1.4.2 Role of ISP1 in flagellar pocket dynamics 
ISP1, which has low peptidase inhibitory activity, has been implicated in 
Leishmania flagellar homeostasis (Morrison et al., 2012). L. major ISP triple 
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knock-out mutant (Δisp1/2/3) populations have enlarged flagellar pockets with 
an accumulation of granular vesicles and membranous whorls, longer flagella, 
and are less motile than WT populations, but Δisp1/2/3:ISP1 populations have a 
phenotype similar to that of WT parasites (Morrison et al., 2012). Based on these 
results, it was proposed that ISP1 has an intracellular function involved in the 
regulation of intraflagellar transport (IFT), disruption of which affects flagellar 
pocket flux, including flagella biosynthesis and flagellar pocket distention, 
culminating in stress response-induced differentiation (Morrison et al., 2012). 
1.4.3 Role of ISP2 as a potential virulence factor 
The main way to investigate the role of putative virulence factors in disease 
progression and host-parasite interactions is to generate Leishmania mutants 
deficient in the putative virulence factor and compare the disease profiles with 
that of the WT parasites. Using L. major deficient in ISP2 and ISP3 (Δisp2/3), 
Eschenlauer et al. (2009) and Faria et al. (2011) showed that the L. major 
Δisp2/3 promastigotes were internalised more efficiently by macrophages of 
susceptible BALB/c and resistant C57BL/6 mice than L. major WT promastigotes 
respectively (Figure 1-6). A partial elimination of intracellular Δisp2/3 parasites, 
or reduced parasite burdens, at 24 h or 72 h post-infection was observed in 
macrophages from BALB/c and C57BL/6 mice respectively; this suggests that ISPs 
are important for the initiation and persistence of infection in the host and that 
early control of SPs can influence the outcome of infection (Faria et al., 2011). 
The presence of rISP2 or a peptidyl synthetic irreversible inhibitor to NE (NEI) 
with macrophages prior to Leishmania infection reduced the internalisation and 
elimination of Δisp2/3 parasites to WT levels, which elucidated NE as the 
primary target of ISP2 and revealed that NE activity present during early 
Leishmania-macrophage contact results in subsequent parasite death 
(Eschenlauer et al., 2009; Faria et al., 2011). 
Internalisation of Δisp2/3 parasites returned to WT levels when macrophages 
were pre-treated with antibodies that block CD11b (Eschenlauer et al., 2009; 
Faria et al., 2011). CD11b of macrophages is implicated in various adhesive 
interactions and also mediates the uptake of complement-coated 
microorganisms, such as iC3b-coated Leishmania parasites. CD11b is a 
component of CR3, which is the receptor for the iC3b fragment; this suggests 
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that the increased uptake of Δisp2/3 promastigotes is mediated by engagement 
of CR3 in macrophages of BALB/c and C57BL/6 mice. Internalisation and 
elimination of Δisp2/3 parasites in macrophages returned to WT levels at 24 h 
post-infection, when macrophages were pre-treated with monoclonal antibodies 
that block TLR4 (Faria et al., 2011). This indicates that TLR4 is responsible for 
the enhanced uptake and elimination of Δisp2/3 parasites in macrophages. In 
addition, neutralisation of both CD11b and TLR4 had similar effects to the 
neutralisation of either CD11b or TLR4 alone; it is plausible that they act in a 
common pathway. The decreased phagocytosis of Δisp2/3 parasites when 
macrophages were pre-incubated with NEI, was no longer observed upon 
activation of TLR4, and Δisp2/3 parasites were poorly infective to TLR4-
defective macrophages from C3HeJ mice; these results indicate that NE activity 
promotes parasite internalisation through TLR4 (Faria et al., 2011). 
ISP2 may also prevent the generation of ROS by preventing the activation of this 
TLR4-mediated response. When infected cultures were treated with EUK134, a 
superoxide scavenger, immediately after parasite internalisation, the numbers 
of Δisp2/3 parasites at 24 h post-infection were similar to those at 3 h; this 
indicates that superoxide strongly contributes to the killing of intracellular 
Δisp2/3 parasites (Faria et al., 2011). 
Faria et al. (2014) have further elucidated the downstream responses of the 
TLR4-NE activation during Δisp2/3 infection in macrophages, attributing parasite 
killing to a dependency of functional protein kinase R (PKR), which may be 
phosphorylated by the associated TLR4 adaptor proteins MyD88 or TRIF, leading 
to the induction of TNF-α and IFN-β production. This investigation also revealed 
that TLR2 and TLR4 may act conjointly in the enhanced internalisation of 
Δisp2/3 promastigotes in macrophages (Faria et al., 2014). TLR4 signalling is 
commonly divided into the MyD88-dependent pathway, which ultimately leads to 
NF-κB and AP-1 activation, and TRIF-dependent pathways, which can lead to the 
activation of interferon regulatory factor (IRF3), as well as NF-κB and AP-1 
(Ulrichts & Tavernier, 2008). The nuclear levels of the NF-κB subunit p65 and 
IRF3 were reduced in Δisp2/3 infection compared with that of WT infection 
(Faria et al., 2014). 
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In summary, Faria et al. (2011) proposed that L. major ISP2 inhibits the activity 
of NE preventing the activation of a TLR4-NE signalling cascade during early 
Leishmania-macrophage contact. Through the inhibition of NE activity, there is a 
downregulation of parasite phagocytosis, which is also mediated by engagement 
of CR3, and an inhibition of ROS production, exerting a beneficial effect for 
intracellular amastigote survival and growth in the macrophages. ISP2 is, 
therefore, proposed as an important virulence factor used by L. major to 
establish a productive infection in the mammalian host. 
 
Figure 1-6 Effect of L. major ISP2 on Leishmania-macrophage interactions. ISP2 has been 
shown to inhibit the activity of the host serine peptidase, neutrophil elastase (NE). This prevents 
the activation of a Toll-like receptor 4 (TLR4)-NE signalling cascade during early Leishmania-
macrophage contact in vitro, resulting in a downregulation of phagocytosis and an inhibition of 
reactive oxygen species (ROS) production. L. major deficient in ISP2 and ISP3, Δisp2/3, are 
internalised more efficiently but have reduced parasite burdens by 24 h. Therefore, ISP2 may 
play a role in the establishment and persistence of infection in the mammalian host. There are 
still some mechanisms to be elucidated, such as the exact interaction of NE and TLR4, which 
leads to TLR4 activation, and the signalling cascades that are stimulated during the TLR4-NE 
interaction, and how the prevention of the TLR4 signalling cascade activation by L. major ISP2 
inhibition of NE activity will affect the immune responses in vivo, for example, through the 
modulation of cytokine and chemokine production. 
1.5 Project aims 
Host serine peptidases, such as NE and CG, expressed by cells of the early innate 
immune response, including neutrophils, macrophages, monocytes, and mast 
cells, are heavily involved in the proteolytic modification of chemokines, and in 
cytokine and cell receptor activation, which can therefore impact upon cell 
recruitment and the activation of cell effector functions. It is hypothesised that 
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L. major ISP2 will inhibit the activity of these SPs during early infection to 
enable the initiation and persistence of L. major infection in vivo. 
The aims of this project are to: 
 Determine the subcellular localisation of ISP1 and ISP2 during the Leishmania 
lifecycle. 
 Assess disease progression during in vivo infection with L. major WT and ISP2 
gene mutants, in terms of parasite burden, to determine whether ISP2 confers 
parasite survival in vivo. 
 Compare the innate immune cell dynamics at the site of inoculation after 
infection with L. major WT and ISP2 gene mutants, with particular regards to the 
innate immune cell recruitment and activation, to determine whether ISP2 
affects functions associated to the activity of SPs during the immune response. 
 Investigate the role of the serine peptidase, neutrophil elastase (NE), in 
mediating the immune responses to L. major WT and ISP2 gene mutants in vivo 
through the use of NE-deficient (Ela-/-) mice. 
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2 Materials and Methods 
2.1 Promastigote parasite culture 
2.1.1 Leishmania cell lines 
The Leishmania cell lines used in this study are given in Table 2-1, together with 
a description of their genetic manipulation and the resistance genes used for 
their selection.  
Table 2-1 Leishmania major cell lines used in this study.  
L. major cell line Description 
Antibiotic 
resistance 
Reference 
L. major Friedlin wild-
type (WT) 
MHOM/JL/80/Friedlin   
Δisp1/2/3 
Knock-out of ISP1, ISP2 
and ISP3 
Blasticidin 
Nourseothricin 
Hygromycin 
Phleomycin 
(Morrison et 
al., 2012) 
Δisp1/2/3:ISP1 
Re-expression of ISP1 
in Δisp1/2/3 
Blasticidin 
Nourseothricin 
Hygromycin 
Phleomycin 
Puromycin 
(Morrison et 
al., 2012) 
Δisp1/2/3:ISP2/3 
Re-expression of ISP2 
and ISP3 in Δisp1/2/3 
Blasticidin 
Nourseothricin 
Hygromycin 
Phleomycin 
Puromycin 
(Morrison et 
al., 2012) 
Δisp2/3 
Knock-out of ISP2 and 
ISP3 
Hygromycin 
Phleomycin 
(Eschenlauer 
et al., 2009) 
Δisp2/3:ISP2/3 
Re-expression of ISP2 
and ISP3 in Δisp2/3 
Hygromycin 
Phleomycin 
Puromycin 
(Eschenlauer 
et al., 2009) 
WT [pXG-ISP2]  
Overexpression of ISP2 
in WT 
Neomycin 
(Morrison et 
al., 2012) 
L. major+LUC2 
L. major expressing 
firefly luciferase 
Puromycin  
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Δisp2/3+LUC2 
Δisp2/3 expressing 
firefly luciferase 
Hygromycin 
Phleomycin 
Puromycin 
 
Δisp2/3:ISP2/3+LUC2 
Δisp2/3:ISP2/3 
expressing firefly 
luciferase 
Hygromycin 
Phleomycin 
Puromycin 
Nourseothricin 
 
2.1.2 Passage of cultures 
2.1.2.1 Media and growth conditions 
Leishmania major were grown in modified Eagle’s medium, designated HOMEM 
medium (Gibco), supplemented with 10% (v/v) heat-inactivated foetal calf 
serum (FCS) (Gibco), and 100 U ml-1 penicillin and 100 μg ml-1 streptomycin 
solution (Sigma). Cultures were incubated at 25 °C. 
2.1.2.2 Antibiotic concentrations 
Cell lines in Table 2-1 were grown in the presence of the appropriate antibiotics. 
ISP gene re-expressing cell lines were selected with 50 μg ml-1 puromycin 
(InvivoGen) and ISP gene overexpressing cell lines were selected with 50 μg ml-1 
G418 neomycin (InvivoGen). Bioluminescent cell lines were selected with 50 μg 
ml-1 puromycin (InvivoGen) or 25 μg ml-1 LEXSY NTC (nourseothricin) (Jena 
Bioscience). 
2.1.3 Preparation and recovery of stabilates 
Cultures were preserved in HOMEM medium supplemented with 20% FCS and 5% 
dimethyl sulfoxide (DMSO). Cryovials were stored at -80 °C overnight then 
transferred to liquid nitrogen storage for cryopreservation. Stabilates were 
recovered in HOMEM/20% FCS and incubated at 25 °C. 
2.1.4 Determination of culture density 
A 1:1 ratio of parasites from culture and 2% formaldehyde solution was 
prepared, 10 µl of fixed cells were placed on a Neubauer chamber (Weber 
Scientific), and parasites were counted on an inverted light microscope. Within 
the centre square of the grid on the haemocytometer, three lines of squares 
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were counted, the count was divided by 3 to give an average, and the culture 
density was calculated as follows: 
Parasites / ml = count x 5 (total cells in centre square) x 2 (dilution factor) x 104 
(volume of chamber) 
2.1.5 Purification of L. major metacyclic promastigotes 
Parasites were harvested from culture, which had been in stationary-phase for 3 
days, at 1000 x g for 10 min and resuspended in HOMEM. Metacyclic 
promastigotes were isolated using peanut lectin agglutination (Sacks et al., 
1985). Peanut lectin (Sigma) was added at 50 µg ml-1 and incubated at room 
temperature for 20 min to agglutinate procyclic promastigotes. Metacyclic 
promastigotes were recovered from the supernatant after centrifugation at 100 
x g for 5 min. Metacyclic promastigotes were washed twice in 1x phosphate 
buffered saline (PBS) [137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4] at 1000 x g for 5 min then resuspended in the appropriate volume of 
PBS. 
2.1.6 Transfection and selection of Leishmania clones 
For each transfection, 5x107 log-phase promastigotes were centrifuged at 1000 x 
g for 5 min, and resuspended in 100 µl Human T Cell Nucleofector Solution, 
provided as part of the Human T Cell Nucleofector Kit (Lonza). Approximately 10 
µg DNA, prepared in up to 10 µl molecular grade water, was added and the 
solution was transferred to a cuvette. Parasites were electroporated using 
program U-033 on the Amaxa NucleofectorTM II. A negative control, in which 10 
µl molecular grade water was used instead of DNA, was performed for each 
transfection. After transfection, the solution was transferred to 10 ml 
HOMEM/20% FCS, the culture was then split into two flasks of 5 ml to yield two 
populations, and flasks were incubated at 25 °C overnight. 
After the parasites had recovered, the appropriate concentration of selection 
antibiotic was added to the flasks, including the negative controls. Serial 
dilution into round-bottom 96-well plates was performed to generate clones of 
the transfected parasites. Dilutions were as follows: dilution 1 consisted of 4 ml 
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culture and 20 ml HOMEM/10% FCS supplemented with the appropriate 
antibiotic; dilution 2 consisted of 2 ml of dilution 1 and 22 ml HOMEM; and 
dilution 3 consisted of 4 ml of dilution 2 and 22 ml HOMEM. One plate was used 
for each dilution at 200 µl per well. Plates were incubated at 25 °C for 3 to 4 
weeks. 
2.1.7 Preparation of genomic DNA from Leishmania spp. 
Total genomic DNA from Leishmania was purified from a cell pellet harvested 
from 10 ml of Leishmania culture using the DNeasy Blood & Tissue kit (Qiagen), 
following the manufacturer’s protocol for “Purification of Total DNA from Animal 
Blood or Cell (Spin-Column)”. Samples were stored at -20 °C. 
2.1.8 Preparation of protein extracts from Leishmania spp. 
Promastigotes were harvested at the desired lifecycle stage at 1000 x g for 10 
min and washed in PBS. Cells were lysed in 1x SDS-PAGE sample buffer [45 mM 
Tris pH 6.8, 10% (v/v) glycerol, 1% (w/v) SDS, 0.01% bromophenol blue, 50 mM 
DTT] at 107 cells in 10 µl, briefly vortexed and boiled for 5 min on a heat block. 
Samples were stored at -20 °C. 
2.1.9 Luciferase reporter gene assay 
To quantify luciferase activity of bioluminescent cell lines, the Luciferase 
Reporter Gene Assay (Roche) was used. The assay was performed in duplicate for 
each cell line; promastigotes were centrifuged at 1000 x g for 10 min, washed in 
phenol red-free RPMI 1640 (PAA), then resuspended in phenol red-free RPMI 1640 
at the required number of cells per 100 µl. The cell suspensions, and a medium 
only control, were added to a 96-well white, clear-bottom plate (Greiner Bio-
One) at 100 µl per well, to which 100 µl luciferase substrate was added. 
Luminescence was read every 2 min over 30 min using an EnVision Multilabel 
Reader with a <700 nm luminescence emission filter or a PHERAstar FS (BMG 
Labtech). 
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2.2 Bacterial culture 
2.2.1 E. coli strains 
The E. coli strains used in this study are given in Table 2-2, together with a 
description of their main features and uses.  
Table 2-2 Competent E. coli strains used in the study.  
E. coli strains Features Uses 
DH5α 
(Invitrogen) 
recA1 for insert stability 
endA1 to improve yield and 
quality of plasmid DNA 
Transformations of plasmid 
DNA or ligation reactions 
for DNA amplification and 
purification 
dam-/dcm-  
(New England Biolabs) 
Methyltransferase-deficient 
cells 
Used to generate 
unmethylated plasmid DNA 
One Shot BL21(DE3)pLysS 
(Invitrogen) 
Produces T7 lysozyme to 
reduce basal level 
expression of the gene of 
interest 
Transformation of plasmid 
DNA for recombinant 
protein expression and 
purification 
2.2.2 Transformation of E. coli with plasmid DNA 
Aliquots of 50 µl of competent cells were thawed on ice, to which 1 µl DNA was 
added. Cells were incubated on ice for 30 min. Cell transformation was 
performed using the heat shock method, in which cells were incubated in a 42 
°C waterbath for 45 sec then immediately incubated on ice for 2 min. The cells 
were recovered through the addition of 450 µl SOC (Invitrogen) or lysogeny broth 
(LB) medium and subsequent incubation in a 37 °C incubator shaking at 225 rpm 
for 1 h. Transformed cells, up to 100 µl, were spread onto LB agar plates 
supplemented with the appropriate antibiotic for selection. Plates were inverted 
and incubated at 37 °C overnight. 
2.2.3 Culture of E. coli 
2.2.3.1 Media and growth conditions 
For cells required for the purification of plasmid DNA, individual colonies were 
selected from the LB agar plates with a sterile pipette tip, placed in 5 ml LB 
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medium supplemented with the appropriate antibiotic and grown overnight in a 
37 °C incubator shaking at 225 rpm overnight. 
For cells required for the expression of recombinant proteins, 5 ml LB cultures 
were prepared as described above. Four 1 L conical flasks containing 400 ml LB 
medium supplemented with the appropriate antibiotic were prepared. A volume 
of 1 ml from the 5 ml overnight culture was transferred to each of the 1 L 
conical flasks, which were grown to an appropriate cell density in a 37 °C 
incubator shaking at 225 rpm. 
2.2.3.2 Antibiotic concentrations 
Plasmids used in this study had either ampicillin or chloramphenicol resistance 
genes. To select for E. coli harbouring the plasmid, ampicillin solution, prepared 
from ampicillin sodium salt (Sigma) in water, or chloramphenicol (Sigma), 
prepared in ethanol, were added to the culture medium at a final concentration 
of 100 µg ml-1. 
2.2.4 Expression of recombinant proteins 
The cell density of the 400 ml cultures was determined using the optical density 
at 600 nm (OD600) measured on a BioPhotometer (Eppendorf), using medium 
only as a blank reference. When the OD600 was between 0.6 and 0.8, protein 
expression was induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). 
For recombinant ISP1 expression, the cultures were incubated at 18 °C 
overnight, and for recombinant ISP2 expression, the cultures were further 
incubated at 37 °C for 4 h. After induction, cells were harvested at 5000 x g for 
15 min, washed with ice-cold PBS then centrifuged at 5000 x g for 15 min. The 
cell pellet was stored at -20 °C until required for protein purification, which was 
performed in-house. 
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2.3 Molecular biology techniques 
2.3.1 Preparation of plasmid DNA from E. coli 
Plasmid DNA from E. coli was purified from a cell pellet harvested from 5 ml of 
LB culture using the QIAprep Spin Miniprep kit (Qiagen), following the 
manufacturer’s protocol for “QIAprep Spin Miniprep Kit Using a Microcentrifuge”. 
2.3.2 Quantification of DNA concentration and purity 
DNA concentration, given in ng ml-1, and purity were quantified on a NanoDrop 
1000 Spectrophotometer (NanoDrop), through absorption at 260 nm (A260), and 
the ratio of A260 to A280 (nucleic acids to proteins) respectively. 
2.3.2 Agarose gel electrophoresis 
Agarose gels were made by dissolving 1% (w/v) agarose, or 0.7% (w/v) agarose 
for gel extraction protocols, into 0.5x Tris-borate-EDTA (TBE) buffer [20 mM Tris, 
20 mM boric acid, 0.5 mM EDTA, pH 7.2] by briefly heating in a microwave. After 
cooling, SYBR Safe DNA gel stain (Invitrogen) was added at 1:20 000 and the gel 
was left to set. 6x loading dye [0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF, 30% glycerol] was added to the DNA samples for loading. A 1 
kb Plus DNA ladder (Invitrogen) was loaded at 0.1 µg per mm lane width 
alongside the samples as a reference. Electrophoresis was performed between 
60 and 120 V until the loading dye had run down at least 80% of the gel. Agarose 
gels were viewed under UV light on a Molecular Imager Gel Doc XR system (Bio-
Rad) using Quantity One software (Bio-Rad). 
2.3.3 Restriction endonuclease digestion 
DNA was digested using restriction endonucleases (New England Biolabs) 
according to the manufacturer’s guidelines regarding reaction buffer and 
reaction incubation temperature. For double digests, the optimum reaction 
buffer was chosen using the ‘Double Digest Finder’ tool on the New England 
Biolabs website. Digestion of large concentrations of DNA were performed in 100 
to 200 µl volumes and incubated overnight. 
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2.3.4 Gel extraction 
DNA was extracted and purified from 0.7% agarose gels using the QIAquick Gel 
Extraction kit (Qiagen), following the manufacturer’s protocol for “QIAquick Gel 
Extraction Kit using a Microcentrifuge”. 
2.3.5 Ethanol precipitation  
To purify and concentrate DNA for transfection into Leishmania spp., a 10% 
volume of 3 M sodium acetate pH 5.2 and one volume of 100% isopropanol were 
added to the sample. The sample was centrifuged at 13 000 x g for 30 min at 4 
°C. The DNA pellet was washed in 700 µl 70% ethanol and centrifuged at 13 000 x 
g for 30 min at 4 °C. The supernatant was removed and the DNA pellet was air-
dried in a fume hood. The DNA pellet was resuspended in 30 µl molecular grade 
water for Leishmania transfection. 
2.3.6 Polymerase chain reaction (PCR) 
2.3.6.1 High-fidelity PCR 
Polymerase chain reactions (PCRs), in a volume of 50 µl with 100 ng template 
DNA, generally consisted of the final concentrations of: 0.2 µM each of the 
oligonucleotide primers, 200 µM dNTPs (Sigma), 2.5 U PfuTurbo DNA polymerase 
(Agilent Technologies), 1x pfu reaction buffer (Agilent Technologies), and 
molecular grade water. PCR reactions were performed in either a Hybaid Px2 
Thermo Cycler (Thermo Scientific) or a Robocycler Gradient 96 (Stratagene), and 
were typically as follows: an initial denaturation step of 95 °C for 2 min, 
followed by 30 cycles of denaturation at 95 °C for 50 sec, annealing at 65 °C for 
40 sec, optimised for each reaction, and extension at 72 °C for 50 sec, 
determined by the extension rate of the polymerase and the length of the 
amplified product, then a final extension step for 10 min at 72 °C. To A-tail the 
PCR product for cloning into a generic cloning vector, 1 µl Taq polymerase (New 
England Biolabs) was added for 20 min at 72 °C after the final extension step. 
2.3.6.2 Colony PCR 
Colonies were picked from LB agar plates with a sterile pipette tip and mixed in 
a PCR mix, in a volume of 20 µl, consisting of the final concentrations of: 0.2 µM 
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each of the oligonucleotide primers, 200 µM dNTPs (Sigma), 0.5 U Taq 
polymerase (New England Biolabs), 1x ThermoPol Reaction Buffer (New England 
Biolabs), and molecular grade water. PCR reactions were performed in a Hybaid 
Px2 Thermo Cycler (Thermo Scientific) and were typically as follows: an initial 
denaturation step of 95 °C for 1 min, followed by 25 cycles of denaturation at 95 
°C for 30 sec, annealing at 55 °C for 30 sec, and extension at 72 °C for 1 min, 
then a final extension step for 10 min at 72 °C. 
2.3.6.3 PCR method of genotyping transgenic mice  
PCRs to genotype NE-deficient mice (Ela-/-), in a final volume of 25 µl with 200 
ng DNA, consisted of the final concentrations of: 0.2 µM each of the 
oligonucleotide primers, 200 µM dNTPs (Sigma), 0.5 U Taq polymerase (New 
England Biolabs), 1x ThermoPol Reaction Buffer (New England Biolabs), and 
molecular grade water. PCR reactions were performed as follows: an initial 
denaturation step of 94 °C for 5 min, followed by 30 cycles of denaturation at 94 
°C for 1 min, annealing at 56 °C for 1 min, and extension at 72 °C for 2 min, 
then a final extension step for 5 min at 72 °C. 
2.3.7 Oligonucleotides used 
Oligonucleotides primers, OL3978 and OL3979 in Table 2-3, were designed using 
Vector NTI software (Invitrogen) and synthesised by Eurofins MWG Operon. 
Table 2-3 Oligonucleotides used in this study. Descriptions and sequences are given. 
Restriction endonuclease sites are underlined, and start or stop codons are in bold. 
Oligo 
number 
Description Oligonucleotide sequence 
OL3336 
(forward) Wild-type 
neutrophil 
elastase gene 
AGACTATCCAGCCGGACTCT 
OL3337 
(reverse) 
ACCAACAATCTCTGAGGGCA 
OL3338 
(forward) 
NEO gene 
(Disrupts wild-
type neutrophil 
elastase gene in 
Ela-/- mice)  
ATGATTGAACAAGATGGATTGCAC 
OL3339 
(reverse) 
TTCGTCCAGATCATCCTGATCGAC 
  Chapter 2 
41 
 
OL3978 
(forward) 
Amplification of 
the SAT gene 
and addition of 
a BamHI 
restriction site 
GCAGGATCCATGAAGATTTCGGTGATCCCTGAGC 
OL3979 
(reverse) 
Amplification of 
the SAT gene 
and addition of 
a SexAI 
restriction site 
TGCACCAGGTTTAGGCGTCATCCTGTGCTCCCGA 
2.3.8 Ligation 
2.3.8.1 Cloning of PCR products into cloning vectors 
PCR products, with A-overhangs, were ligated into pGEM-T Easy Vector 
(Promega) then transformed into competent E. coli cells following the 
manufacturer’s instructions. Transformants were selected based on blue/white 
colony screening and confirmed by colony PCR with T7 and SP6 primers. 
2.3.8.2 Cloning of digested inserts into destination plasmids 
Digested inserts were ligated into similarly digested plasmids at a 3:1 
insert:vector ratio, in a 20 µl reaction volume comprising T4 DNA ligase (New 
England Biolabs), T4 DNA ligase buffer (New England Biolabs), and molecular 
grade water. Ligation reactions were incubated at 16 °C overnight, after which 2 
µl of the ligation reaction was transformed into competent E. coli cells, which 
were plated onto LB agar plates supplemented with the appropriate antibiotic 
for selection. Colonies were selected and verified by colony PCR using vector-
specific primers or through restriction digest analysis of the purified plasmid. 
2.3.9 DNA sequencing 
DNA sequencing was performed by DNA Sequencing and Services at the 
University of Dundee and analysed using CLC Genomics Workbench 4 (CLC Bio). 
2.3.10 Plasmids used 
Plasmids used and generated in this study are listed in Table 2-4, together with a 
description of their use in this study. 
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Table 2-4 Plasmids used or generated in this study.  
Plasmid 
number 
Backbone Description 
pGL573 pGEM-T 
Contains SAT gene 
Used to change the resistance cassette of 
pGL2127 to generate pGL2276 
pGL998 PET15b 
Protein expression of recombinant L. major 
ISP1 
pGL999 PET15b 
Protein expression of recombinant L. major 
ISP2 
pGL2126 
pRIB (pGL631) 
(Misslitz et al., 2000) 
Integrates into the 
Leishmania rRNA locus 
Contains LUC2 and PAC genes 
pGL2127 Contains mCherry and PAC genes 
pGL2276 
Contains mCherry and SAT genes 
Used to generate pGL2357 
pGL2357 Contains LUC2 and SAT genes 
 
2.4 Protein techniques 
2.4.1 SDS-PAGE 
Leishmania protein extracts were separated on sodium dodecyl sulphate (SDS) 
polyacrylamide gels. Each 12% separating polyacrylamide gel was prepared in a 
volume of 12.5 ml  [3.55 ml distilled water, 3.15 ml 1.5 M Tris pH 8.8, 5 ml 30% 
acrylamide solution, 125 µl 10% SDS, 125 µl 10% ammonium persulfate, 5 µl 
TEMED] and cast in a 1.0 mm mini gel cassette (Invitrogen). A 5% stacking gel 
was prepared in a volume of 4 ml [2.25 ml distilled water, 500 µl Tris pH 6.8, 
650 µl 30% acrylamide solution, 40 µl 10% SDS, 40 µl 10% ammonium persulfate, 4 
µl TEMED], cast over the 12% separating gel and a cassette comb (Invitrogen) 
was set in place. A Spectra Multicolor Broad Range Protein Ladder (Thermo 
Scientific) was used as a protein marker. Electrophoresis was performed in an 
XCell SureLock Mini-Cell Electrophoresis System (Invitrogen) with 1x SDS-PAGE 
running buffer [25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS]. 
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2.5 Antibody purification 
Anti-ISP1 and anti-ISP2 antibodies were purified from sheep antisera 
(Eschenlauer et al., 2009) using AminoLink Plus Coupling Resin (Thermo 
Scientific). To prepare the AminoLink Plus Coupling Resin (Thermo Scientific), 4 
ml of slurry was centrifuged at 1000 rpm for 5 min, to remove the storage 
solution, leaving 2 ml resin. The resin was washed twice in 10 ml PBS at 1000 
rpm for 5 min. 
Recombinant ISP protein was concentrated to approximately 10 mg in 1 ml using 
a Vivaspin 2 Centrifugal Concentrator with a molecular weight cut-off value 
(MWCO) of 10 000 (Sartorius Stedim Biotech) centrifuged at 3000 rpm for 10 min. 
The concentrated protein was collected and diluted in 3 ml coupling buffer [0.1 
M sodium phosphate, 0.15 M sodium chloride, pH 7.2]. The protein solution was 
added to the resin with 40 µl cyanoborohydride solution [5 M sodium 
cyanoborohydride in 1 M sodium hydroxide] and incubated on a rotating mixer at 
4 °C overnight to immobilise the protein. 
All centrifugations, including wash steps, were performed at 1000 rpm for 5 min 
at 4 °C. The resin with the immobilised protein was centrifuged, washed in 4 ml 
coupling buffer then washed in 10 ml quenching buffer [1 M Tris pH 7.4]. 
Thereafter, 2 ml quenching buffer and 40 µl cyanoborohydride solution were 
added and incubated on a rotating mixer at room temperature for 30 min. The 
resin was washed three times in 6 ml wash buffer [1 M sodium chloride, 0.05% 
sodium azide] then washed in 10 ml ImmunoPure (Protein A) IgG Binding Buffer 
(Thermo Scientific). After which, 2.5 ml binding buffer and 5 ml anti-sera were 
incubated on a rotating mixer at 4 °C overnight. 
The 10 ml solution was gently pipetted into a 2 ml column (Thermo Scientific) 
and allowed to run until the resin had settled. The resin was washed with 20 ml 
binding buffer then eluted with 8 ml IgG Elution Buffer (Thermo Scientific). 
Elutions were collected in 0.5 ml fractions and protein concentration was 
determined using the absorbance at 260 nm, measured on a BioPhotometer 
(Eppendorf) using water as a blank reference. For re-use, the column was 
washed with 20 ml wash buffer and stored upright at 4 °C. 
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2.5.1 Antibody storage 
Antibody solutions of 0.5 ml were neutralised with 25 µl 1 M Tris pH 9. Sodium 
azide was added, at a final concentration of 0.01% (w/v), to inhibit microbial 
growth, and glycerol was used, at a final concentration of 20%, as a 
cryoprotectant. Antibodies were stored at -20 °C. 
2.6 Immunostaining 
2.6.1 Western blotting 
Proteins from SDS-PAGE gels were transferred onto Hybond C-Super 
nitrocellulose membranes (Amersham) using the XCell SureLock XCell II Blot 
Module (Invitrogen) in the presence of transfer buffer [25 mM Tris, 192 mM 
glycine, 20% methanol] at 30 V for 1 h. Membranes were blocked in Tris-buffered 
saline (TBS) [10 mM Tris pH 8, 150 mM NaCl, pH 7.4] supplemented with 0.05% 
Tween-20 (TBST) and 5% (w/v) Marvel at 4 °C overnight. Freshly affinity-purified 
primary antibodies to either rISP1 or rISP2 were used at 1:50 (v/v) in TBST with 
5% (w/v) Marvel, and purified anti-oligopeptidase B (OPB) antibodies (Munday et 
al., 2011) were used at 1:20 000 (v/v) for 2 h at room temperature. The donkey 
anti-sheep IgG-HRP (Santa Cruz Biotechnology) secondary antibody was used at a 
1:10 000 dilution for 1 h. The reactive bands were detected using ECL Western 
Blotting Detection Reagent (Amersham). 
2.6.2 Immunofluorescence microscopy 
Parasites were harvested at 1000 x g for 5 min and washed twice in PBS at 1000 
x g for 3 min. Cells were resuspended in 100 µl PBS and fixed in 1% methanol-
free formaldehyde (Thermo Scientific) for 30 min at room temperature. Cells 
were permeabilised with 0.1% Triton X-100 detergent for 10 min then reactive 
products were neutralised with 0.1 M glycine for 10 min at room temperature. 
Cells were centrifuged at 2000 rpm for 10 min then resuspended in an 
appropriate volume of PBS. A volume of 200 µl of cells was added to each well of 
an 8-well chamber slide (Lab-Tek) and parasites were left to adhere to the slide 
for 10 min at room temperature. Excess PBS was removed from the well and 
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cells were blocked in blocking buffer [0.1% (v/v) Triton X-100, 0.1% (w/v) BSA, in 
PBS] for 1 h at room temperature. 
Freshly affinity-purified primary antibodies were used at a 1:50 (v/v) dilution in 
blocking buffer and slides were incubated for 2 h at room temperature. A 
secondary antibody only control was performed, in which blocking buffer was 
used instead of primary antibody, to determine background fluorescence. The 
wells were washed three times with PBS and incubated with donkey anti-sheep 
Alexa Fluor 488-conjugated antibody (Invitrogen) at 1:2000 (v/v) in blocking 
buffer for 1 h in a dark box at room temperature. The wells were washed three 
times in PBS, the chamber was removed, and VectaShield Mounting Medium with 
DAPI (Vector Laboratories) was applied to the slide. 
Cells were observed and imaged at 100x magnification on a DeltaVision RT or 
DeltaVision Core epifluorescent microscope (Applied Precision) equipped with 
DAPI (381-399 nm) and FITC (461-489 nm) filters, and images were captured with 
a CoolSNAP HQ or HQ2 camera (Photometrics) respectively. 
2.7 Flow cytometry 
2.7.1 Staining cell surface antigens 
All steps were performed at 4 °C and all centrifugation steps were performed at 
380 x g for 5 min. Single-cell suspensions from mouse ear or lymph nodes were 
incubated with an anti-Fc-γ III/II (CD16/32) receptor antibody (2.4G2, BD 
Biosciences) for 30 min, washed twice with PBS, then stained in the dark with 
the fluorochrome-conjugated antibodies, given in Table 2-5, for 30 min. The 
appropriate rat IgG2a, rat IgG2b, rat IgG2c, or Armenian hamster IgG isotype 
controls were used. After staining of surface markers, the cells were washed 
twice with PBS, and stained with Fixable Viability Dye eFluor 506 or eFluor 660 
(eBioscience) for 30 min, following the manufacturer’s protocol. The cells were 
washed twice in FACS buffer [1% dialysed FCS, 0.05% sodium azide, 2 mM EDTA, 
in PBS] then fixed with methanol-free formaldehyde (Thermo Scientific) for 5 
min. Cells were washed twice in FACS buffer, then resuspended in FACS buffer 
and passed through a Nitex mesh with a pore size of 50 µm (Cadisch). 
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2.7.2 Staining cytoplasmic intracellular antigens 
Single-cell suspensions were blocked with an anti-Fc-γ III/II (CD16/32) receptor 
antibody (2.4G2, BD Biosciences), cell surface antigens were stained, and 
Fixable Viability Dye eFluor 660 (eBioscience) was added as above. All 
subsequent steps were performed at room temperature and all centrifugation 
steps were performed at 380 x g for 5 min. The cells were then washed twice 
with PBS, pulse-vortexed and fixed in 100 µl IC Fixation Buffer (eBioscience) for 
20 min in the dark. Cells were washed twice in 1x Permeabilization Buffer 
(eBioscience) then cytoplasmic intracellular antigens, given in Table 2-5, were 
stained for 20 min in the dark. Cells were washed twice with FACS buffer, then 
resuspended in FACS buffer and passed through a Nitex mesh with a pore size of 
50 µm (Cadisch). 
Table 2-5 Antibodies used for flow cytometry.  
Marker Fluorophore Clone Manufacturer 
Cell surface antigens   
CD11b APC M1/70 eBioscience 
CD11b PE-Cy7 M1/70 eBioscience 
CD11c PE N418 eBioscience 
CD11c  PerCP-Cy5.5 N418 eBioscience 
CD45 APC-Cy7 30-F11 BD Biosciences 
CD80 (B7-1) FITC 16-10A1 eBioscience 
CD86 (B7-2) PE-Cy7 GL1 eBioscience 
F4/80 APC BM8 eBioscience 
Ly-6C eFluor 450 HK1.4 eBioscience 
Ly-6C PerCP-Cy5.5 HK1.4 eBioscience 
Ly-6G PE 1A8 BD Biosciences 
Ly-6G APC-Cy7 1A8 BD Biosciences 
Ly-6G (Gr-1) PE RB6-8C5 eBioscience 
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MHCII (I-A/I-E) APC-eFluor780 M5/114.15.2 eBioscience 
MHCII (I-A/I-E) eFluor 450 M5/114.15.2 eBioscience 
MHCII (I-A/I-E) FITC M5/114.15.2 eBioscience 
MHCII (I-A/I-E) FITC 2G9 BD Biosciences 
   
Cytoplasmic intracellular antigens   
Myeloperoxidase 
(MPO) 
FITC 8F4 Hycult Biotech 
NOS2 PE CXNFT eBioscience 
2.7.3 Data acquisition and analysis 
The data were collected using either a MACSQuant Analyzer (Miltenyi Biotec) or 
a BD LSR II Flow Cytometer (BD Biosciences), and analysed using FlowJo. 
Compensation settings were optimised using lymph node cells single-stained with 
anti-mouse CD4 antibodies conjugated to the corresponding fluorophores used in 
Table 2-5, (RM4-5, eBioscience and GK1.5, BD Biosciences). Live (based on 
Fixable Viability Dye staining) innate immune cells from the ear and draining 
lymph node were identified based on size (forward scatter) and granularity (side 
scatter), as well as by surface phenotype as indicated in the text and figure 
legends. 
2.8 Enzyme-linked immunosorbent assay (ELISA) 
The mouse IFN-γ ELISA Ready-Set-Go! kit (eBioscience) was used following the 
manufacturer’s protocol, using supernatant isolated from mouse ears and 
draining lymph nodes as samples. Plates were read on a Dynex MRX TC II 
microplate reader (Dynex Technologies) at 450 nm. 
2.9 Mice 
2.9.1 Regulations 
All procedures were conducted under Home Office Licence, after institutional 
ethical review. Prior to the removal of tissues or organs, mice were culled using 
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approved Schedule 1 methods, either by exposure to rising concentrations of 
carbon dioxide gas, generally for mice infected in the ear, or the dislocation of 
the neck for mice infected in the footpad. 
2.9.2 Strains 
Female BALB/cJ and C57BL/6J mice were purchased from Charles River 
Laboratories International, and female neutrophil elastase (NE)-deficient mice 
(129-S2-Ela2), Ela-/-, were obtained from the in-house breeding facility, but 
were originally from MRC Harwell. Mice were typically inoculated between 8 to 
14 weeks of age. 
Ela-/- were originally generated in the 129X1/SvJ background through the 
disruption of the endogenous NE gene with a targeting vector containing 
neomycin phosphotransferase cDNA driven by the phosphoglycerate kinase 
promoter (PGK-neo) (Belaaouaj et al., 1998). Mice were then backcrossed to 
C57BL/6 mice for at least 10 generations. 
2.9.3 Mouse infections and inoculations 
For intradermal inoculations, the ear dermis was inoculated with 104 metacyclic 
promastigotes in 10 μl PBS, and for the controls, injected with 10 μl PBS or with 
the needle only, whilst the mice were kept under general anaesthesia with 2% 
isoflurane/1.5 L O2.min
-1. Injections were performed using a 0.3 ml 29G insulin 
syringe (VWR). 
For subcutaneous inoculations, the footpad was inoculated with up to 2x106 
parasites in 40 µl. Injections were performed using a 0.3 ml 29G insulin syringe 
(VWR). Parasites were routinely passaged in BALB/c mice, in this manner, to 
maintain infectivity. Once the lesion size of the infected footpad was above 3 
mm, the mice were culled, and the footpads and draining popliteal lymph nodes 
were removed and placed into flasks containing HOMEM/10% FCS supplemented 
with 0.5% gentamicin solution (Sigma) then incubated at 25 °C to obtain 
promastigotes. 
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To elicit peritoneal macrophages, up to 0.5 ml of 3% thioglycollate was injected 
into the peritoneal cavity using a syringe with 25G needle attached, and mice 
were culled between 4 and 24 h later. Elicited peritoneal macrophages were 
used as positive controls for some flow cytometry experiments. Other 
intraperitoneal injections, of luciferin and luminol, were performed using a 1 ml 
syringe with 25G needle attached. 
2.9.4 Measurement of lesions and tissues 
2.9.4.1 Size measurements 
For lesion progression, the infected ear or footpad thickness was measured 
weekly with a dial caliper, with the uninfected ear or footpad as a control. 
Draining lymph nodes were removed and three diameter measurements were 
taken with a Vernier caliper. 
2.9.4.2 Mass measurements 
To obtain the mass measurements of the liver and spleen, glass universals 
containing a volume of HOMEM/10% FCS supplemented with 0.5% gentamicin 
solution were weighed before and after the addition of the excised organs. The 
difference corresponded to the mass of the organ. 
2.9.5 Tissue processing 
2.9.5.1 Flow cytometry 
Ears were deposited in PBS and cut repeatedly with surgical scissors, 4 mg ml-1 
collagenase D (Roche) and 100 U ml-1 DNase I were added, then the tissue was 
incubated in a Thermomixer Comfort Eppendorf shaking incubator (Eppendorf) at 
37 °C shaking at 1000 rpm for 45 min. Digested tissue was transferred to a 
gentleMACS C tube (Miltenyi Biotec) containing RPMI 1640 and processed in the 
gentleMACS dissociator (Miltenyi Biotec). Tissue homogenates were filtered 
through a 40 μm cell strainer (BD Biosciences). 
Draining retromaxillary lymph nodes were collected and mechanically 
dissociated with the back of a syringe through a 70 μm cell strainer (BD 
Biosciences). 
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Homogenised tissue samples were centrifuged at 380 x g for 10 min at 4 °C, 
washed in PBS, and resuspended in 1 ml PBS. Cell number was then determined 
by taking 10 µl of cells with a 1:1 ratio of cells to trypan blue (Sigma), and 
counting on a Neubauer chamber, as described earlier. 
2.9.5.2 ELISAs 
Ears and draining retromaxillary lymph nodes were removed and placed in ice-
cold PBS, samples were then transferred to 2 ml conical microcentrifuge tubes 
(Thermo Scientific) containing 500 µl T-PER Tissue Protein Extraction Reagent 
(Thermo Scientific) with 1% protease inhibitor cocktail (Roche). Lysis was 
performed by adding two 5 mm stainless steel beads (Roche) to each tube and 
running the samples on a TissueLyser LT (Qiagen) at 50 Hz for 2 min. Samples 
were then centrifuged at 13 000 rpm for 10 min at 4 °C. The supernatant was 
transferred to a new Eppendorf and stored at -80 °C. 
2.9.5.3 Limiting dilution assays (LDAs) 
Ears were sprayed with 70% ethanol and deposited in 500 µl HOMEM 
supplemented with 1% (v/v) penicillin/streptomycin, and 1% (v/v) gentamicin 
solution, cut repeatedly with surgical scissors, then digested with 4 mg ml-1 
collagenase D and incubated at 37 °C for 2 h. Digested tissue was transferred to 
a gentleMACS C tube and processed in the gentleMACS dissociator. Tissue 
homogenates were filtered through a 70 μm cell strainer (BD Biosciences). 
Draining retromaxillary lymph nodes were collected and mechanically 
dissociated with the back of a syringe through a 70 μm cell strainer (BD 
Biosciences). 
2.9.6 Peritoneal macrophage isolation 
Peritoneal macrophages were isolated from mice, either injected with 
thioglycollate or not, which were used as controls in flow cytometry. Mice were 
culled by CO2 asphyxiation. Mice were sprayed with 70% ethanol and the skin 
incised at the abdomen and pulled away to reveal the peritoneum, which was 
sprayed again with 70% ethanol. The cavity was filled with up to 10 ml RPMI 1640 
supplemented with 1% (v/v) penicillin/streptomycin and 0.5% gentamicin, using 
  Chapter 2 
51 
 
a charged syringe with 26G needle attached. The mouse was shaken for 30 sec to 
dislodge cells in the peritoneal cavity. The peritoneal fluid was removed using an 
empty syringe with a 21G needle attached. Cells were harvested by 
centrifugation at 1500 rpm for 10 min at 4 °C. Macrophages were then washed in 
PBS. 
2.9.7 Purification of amastigotes from tissues 
Mouse organs were removed, cut into small pieces and transferred to a Dounce 
glass tissue grinder with 400 ml PSGEMKA buffer (Hart et al., 1981) until no large 
pieces remained. Then 50 mg saponin was resuspended in 1 ml PSGEMKA buffer 
and added to the 400 ml crude suspension. The crude suspension was 
centrifuged at 3400 rpm for 10 min, the supernatant was discarded, and the 
pellet was washed three times in PSGEMKA buffer. The pellet was resuspended 
in a final volume of 100 ml PSGEMKA buffer.  A column was prepared with glass 
wool and a 100 ml sephadex solution (2.5 g sephadex CM25 swelled in 100 ml 
PSGEMKA at 4 °C overnight). The 100 ml amastigote suspension was pipetted 
into the column. The first 100 ml of flow-through was discarded and the 
subsequent volume collected as the amastigote preparation. The amastigote 
preparation was centrifuged at 3400 rpm for 10 min and the pellet was washed 
three times in PSGEMKA buffer. 
2.10 Quantification of parasite burden from tissues 
Quantification of parasite burdens were performed using the LDA method (Titus 
et al., 1985). Ear and lymph node homogenates were resuspended in 3.2 ml and 
1.6 ml HOMEM/20% FCS supplemented with 1% (v/v) penicillin/streptomycin 
respectively; liver and spleen homogenates were resuspended in 6.4 and 3.2 ml 
respectively. The cell homogenates were submitted to 2-fold serial dilutions in 
96-well flat-bottom plates. Samples were performed in duplicate. Plates were 
sealed and incubated in humidified box at 25 °C for 7 to 10 d, after which the 
wells were visually analysed for the presence of parasites. The highest dilution 
well was used to estimate the number of parasites multiplied by the dilution 
factors. Parasite numbers are given as total per tissue or organ. 
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2.11 Bioluminescence imaging (BLI) 
2.11.1 Preparation of luciferin 
A stock solution of D-luciferin potassium salt (Promega) was prepared at 15 mg 
ml-1 in PBS. The solution was filtered through a 0.2 µm syringe filter. Luciferin 
was administered at 150 mg per kg body weight, 10 µl per g body weight, 
intraperitoneally. 
2.11.2 Preparation of luminol sodium salt 
A stock solution of luminol sodium salt (Sigma) was prepared at 50 mg ml-1 in 
PBS. The solution was filtered through a 0.2 µm syringe filter. Luminol was 
administered at 200 mg per kg body weight, 4 µl per g body weight, 
intraperitoneally. 
2.11.3 BLI image analysis 
Mice were anaesthetised at 4% isoflurane/1.5 L O2 min
-1 then bioluminescent 
light emission was imaged at 10 to 15 min after luciferin or luminol injection, 
using the IVIS Spectrum bioluminescence imaging system (Caliper Life Sciences). 
Mice were maintained under anaesthesia at 1.5% isoflurane/1.5 L O2 min
-1 whilst 
in the IVIS. Imaging was performed with an open emission filter, for 1 min 
exposures, large binning, and 1 f/stop, and captured with a charge-coupled 
device (CCD) camera. Analysis was performed using Living Image software 
(Caliper Life Sciences). The absolute unit of photon emission was given as 
radiance (photons/second/cm2/steradian). Regions of interest (ROIs) were 
manually selected over the entire ear to quantify the amount of photon emission 
as total photon flux in photons per second (photons sec-1). 
2.12 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5. The analysis of 
significance of the data was performed by an unpaired t-test when comparing 
data from WT and Δisp2/3 infections, or one-way ANOVA with Tukey post-test 
when comparing data from WT, Δisp2/3, and/or Δisp2/3:ISP2/3 or WT [pXG-
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ISP2] infections with controls, as indicated in the figures. Scores showing 
statistical significance are indicated in the figures with asterisks. 
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3 Localisation of the inhibitors of serine peptidases 
in Leishmania major 
3.1 Introduction 
3.1.1 ISP expression during the Leishmania lifecycle and 
inhibitory activity against host serine peptidases 
Three ecotin-like peptide inhibitors of serine peptidases, ISPs, have been 
identified in the L. major genome, designated ISP1, ISP2, and ISP3. Of the three 
ISPs, only ISP1 and ISP2 are detected at the protein level during the Leishmania 
lifecycle (Eschenlauer et al., 2009). ISP3 is not detected in any of the 
Leishmania lifecycle stages and has been suggested to be a pseudogene. There 
does, however, appear to be stage-regulated expression of ISP1 and ISP2; ISP1 is 
expressed during the vector-borne promastigote stages, whereas ISP2 is 
expressed in all three lifecycle stages, with particularly high levels in the 
infective metacyclic promastigote and amastigote stages (Eschenlauer et al., 
2009). 
The inhibitory activities of ISP1 and ISP2 have been tested against serine 
peptidases that L. major may come into contact with during its lifecycle, either 
in the mammalian host or the sandfly vector. The SPs chosen included those of 
the S1A trypsin-fold peptidase family of clan PA(S), of which bacterial ecotin has 
already been shown to inhibit (Chung et al., 1983; Eggers et al., 2004). 
Unexpectedly, however, recombinant ISP1 has been shown to have no inhibitory 
activity towards bovine trypsin, and low inhibitory activity against human NE, 
with only 50% inhibition at 670 nM (Morrison et al., 2012). Recombinant ISP1 also 
has low inhibitory activity against sandfly midgut extract with only 40% inhibition 
at 6.7 µM, compared to 60% inhibition at 2 nM for recombinant ISP2 (Morrison et 
al., 2012). ISP1 was, in fact, shown to have an endogenous role in flagellar 
homeostasis of Leishmania promastigotes (Morrison et al., 2012), the target of 
which is, as yet, unidentified, as Leishmania lack endogenous S1A serine 
peptidases (Ivens et al., 2005). 
Recombinant ISP2, however, has been shown to inhibit the human serine 
peptidases, NE, trypsin, and chymotrypsin with Kis of 7.7 (±1.4) nM, 83 (±2.3) 
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nM, and 19 (±4.2) nM respectively (Eschenlauer et al., 2009). These data 
indicate a potential role for ISP2 in the inhibition of host SP activity. 
3.1.2 Serine peptidases and the S1A serine peptidase family 
SPs are ubiquitously found in prokaryotes and eukaryotes, and are responsible 
for various functions in humans and other mammals, including immunity, 
digestion, development, reproduction, blood coagulation, and fibrinolysis. As of 
2014, the SPs have been grouped into 16 clans, based on catalytic mechanism, 
and 53 families, based on common ancestry. The majority of SPs belong to the 
S1 family of clan PA, of which there are subfamilies that are distinguished based 
on their substrate specificity; these are trypsin-like, chymotrypsin-like, and 
elastase-like serine peptidases. Leishmania spp., including L. major, L. 
mexicana, L. infantum, and L. braziliensis lack S1 serine peptidase homologues. 
There are six subfamilies within the S1 family, but subfamilies S1A and S1B are 
the most well-defined, in that S1B serine peptidases are involved in intracellular 
protein turnover, whereas S1A peptidases mediate extracellular processes. Like 
ecotin, ISP2 has been shown to have inhibitory activity against S1A serine 
peptidases, suggesting it may be involved in protecting the parasite against the 
digestive S1A serine peptidases in the sandfly gut and/or modulating the immune 
response in the mammalian host through the inhibition of the activity of host SPs 
with roles in immunity. However, the inhibitory activity of neither ecotin nor the 
ISPs has been tested against SPs of the other S1 subfamilies. 
3.1.3 S1A serine peptidase expression in the sandfly vector 
Trypsin and chymotrypsin are two of the most studied S1A serine peptidases. 
These SPs are common endoprotease digestive enzymes, found in the digestive 
systems of many species of animals including blood-feeding arthropods. Trypsin 
and chymotrypsin are the main digestive enzymes in the midgut of Diptera flies, 
which includes the subfamily Phlebotominae (Ramalho-Ortigão et al., 2003; 
Telleria et al., 2010). These SPs are produced and secreted by midgut epithelial 
cells upon the ingestion of blood and are active within the midgut lumen. They 
have been shown to be a potential barrier to Leishmania growth and 
development; however, the peritrophic membrane, a matrix secreted by the 
  Chapter 3 
56 
 
midgut epithelium that separates the blood meal from the midgut tissue, 
typically protects Leishmania from these enzymes. 
3.1.4 S1A serine peptidase expression in the mammalian host 
Upon inoculation of Leishmania into the skin of the mammalian host, a local 
inflammatory immune response is initiated, and Leishmania encounter innate 
immune cells and their antimicrobial components, including SPs. The most 
abundant leukocyte in mammals, the neutrophils, are a major source of SPs, and 
are the first immune cells to be recruited to the site of Leishmania infection. 
Three S1A serine peptidases, often referred to as neutrophil serine peptidases 
(NSPs), NE, CG, and proteinase 3 (PR3), are stored in high concentrations in the 
cytoplasmic azurophilic (or primary) granules of neutrophils. Azurophilic 
granules also contain other antimicrobial factors, such as MPO and defensins, as 
well as a monocyte chemotactic antibiotic protein, azurocidin. However, NE is 
also localised in the nuclear envelope (Clark et al., 1980; Benson et al., 2003). 
Granules fuse with the phagolysosome, a cytoplasmic body formed upon 
sequestration of microorganisms by the fusion of the phagosome with a 
lysosome. In conjugation with antimicrobial factors, these NSPs digest 
phagocytosed microorganisms within the phagolysosomes. 
Catalytically active NSPs can also be released extracellularly from both activated 
and apoptotic neutrophils, as they also play a vital role in the modulation of the 
immune response through the processing of cytokines, chemokines, and growth 
factors, as well as the cleavage and activation of specific cell surface receptors 
(reviewed in Pham, 2008). Extracellular secretion occurs by highly controlled 
exocytosis upon neutrophil activation at sites of inflammation. Extracellular 
NSPs can bind to the neutrophil cell surface through interactions with 
chondroitin sulfate and heparin sulfate proteoglycans; there is up to a 20-fold 
increase in neutrophil surface-bound NSPs upon neutrophil activation (Campbell 
& Owen, 2007). Surface-bound NSPs function in the regulation of leukocyte 
function by peptidase signalling through cell surface binding sites or other 
surface proteins. 
In addition, activated neutrophils release NETs, which are web-like structures of 
decondensed chromatin that ensnare extracellular microorganisms, in an active 
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process termed NETosis (Brinkmann et al., 2004). NSPs are found bound to NETs 
in high concentrations, along with histones, active MPO, and other antimicrobial 
peptides (Papayannopoulos et al., 2010; Metzler et al., 2011). 
Inflammatory monocytes are another source of all three of the mentioned NSPs, 
whilst other sources of NE and PR3 include mast cells and the other 
granulocytes, the eosinophils and basophils. CG and NE have both been shown to 
localise to peroxidase-positive cytoplasmic granules in monocytes (Kargi et al., 
1990); whilst in mast cells, eosinophils, and basophils, NE has been found in 
secretory granules. NE has also been found in association with CR3 on 
neutrophils, macrophages, and NK cells (Cai & Wright, 1996). 
Immunofluorescence performed by Faria et al. (2011) revealed that NE was 
localised to the surface of elicited macrophages from C57BL/6 mice. 
3.1.5 Aims 
The protein expression of the ISPs throughout the Leishmania lifecycle has 
previously been reported (Eschenlauer et al., 2009); however, the localisation of 
the ISPs within these lifecycle stages has not been investigated. In vitro studies 
have shown that L. major ISP2 inhibits the activity of NE, which in turn prevents 
the activation of a TLR4-NE signalling cascade in macrophages (Faria et al., 
2011). The aim of this chapter is to determine the localisation of ISP1 and ISP2 
within L. major promastigotes and amastigotes to provide an indication of 
potential interactions of the ISPs with the host SPs. 
3.2 Results 
3.2.1 Validation of affinity-purified anti-ISP1 and anti-ISP2 
antibodies 
To determine the localisation of ISP1 and ISP2 in L. major WT, polyclonal 
antibodies were first affinity-purified from sheep serum using the AminoLink Plus 
Coupling Resin (Thermo Scientific). The cross-reactivity of the anti-ISP1 and 
anti-ISP2 antibodies was then tested against recombinant ISP1 (rISP1) and ISP2 
(rISP2) proteins (Figure 3-1, A and B), which had been expressed and purified 
from E. coli. The molecular weights of the recombinant ISPs were as expected 
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(Figure 3-1, A and B), as the predicted sizes of ISP1 and ISP2 are 16.5 kDa and 
17.5 kDa respectively (Eschenlauer et al., 2009). The ISP2 antibody did not cross-
react with ISP1 (Figure 3-1B), but the ISP1 antibody recognised both ISP1 and 
ISP2 (Figure 3-1A). The specificity of the ISP1 antibody was then tested against 
cell extracts from L. major WT promastigotes, an ISP2/3 double knock-out 
(Δisp2/3) generated by Eschenlauer et al. (2009), and an ISP1/2/3 triple knock-
out (Δisp1/2/3) generated by Morrison et al., 2012) (Figure 3-1C). It appears as 
though two bands were detected in WT parasite extracts, which could be due to 
the cross-reactivity of the ISP1 antibody resulting in detection of both the ISP1 
and ISP2, while only one band was detected in cell lines deficient in ISP2, 
Δisp2/3, representing ISP1 (Figure 3-1C). In accordance with this, no bands were 
detected in the extracts from Δisp1/2/3 parasites (Figure 3-1C). Antibodies 
against oligopeptidase B (OPB), an 83 kDa enzyme present in various Leishmania 
species including L. major, were used as to show equal loading of the protein 
samples (Munday et al., 2011). 
Previously, Eschenlauer et al. (2009) had shown that ISP1 and ISP2 are expressed 
in log-phase promastigotes, which they referred to as procyclic promastigotes, 
and in purified metacyclic promastigotes. Cell extracts were prepared from 
stationary-phase cultures for Figure 3-1, the populations of which consist of 
procyclic and metacyclic promastigotes, as well as the other intermediate forms, 
the nectomonad, leptomonad, and haptomonad promastigotes. Therefore, the 
levels of ISP expression in the cell lines are likely to vary between samples 
collected at different times, dependent upon the composition of the culture 
population, as ISP2 was shown to be more highly expressed in metacyclic 
promastigotes compared to the procyclic promastigotes (Eschenlauer et al., 
2009). This could explain the differences observed between ISP levels in the 
different Western blots, given in Figure 3-1, with extracts from the same cell 
line collected at different times. 
The antibodies were also tested against an ISP1 re-expressor (Δisp1/2/3:ISP1) 
(Figure 3-1D) and an ISP2/3 re-expressor (Δisp1/2/3:ISP2/3) (Figure 3-1E) in the 
triple knock-out background, generated by Morrison et al. (2012). ISP1 and ISP2 
were detected in the promastigote forms of WT, and the re-expressing cell lines, 
Δisp1/2/3:ISP1 and Δisp1/2/3:ISP2/3 (Figure 3-1, D and E respectively), but not 
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in Δisp1/2/3. Again, two bands were detected in Δisp1/2/3:ISP1 with the ISP1 
antibody (Figure 3-1D), this could indicate post-translational modification of 
ISP1, as in this cell line ISP2 should not be present and in the background cell 
line, Δisp1/2/3, no bands were detected. The expression of ISP1 and ISP2 in the 
re-expressing cell lines was higher than that detected in WT parasites (Figure 3-
1, D and E respectively), which has been shown to occur from genes integrated 
into the ribosomal locus under a polymerase I promoter (Lodes et al., 1995; 
Misslitz et al., 2000). 
Additionally, the ISP2 antibody was used to confirm the presence or absence of 
ISP2 in the cell lines, which would be used for in vivo experiments, discussed in 
Chapters 4 and 5. These cell lines included an ISP2 over-expressor (WT [pXG-
ISP2]) generated by Morrison et al. (2012) (Figure 3-1F), and an ISP2/3 re-
expressor in the double knock-out background (Δisp2/3:ISP2/3) generated by 
Eschenlauer et al. (2009) (Figure 3-1G). A single band, around 17 kDa, the 
predicted size for ISP2, was detected in the extracts from WT, WT [pXG-ISP2], 
and Δisp2/3:ISP2/3 parasites, but not Δisp2/3 parasites. The expression of ISP2 
in the overexpressing cell line, which express ISP2 from episomal plasmids, and 
the re-expressing cell line was, again, higher than that detected in WT parasites 
(Figure 3-1, F and G respectively). 
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Figure 3-1 Validation of anti-ISP antibodies against extracts from L. major ISP gene mutants. 
Western blots of recombinant ISP1 and ISP2 using purified A) anti-ISP1 (α-ISP1) or B) anti-ISP2 (α-
ISP2) primary antibody. Western blots of cell extracts from 107 promastigotes of L. major WT, 
Δisp1/2/3, Δisp1/2/3:ISP1, Δisp1/2/3:ISP2/3, WT [pXG-ISP2], Δisp2/3, or Δisp2/3:ISP2/3 using 
purified C and D) α-ISP1, or E to G) α-ISP2. Antibodies against oligopeptidase B (OPB) were used 
as a loading control. 
A B 
C D 
E F 
G 
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3.2.2 Immunolocalisation of ISP1 and ISP2 
To determine the localisation of ISP1 and ISP2 in L. major promastigotes, 
immunofluorescence was performed using the ISP antibodies against 
promastigotes from culture. The Δisp1/2/3 cell line was chosen as a negative 
control; as neither α-ISP1 nor α-ISP2 had cross-reacted with extracts from this 
cell line in the Western blots (Figure 3-1, C to E). ISP1 and ISP2 were not 
detected in immunofluorescence performed with the Δisp1/2/3 promastigotes 
(Figure 3-2, A and B respectively), including in the intermediate promastigote 
form, the haptomonad (Figure 3-2, C and D respectively), which is easily 
distinguished from the other promastigote forms by the hemidesmosome 
structure, an expansion of the flagellar tip (Wakid & Bates, 2004). 
In L. major WT promastigotes, ISP1 and ISP2 were generally localised in the 
cytosol, with punctate distribution, and along the flagellum, with a noticeable 
accumulation at the tip of the flagellum (Figure 3-2, G to I). There was also 
prominent labelling of ISP1 and ISP2 in the haptomonad promastigotes, with an 
accumulation in the hemidesmosome structure (Figure 3-2, E and F). The 
hemidesmosome is an expansion of the flagellar tip that enables attachment of 
haptomonads to the cuticular intima of the stomodeal valve in the sandfly 
(Killick-Kendrick et al., 1974; Walters et al., 1989). ISP2 was also present on the 
cell surface of the haptomonad promastigotes (Figure 3-2F), which was not 
observed for ISP1 (Figure 3-2E). 
  Chapter 3 
62 
 
 
Figure 3-2 ISP1 and ISP2 localisation in L. major promastigotes. Fixed L. major promastigotes 
were labelled with α-ISP1 (A, C, E, G, and I) or α-ISP2 (B, D, and F) and donkey anti-sheep Alexa 
488-secondary antibody. Nuclear and kinetoplast DNA were stained with DAPI. Left panel, DIC 
image. Right panel, merged image of ISP (green) and DAPI (blue). Scale bar = 5 µm. 
Eschenlauer et al. (2009) previously showed that only ISP2 was expressed in the 
amastigote lifecycle stage. To determine where ISP2 is localised, amastigotes 
were harvested from the footpads of L. major WT- and Δisp2/3-infected mice 
and labelled with the ISP2 antibodies. The Δisp2/3 cell line was used as a 
negative control in these experiments, as ISP2 had not been detected in the 
extracts from this cell line in the Western blots (Figure 3-1G), and this cell line 
would be used for the following in vivo infections in Chapters 4 and 5. ISP2 was 
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not detected in immunofluorescence performed with the Δisp2/3 amastigotes, 
and as was observed in the promastigotes, ISP2 in WT amastigotes had punctate 
localisation within the cytosol (Figure 3-3). 
 
Figure 3-3 ISP2 localisation in L. major amastigotes. Fixed L. major amastigotes were labelled 
with α-ISP2 and donkey anti-sheep Alexa 488-secondary antibody. Nuclear and kinetoplast DNA 
were stained with DAPI. Left panel, DIC image. Right panel, merged image of ISP2 (green) and 
DAPI (blue). Scale bar = 5 µm. 
3.3 Discussion 
Ecotin of Gram-negative bacteria is a periplasmic protein, which has been shown 
to be required for Burkholderia pseudomallei infection of macrophages (Chung 
et al., 1983; Ireland et al., 2014). L. major ISP1 and ISP2 were generally 
localised in the cytosol and along the flagellum in the promastigote stage of the 
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Leishmania lifecycle (Figure 3-2, G to I), with a similar cytosolic localisation of 
ISP2 in the amastigote stage (Figure 3-3). 
Interestingly, ISP1 and ISP2 showed prominent labelling in the hemidesmosome 
structure of haptomonad promastigotes (Figure 3-2, E and F), which are one of 
the intermediate promastigote forms found during development in the sandfly 
vector. The hemidesmosome is involved in the attachment of haptomonad 
promastigotes to the chitin lining of the stromodeal valve in the sandfly (Killick-
Kendrick et al., 1974). However, the proteomic composition and further 
potential roles of the hemidesmosome are still unknown. The localisation within 
the other promastigote forms, the procyclic, nectomonad, leptomonad, and 
metacyclic promastigotes, was not assessed on an individual basis as there are 
only subtle morphological differences, such as the length of the cell body and 
flagellum, by which to distinguish these forms (Rogers et al., 2002); however, all 
the promastigotes observed and imaged had the same cytosolic and flagellar 
localisation. High resolution immuno-electron microscopic analysis could be 
performed to further determine the subcellular localisation of ISP1 and ISP2 in L. 
major WT promastigotes. The hemidesmosome localisation, in addition to the 
flagellar localisation, would mean that the ISPs are in close contact with the 
sandfly SPs, such as trypsin and chymotrypsin, which ISP2, in particular, has 
been shown to inhibit (Eschenlauer et al., 2009). ISP2 could, therefore, aid in 
the protection against the proteolytic activity of these enzymes in the sandfly 
gut (Borovsky & Schlein, 1987). In addition, metacyclic promastigotes are 
internalised by neutrophils, which are considered the first host cell type for 
Leishmania; azurophilic granules containing NSPs fuse with the Leishmania-
containing phagosomes (Mollinedo et al., 2010). Microorganisms are degraded in 
these vacuoles due to acidification and exposure to antimicrobial peptides and 
proteolytic enzymes, which occurs through the fusion of tertiary granules. 
However, Leishmania are able to survive in the intracellular environment of the 
neutrophil, as they can selectively prevent the fusion of tertiary granules 
impeding phagosome acidification and ROS production (al Tuwaijri et al., 1990; 
Mollinedo et al., 2010). There are no reports that host proteases directly affect 
Leishmania viability, which may be due to the inhibition of NSPs by ISP2. 
Furthermore, targets of the NSPs, such as the cytokines and cell receptors, are 
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not present in this environment; therefore, it is unlikely that the inhibition of 
intracellular NSPs by ISP2 affects cellular responses in neutrophils. 
ISP1, which is only expressed, in the promastigote lifecycle stages (Eschenlauer 
et al., 2009), has low inhibitory activity against trypsin and NE, and has been 
shown to have an endogenous role in flagellar pocket dynamics and promastigote 
differentiation (Morrison et al., 2012). ISP1 may target an exogenous SP that has 
yet to be identified.  
ISP1 and ISP2 have not been detected in the Leishmania secretome (or 
exoproteome) (Silverman et al., 2008; Peysselon et al., 2013), in which over 300 
proteins are secreted in a non-classical, vesicle-based mechanism (Silverman et 
al., 2010a). The vast majority of characterised Leishmania secreted proteins do 
not have an identifiable secretion signal sequence, typically only GPI-anchored 
surface proteins, such as gp63, LPG, and PPGs, have a signal sequence 
(Silverman et al., 2008). Protein secretion from Leishmania can be induced by a 
temperature shift, as would be experienced by the parasite during transition 
from the sandfly vector, around 25°C, to the mammalian host at 37°C 
(Silverman et al., 2010a; Hassani et al., 2011). Leishmania exosomes (or 
microvesicles) have been implicated in the priming of host target cells for 
Leishmania invasion and the modulation of host immune responses (Silverman et 
al., 2010b; Hassani et al., 2011). L. donovani exosomes had immunosuppressive 
effects of human monocytes and moDCs, but this was dependent upon the 
composition of the exosome cargo (Silverman et al., 2010b). Further studies are 
required into the potential exosome localisation of the ISPs. In vitro assays by 
Faria et al. (unpublished) showed that L. major WT and Δisp2/3:ISP2/3 
promastigotes, but not Δisp2/3 promastigotes, inhibit cytokine secretion from 
macrophages, but this does not occur in Transwell plates. In the Transwell 
assays, parasites were separated from the macrophages suggesting that the 
parasites do require contact to exert the effects associated with ISP2. 
L. major amastigotes also showed cytosolic localisation of ISP2. Leishmania 
metacyclic promastigotes differentiate into amastigotes inside the PV of 
macrophages and DCs (Courret et al., 2002; Körner et al., 2006). Macrophages 
are recruited to the site of Leishmania inoculation at 2 to 3 d post-infection to 
become the main host cell type for the productive Leishmania infection 
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(Thalhofer et al., 2011; Ribeiro-Gomes et al., 2012). SPs have not been detected 
in the PVs of macrophages and DCs, but NE has been found localised to the cell 
surface of macrophages, possibly in association with CR3 (Cai & Wright, 1996; 
Faria et al., 2011). It is still not known whether macrophage clearance of 
apoptotic neutrophils harbouring parasites leads to the indirect uptake of 
Leishmania (van Zandbergen et al., 2004), or parasites escape or are released 
from apoptotic neutrophils and are taken up directly by macrophages together 
with the apoptotic cells (Peters et al., 2008; Ritter et al., 2009). Once the 
parasites have been internalised by the macrophages and DCs, however, it is 
unlikely that ISP2 will have any effect, as the NSPs are primarily found bound to 
the surface of these cells, or in the extracellular environment. NE released from 
neutrophils has been shown to induce parasite killing in L. major-infected 
C57BL/6 macrophages in vitro (Ribeiro-Gomes et al., 2004, 2007). However, in 
vivo the number of neutrophils present at the site of Leishmania infection is very 
low by the time macrophages become the predominant infected host cell. In 
addition, there will be extracellular parasites present; therefore, the neutrophil-
macrophage co-cultures used by Ribeiro-Gomes et al. (2004, 2007) may not 
reflect the situation at the site of infection in vivo.  
It has also been reported that C57BL/6 mice infected with L. mexicana have 
higher numbers of degranulated mast cells than BALB/c mice at 3 d post-
infection (Villaseñor-Cardoso et al., 2008). Mast cells are another source of NE 
and PR3. ISP2 may have effects throughout Leishmania infection due to the 
continuous cellular recruitment of SP sources. It is not clear how amastigotes are 
released from macrophages and DCs; the cells may burst or the PVs may be 
released by exocytosis. ISP2 from extracellular amastigotes could possibly inhibit 
the activity of NSPs released by cellular degranulation events, as has been shown 
with neutrophils and mast cells that occur later in Leishmania infection. It was 
hypothesised by Eschenlauer et al. (2009) and Faria et al. (2011) that ISP2 would 
have an effect during the early phase of mammalian infection, specifically on 
the innate immune response involving neutrophils. ISP2 of metacyclic 
promastigotes and amastigotes could, however, mean the inhibition of NSPs over 
the course of L. major infection. This means ISP2 could have a multitude of 
effects on Leishmania disease progression, due to differential concentrations of 
NSPs, based on the cell populations present and timings of degranulation events, 
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as well as the numerous functions of NSPs in vivo, such as the regulation of cell 
recruitment and activation. 
Faria et al. (2011) showed that ISP2 inhibits the activity of NE; the other NSPs, 
CG and PR3, are also potential targets of ISP2 during Leishmania infection in the 
mammalian host. Once released from the innate immune cells into the 
extracellular environment, the NSPs are able to remain active through several 
mechanisms, despite the presence of naturally occurring protease inhibitors. The 
main inhibitor of NE, CG, and PR3 is α-1 antitrypsin (AAT, or α-1 proteinase 
inhibitor) from the serpin family, which is produced predominantly by 
hepatocytes, in addition to other sources including epithelial cells, neutrophils, 
and macrophages (Korkmaz et al., 2010). AAT is the most abundant serpin 
present in human blood at between 1.2 and 2 mg ml-1 in a healthy human. 
Monocyte neutrophil elastase inhibitor (MNEI) synthesised and secreted by 
neutrophils and macrophages also inhibits all three NSPs. Another inhibitor of CG 
is the serpin, α-1-antichymotrypsin (ACT). Serpins function by presenting their 
reactive site as a substrate for the protease, which traps the enzyme and 
distorts its catalytic site (Huntington, 2011). Elafin (or skin-derived 
antileukoprotease, SKALP) from the chelonianin family inhibits NE and PR3, and 
secretory leukocyte protease inhibitor (SLPI), also from the chelonianin family 
and secreted by epithelial cells, neutrophils, and macrophages, inhibits NE and 
CG. These inhibitors regulate excessive extracellular activity of the NSPs. 
However, the NSPs can evade the action of the host protease inhibitors. High 
local concentrations of NSPs at sites of inflammation can overwhelm the action 
of the protease inhibitors, and through the binding of NSPs to the surface of 
neutrophils and other innate immune cells, the protease inhibitors are unable to 
gain access to the NSPs. The addition of L. major ISP2 at the site of infection 
could overcome this protease-protease inhibitor equilibrium, and inhibit the 
activity of NSPs, leading to a modulation of the host immune responses. 
Faria et al. (2011) have previously shown that the NE produced by RAW 264.7 
monocytes/macrophages in vitro, which have not been exposed to other SP 
sources, was sufficient for the upregulation of L. major Δisp2/3 promastigote 
internalisation compared with that of WT promastigotes. In addition, ISP2 
produced by L. major WT was sufficient to inhibit the activity of NE found on 
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macrophages isolated from the peritoneal cavity of C57BL/6 mice preventing the 
upregulation of internalisation and the production of ROS. Macrophages are 
considered the main host cell for Leishmania spp. so these data are important in 
showing that ISP2 can suppress the microbicidal activities of these host cells to 
allow intracellular parasite survival and growth. However, in vivo there is an 
influx of other inflammatory cells to the site of infection, including neutrophils 
and monocytes, which are important sources of the putative target S1A serine 
peptidases. It is not known yet whether the internalisation and parasite killing 
processes of these phagocytic cell types are affected in the same way as the 
macrophages by L. major ISP2. There could be an important role for ISP2 in the 
establishment of the initial L. major infection, as neutrophils are considered the 
primary host cell type for Leishmania. Faria et al. (2011) also showed that ISP2 
produced by L. major WT is sufficient to inhibit the activity of NE on 
macrophages in vitro, however the case in vivo will likely be very different. The 
site of Leishmania infection will be flooded with SPs from multiple sources, 
including the neutrophils, monocytes, macrophages, and mast cells. Addition of 
exogenous NE to C57BL/6 macrophages during interaction with L. major WT and 
Δisp2/3 promastigotes in vitro caused an increase in internalisation of WT 
parasites in a dose-dependent manner, and reduced intracellular parasites at 72 
h post-infection, but there was no effect on the uptake of Δisp2/3 parasites 
(Faria et al., 2011). The addition of parasites to co-cultures of macrophages and 
neutrophils could give a better indication of whether the additional presence of 
NSPs from other innate cells affects the inhibitory activity of ISP2, consequently 
affecting the internalisation and parasite killing processes of the macrophages. 
This also poses the question as to whether the ISP2 produced by L. major is 
sufficient to inhibit the activity of NE to enable parasite survival in phagocytic 
cells in vivo. L. major Δisp2/3 parasites were internalised more efficiently by 
macrophages in vivo at 3 h after an intraperitoneal infection of C57BL/6 mice, in 
the presence of the resident and recruited cells (Faria et al., 2011). The parasite 
burdens within these macrophages were determined after 24 h of culture in 
vitro to evaluate parasite survival, which showed the same as the in vitro 
macrophage infection assays, with higher parasite burdens of L. major WT 
compared to Δisp2/3 parasites. 
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Although the expression of ISP2 is abundant in L. major WT, if there is no 
secretion of ISP2, will cell surface localisation allow for the inhibition of the 
extracellular SP activity and the activity of those that are bound to the surface 
of the innate immune cells? Furthermore, would this contribute to differences in 
disease progression depending on the initial parasite dose? Addition of exogenous 
NE promoted higher internalisation and reduced parasite burdens of L. major WT 
in vivo (Faria et al., 2011), which suggests the ISP2 produced by L. major WT is 
sufficient to inhibit the activity of the NE at the site of inoculation. In this case, 
however, an intraperitoneal infection was used, which is not the best model for 
L. major infection, as will be discussed in Chapter 4, as the parasites are able to 
disperse further, and therefore, the concentration of SPs may be lower, in 
contrast to the low dose intradermal inoculations of Leishmania, where the 
parasites and SPs are limited to the site of inoculation. In addition, it has been 
reported that the innate cell recruitment differs based on the site of 
inoculation, in that neutrophils are not necessarily the principal responders in 
peritoneal infections, which could alter the contribution of SPs in the different 
sites of inoculation (Ribeiro-Gomes et al. 2014). To address whether ISP2 is able 
to promote L. major survival in vivo, it would be useful to assess the parasite 
burden in infected macrophages from dermal sites.  
The activation of specific cell receptors by NSPs has also had an effect on the 
production and secretion of cytokines and chemokines: an increase in CXCL1 
(KC), CXCL2 (MIP-2), TNF-α, and IL-6 release has been observed from C57BL/6 
macrophages infected with L. major Δisp2/3 promastigotes compared with those 
infected with WT promastigotes (Faria et al., unpublished). This suggests that 
preventing the activation of the TLR4-NE signalling cascade by ISP2 could have 
additional effects that have not, as yet, been fully studied. One of the major 
functions of NSPs is the proteolytic modification of cytokines and chemokines 
(Pham, 2008). It is possible that these functions are also affected by the 
presence of L. major ISP2 in vivo, in that, inhibition of NSP activity could 
modulate the recruitment and activation of specific innate immune cell types in 
vivo, which will be discussed in Chapter 5. In Chapters 4 and 5, the role of L. 
major ISP2 in parasite survival and the modulation of innate immune responses 
in vivo will be assessed. 
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4 Comparison of parasite dissemination and 
burdens of L. major wild-type and ISP2 gene 
mutants in vivo 
4.1 Introduction 
4.1.1 Considerations for an experimental mouse model to mimic 
natural L. major infection 
At the site of Leishmania infection, there is a complex interplay between the 
parasites and the cells, and other components, of the host immune response. In 
vivo experimental animal models have been a powerful tool in dissecting these 
host-parasite interactions and elucidating the roles of immune cells, cytokines, 
chemokines, and signal transduction cascades, during infection with the 
different Leishmania species. However, heterogeneity in the parameters that 
can affect the immune response in animal models exists between studies. This 
creates a challenge in relating and assembling the findings made in such studies 
together in order to generate a potential description of the host immune 
responses that may be relevant to the human disease. To more reliably translate 
and extrapolate the discoveries made in animal models to that of the 
corresponding human disease, there is a requirement for a reproducible model 
of “natural” infection, with focus on L. major infection, as proposed by Belkaid 
et al. (2000). In terms of the animal model, these factors include the host 
species or strain, the sex and age of the host, and the site of inoculation. Whilst 
in terms of the parasite, these include the L. major strain, the inoculation dose, 
and the lifecycle stage. Other considerations are the method of parasite 
delivery, whether parasites are delivered by needle inoculation or sandfly bite, 
the needle gauge, the volume of parasite suspension injected, and the use of 
sandfly salivary components, as well as the time-points after infection which are 
assessed. 
The inbred mouse strains, C57BL/6 and BALB/c, have long been used to 
investigate the mechanisms involved in the differentiation of polarised Th1 or 
Th2 responses during L. major infection that control resistance or susceptibility 
to infection respectively. The resistance and susceptibility disease phenotypes of 
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mouse strains to L. major infections have been determined based on their ability 
to resolve cutaneous lesions, the parasite burdens at the site of inoculation and 
in the dLNs, and the T helper response profile induced during infection. The 
homogeneity of the genetic backgrounds of the defined inbred mouse strains has 
provided reproducible systems for studying the immune responses in 
experimental diseases that resemble the spectrum of clinical manifestations of 
leishmaniasis observed in humans. Obviously, this is not the case in human 
disease, where the host genetics of the individual can affect the outcome of 
disease, but this is impossible to replicate in experimental models of infection. 
L. major infection in BALB/c mice leads to the development of non-healing 
lesions due to uncontrolled parasite replication, which is attributed to the 
development of Th2 cells (Locksley et al., 1991). The C57BL/6 mouse model, 
however, is thought to be more relevant to the human cutaneous disease, due to 
the spontaneous healing of localised lesions following L. major infection, which 
is typically seen in immunocompetent patients with cutaneous leishmaniasis. 
The resistance phenotype of C57BL/6 mice involves the production of IFN-γ by 
Th1 cells, which stimulates the synthesis of iNOS generating the production of 
NO, a potent cytotoxin responsible for the killing of Leishmania parasites 
(Locksley et al., 1991; Park et al., 2000). There are other murine models 
available, which exhibit resistance to L. major, including C3H/He, CBA/H, and 
129/Sv (Lipoldová & Demant, 2006), although these models are less frequently 
used because less is known about the immune response mechanisms mediating 
the resistance to L. major in these models. Recently, humanised mice, in which 
human hematopoietic stem cells are transplanted into immunodeficient NOD-
scid IL2rγnull mice, have been used to characterise L. major infection in the 
context of the cellular components of the human immune system, such as T, B, 
and NK cells (Wege et al., 2012). This novel model of a human immune system in 
a murine environment could be useful to characterise interactions between 
specific human immune cell subsets and the Leishmania parasites; however, a 
systemic disease, with no self-healing, developed upon L. major infection, which 
is not indicative of an L. major infection in immunocompetent humans. It is 
important to take into account the genetic background of transgenic mice used 
in studies for the selection of appropriate controls, and to be able to explain 
discoveries in the context of human disease. Often overlooked is the fact that 
differences have been reported in the immune response of the mouse models to 
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Leishmania attributed to the sex and age of the host (Giannini, 1974; Alexander, 
1988; Snider et al., 2009). To reduce biological variation in studies, mice are of 
the same strain and sex, and are often age-matched. 
Generally lesion size over the course of L. major infection is taken as a measure 
of disease progression. Weekly dial or vernier caliper measurement of footpad 
thickness after subcutaneous inoculation of L. major is the simplest technique to 
track lesion formation and resolution. However, sandfly bites are typically 
intradermal, rather than subcutaneous or intraperitoneal, as the proboscis is less 
than 0.5 mm in length, and so can only penetrate the superficial layers of the 
skin. Intradermal inoculations can be performed at the base of the tail or in the 
ear pinna. The skin is comprised of specialised cells, such as keratinocytes, LCs, 
as well as dermal macrophages and DCs, which rapidly respond to tissue damage 
and pathogen invasion by producing inflammatory mediators. The cellular 
composition of the skin can vary so even the site of intradermal inoculation, the 
tail or ear, can affect the generation of the T helper cytokine profile, in terms 
of IFN-γ and IL-4, and the severity of disease (Baldwin et al., 2003). Differences 
in the cellular compositions of the tissue at the site of inoculation can affect the 
production of inflammatory mediators and the recruitment of innate immune 
cells, as has been shown in the phagocyte response to intradermal, 
subcutaneous, and intraperitoneal inoculation of L. major (Goncalves et al., 
2011; Ribeiro-Gomes et al., 2014). 
L. major Friedlin, a laboratory substrain first isolated from a patient in Israel, is 
often used to study L. major infections, as this substrain has been completely 
sequenced and is easily available (Ivens et al., 2005; Peacock et al., 2007). 
When investigating the role of Leishmania virulence factors in host-parasite 
interactions and disease progression it is necessary to use a laboratory strain, of 
which the gene sequence is known, in order to genetically manipulate the 
parasites to generate cell lines deficient in, or harbouring mutant versions of, 
the putative virulence factor. Other L. major substrains are occasionally used 
including LV39, isolated from a gerbil in Russia, and IR75 and IR173, which were 
isolated from humans in Iran. Different substrains have been shown to induce 
distinct immune responses, as has been shown in the role of B cells in the 
development of Th2 responses for the susceptibility of BALB/c mice to LV39 
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infection, but not IR75 or IR173 (Ronet et al., 2008). In addition, to achieve the 
same level of parasite killing in infected macrophages, LV39 has been shown to 
require 25 to 500-fold greater concentrations of IFN-γ than that required for the 
killing of IR173 (Noben-Trauth et al., 2003). All these substrains have been 
continually passaged in vitro; long-term in vitro culture has been demonstrated 
to reduce Leishmania infectivity and virulence in animal models compared to 
those which have been passed through animals (Giannini, 1974). Substrains may 
also differ from wild L. major strains isolated from patients (Kébaïer et al., 
2001). 
The average number of parasites transmitted by individual sandflies has been 
determined to be less than 1000 per bite, although the range is from 100 to 100 
000 parasites per bite, of which the majority are metacyclic promastigotes 
(Warburg & Schlein, 1986; Kimblin et al., 2008; Rogers et al., 2010). Parasites 
collected in the stationary-phase of in vitro growth are heterogeneous 
populations composed of procyclic, nectomonad, leptomonad, haptomonad, and 
metacyclic promastigotes, of which metacyclic promastigotes comprise less than 
20% of the population (da Silva & Sacks, 1987; Morrison et al., 2012). L. major 
metacyclic promastigotes can be purified through negative selection with peanut 
agglutination (Sacks et al., 1985), which enables control over the composition of 
the promastigote inoculation into the experimental model. The infective 
amastigote lifecycle stage can also be used in infections; these can be harvested 
from the lesions of infected animals and immediately re-inoculated into the 
experimental model, or grown in axenic culture (Wenzel et al., 2012). The use 
of amastigotes for in vivo infection does not reflect a natural sandfly-derived 
infection, however, if a putative virulence factor is differentially expressed or 
stage-specific it may be necessary to use amastigotes (Leifso et al., 2007). High 
dose inoculation of parasites or the inoculation of amastigotes has been used in 
studies to induce a faster or greater immune response to the parasites. It has 
been shown that the use of low dose inocula, 100 metacyclic L. major 
promastigotes, produces a “silent” phase of parasite growth, in which parasites 
are present but there is no detectable lesion over the first few weeks of 
infection (Lira et al., 2000; Kimblin et al., 2008), which may prevent the 
detection of differences between the infection profiles caused by different cell 
lines. However, excessive parasites present in high dose inocula may be 
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internalised by other immune cell types, forcing an immune response that may 
not be representative of a “natural” infection. 
The proboscis of the sandfly is less than 0.5 mm long with a diameter of around 
30 µm (Peters et al., 2008); there are no syringe needles available that can 
replicate these dimensions, so it is important to consider the needle gauge and 
the depth at which the inoculation is performed. It is important to distinguish 
the parasite-specific immune responses from the inflammatory responses to 
tissue damage, as has been demonstrated by Peters et al. (2008), who showed 
that neutrophil recruitment to needle injection in the absence of parasites was 
not as prolonged as when parasites were inoculated. In addition, the volume of 
saline, in which the parasites are often suspended, may contribute to tissue 
damage. 
During a sandfly bite, salivary components are transmitted along with the 
Leishmania parasites. Selective components of the sandfly saliva, such as anti-
hemostatic or immunomodulatory molecules, or homogenised salivary gland 
lysate or salivary gland sonicate (SGS), can be co-inoculated with Leishmania 
into experimental models, which has been shown to exacerbate the disease, 
producing destructive lesions with greater parasite burdens (Titus & Ribeiro, 
1988; Belkaid et al., 1998). Pre-exposing mice to the bites of uninfected 
sandflies, SGS, or specific salivary proteins, however, abrogates these effects 
(Kamhawi et al., 2000; Teixeira et al., 2014). In Leishmania endemic regions, it 
is likely that individuals will have prior exposure to sandfly saliva from the bites 
of uninfected sandflies. The composition of the sandfly saliva is likely to vary 
between sources, in terms of the sandfly species and on an individual sandfly 
basis. If the purpose of a study is to investigate the role of a putative Leishmania 
virulence factor in vivo, the addition of sandfly saliva components prior to or 
upon Leishmania infection may mask the effects caused by the virulence factor. 
In this study, disease progression and immune cell dynamics at the site of 
infection and in the dLN was assessed in response to L. major Friedlin WT and 
ISP2 gene mutant infection, using a low-dose intradermal model of infection. 
Resistant C57BL/6 mice, female and usually 8 to 10 weeks old upon inoculation, 
were used. Mice were infected using a 29G insulin needle, which has a 0.3 mm 
needle diameter, into the ear dermis with a parasite inoculation dose of 10 000 
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purified metacyclic L. major promastigotes in only 10 µl PBS. A dose of 10 000 
metacyclic promastigotes was chosen, as it was within the range determined for 
the number of parasites transmitted by a sandfly bite, and thought to enable 
differences between the immune responses to L. major WT and the ISP2 gene 
mutants to be more easily observed. Salivary gland components were not used, 
as the intention of this study is to determine the differences caused by L. major 
ISP2. The expression of ISP2 has been shown to be more highly expressed in 
metacyclic promastigotes and amastigotes compared to procyclic promastigotes 
(Eschenlauer et al., 2009); therefore, it is expected that if ISP2 is to have an 
effect on the modulation of the host immune responses, it will be upon the early 
responses. 
4.1.2 The luciferase gene reporter system 
To quantify parasite burden in vivo at a specific time-point during infection, 
often large groups of animals must be euthanised and the tissue of interest 
taken for microscopic examination, limiting dilution analysis (LDA), or 
quantitative PCR (qPCR) amplification of parasite DNA. These estimations are 
often based on a limited sample size, which may not be representative of the 
parasite burden in the entire organ, particularly if not all the infected tissue is 
excised or analysed. Non-invasive bioluminescence imaging (BLI) of luciferase-
expressing pathogens in live animals has been available for almost 20 years 
(Contag et al., 1995). Real-time imaging of luciferase-expressing parasites in 
vivo has negated the use of numerous animals for the purpose of determining 
parasite burdens and tracking disease progression, in accordance with the 
National Centre for the Replacement, Refinement and Reductions of Animals in 
Research (NC3Rs). Animals are inoculated with the luciferase-expressing 
parasites then injected with D-luciferin substrate at each imaging time-point, 
which enables real-time longitudinal imaging of live, metabolically active 
parasites in the same individual animals over the entire course of the 
experiment. D-luciferin is rapidly oxidised with adenosine triphosphate (ATP) by 
the luciferase-emitting photons, and this bioluminescent signal can be detected 
with a charge-coupled device (CCD) camera in an in vivo imaging system (IVIS) to 
non-invasively visualise and monitor the infections inside the live animal. The 
use of the same animals also minimises the biological variation often seen within 
  Chapter 4 
76 
 
and between animal groups, and between time-points investigated in the 
parasite burden quantification methods.  
In vivo BLI has become a powerful tool in following the dissemination of 
pathogens at the tissue/organ level in many infectious disease models, including 
trypanosomes (Myburgh et al., 2013), and some Leishmania species, such as L. 
amazonensis (Lang et al., 2005; Reimão et al., 2013), L. donovani (de La Llave 
et al., 2011), L. infantum (Michel et al., 2011), L. tropica (Talmi-Frank et al., 
2012), and L. major (de La Llave et al., 2011; Giraud et al., 2014), and 
evaluating the effect of drugs on parasites in vivo (Lang et al., 2005; Michel et 
al., 2011; Reimão et al., 2013). The BLI system, as yet, has not been used to 
investigate parasite survival and growth of luciferase-expressing cell lines 
deficient in putative virulence factors directly compared with the luciferase-
expressing reference strain. 
4.1.3 The role of ISP2 on parasite survival in vitro 
In vitro studies conducted by Faria et al. (2011) showed that L. major deficient 
in ISP2 and ISP3 (Δisp2/3) were internalised more efficiently by thioglycollate-
elicited macrophages of C57BL/6 mice than L. major WT parasites or a cell line 
re-expressing ISP2 and ISP3 (Δisp2/3:ISP2/3). The numbers of intracellular 
Δisp2/3 parasites then dropped by 50% by 24 h post-infection, attributed to the 
production of ROS, compared with L. major WT parasites, indicating a role in the 
establishment of a productive infection (Faria et al., 2011). 
To investigate whether this effect also occurred in vivo, Faria et al. (2011) 
inoculated 2x107 stationary-phase promastigotes directly into the peritoneal 
cavity of C57BL/6 mice, and again Δisp2/3 parasites were found at higher 
numbers than WT parasites at 3 h post-infection. After cultivation of the 
parasites for 24 h in vitro, intracellular Δisp2/3 parasites were approximately 
half the initial number compared to WT parasites. To follow on from this work, 
the role of L. major ISP2 will be investigated in vivo. A low dose intradermal 
infection model will be employed to determine whether the ISP2 present in a 
low parasite dose, 104 metacyclic promastigotes, inoculated intradermally is 
sufficient to confer L. major survival in the C57BL/6 mouse model at later stages 
of infection. 
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4.1.4 Aims 
In vitro studies indicate that ISP2 is required for L. major intracellular survival 
and growth in macrophages upon early parasite-macrophage contact (Faria et 
al., 2011). In this chapter, the role of ISP2 on parasite survival in a low dose 
intradermal C57BL/6 infection model will be evaluated up to 10 wk post-
infection through the comparison of infection profiles with L. major WT 
parasites, the cell line deficient in ISP2/3, Δisp2/3, and the cell line re-
expressing ISP2/3, Δisp2/3:ISP2/3. As ISP3 is not detected in any Leishmania 
lifecycle stage, and is thought to be a pseudogene (Eschenlauer et al., 2009), it 
is assumed that differences observed between these cell lines is due to the role 
of ISP2. 
The aims of this chapter are to: 
 Monitor lesion progression over the course of infection  
 Generate reporter cell lines expressing firefly luciferase (LUC2) 
 Track disease progression through BLI 
 Evaluate parasite burdens in various organs  
4.2 Results 
4.2.1 Lesion measurements over the course of infection 
Typically lesion size is taken as a measure of disease progression over the course 
of L. major infection, although lesion size does not always directly correlate 
with parasite burden (Belkaid et al., 2000; Lira et al., 2000; Kimblin et al., 2008; 
Giraud et al., 2014). Lesion size was first evaluated following low dose 
subcutaneous inoculation of 104 L. major WT or Δisp2/3 metacyclic 
promastigotes into the footpads of C57BL/6 mice (Figure 4-1). Metacyclic 
promastigotes were harvested from in vitro culture using peanut lectin 
agglutination (Sacks et al., 1985), resuspended in PBS, and inoculated into mice. 
Over the first 5 wk post-infection, the lesions of Δisp2/3-infected mice were 
significantly higher than those of WT-infected mice. After 5 wk, the lesions of 
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WT-infected mice began to increase in size, becoming significantly larger than 
those of Δisp2/3-infected mice, which were decreasing at this point. 
The lesion size was then evaluated in the low dose intradermal infection model 
following inoculation of 104 L. major WT or Δisp2/3 metacyclic promastigotes 
into the ears of C57BL/6 mice, as this will be the model of infection used in this 
study. The mean ear thickness of the uninfected ears of these mice over the 
course of this experiment was 0.3 mm. Due to the thinness of the ear, accurate 
measurements were more technically difficult than the footpad thickness 
measurements. There were no significant differences between the lesions of WT- 
or Δisp2/3-infected mice (Figure 4-2). 
 
Figure 4-1 Lesion development in the footpads of C57BL/6 mice. Purified metacyclic 
promastigotes (104 in 40 µl PBS) were subcutaneously inoculated into the footpads of C57BL/6 
mice (n=4). Footpad thickness was measured weekly with a dial caliper. ■, WT; ○, Δisp2/3. Error 
bars represent S.E.M. Asterisks indicate statistical significance between the groups at p < 0.05 
(*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****), as determined by an unpaired t-test. 
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Figure 4-2 Lesion development in the ears of C57BL/6 mice. Purified metacyclic promastigotes 
(104 in 10 µl PBS) were intradermally inoculated into the ears of C57BL/6 mice (n=5). Ear 
thickness was measured weekly with a dial caliper. ■, WT; ○, Δisp2/3. Error bars represent 
S.E.M. 
4.2.2 Generation and characterisation of transgenic 
bioluminescent cell lines 
To enable longitudinal monitoring of transgenic bioluminescent cell lines in vivo, 
L. major cell lines expressing the firefly luciferase (LUC2) reporter gene were 
generated. Transgenic parasites were generated through the integration of the 
luc2 gene into the Leishmania 18S ribosomal RNA locus of the genome through 
homologous recombination. This enabled stable constitutive gene expression 
under the control of the ribosomal promoter, as opposed to episomal expression, 
which has been reported to cause varying levels of expression due to the copy 
number variation of the transfected plasmids in each parasite (Roy et al., 2000). 
Plasmids containing the luc2 gene, pGL2126 and pGL2357, which have puromycin 
(PAC) and streptothricin (SAT) resistance cassettes respectively, had a pRIB 
backbone (pGL631) and were linearised with PacI and PmeI. The DNA was 
transfected into the L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 cell lines. Several 
clones of the transfected cell lines giving high levels of in vitro LUC2 expression 
were then selected, as assessed through bioluminescent signal using the 
Luciferase Reporter Gene Assay (Roche) with the parental cell lines as controls. 
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The levels of in vitro bioluminescence were compared between the clones of 
each cell line at different stages of in vitro parasite growth. One clone of each 
of the bioluminescent cell lines, L. major+LUC2, Δisp2/3+LUC2, and 
Δisp2/3:ISP2/3+LUC2, was chosen, which had the closest levels of LUC2 
expression within a particular range. Figure 4-3 shows the in vitro 
bioluminescence, with metacyclic promastigotes of the clones chosen for in vivo 
infections, as this is the lifecycle stage that will be used for the in vivo 
infections. The graph shows that the in vitro bioluminescence of the L. 
major+LUC2 cell line was significantly higher than that of the Δisp2/3+LUC2 and 
Δisp2/3:ISP2/3+LUC2 cell lines, despite attempts to select clones with similar 
levels of LUC2 expression. 
The in vitro growth rates of the LUC2-expressing cell lines, L. major+LUC2, 
Δisp2/3+LUC2, and Δisp2/3:ISP2/3+LUC2, were compared against the parental 
cell lines, parasites lacking the luc2 gene, L. major WT, Δisp2/3, and 
Δisp2/3:ISP2/3, showing there was no difference in the in vitro growth 
phenotype (Figure 4-4). 
 
Figure 4-3 In vitro luciferase reporter gene assays of LUC2-expressing cell lines. Assays were 
performed using purified metacyclic promastigotes in the Luciferase Reporter Gene Assay 
(Roche). Black bar, L. major+LUC2; grey bar, Δisp2/3+LUC2; white bar, Δisp2/3:ISP2/3+LUC2. 
Data are shown on a logarithmic scale. Error bars represent S.E.M of replicate wells. Dashed line 
indicates background bioluminescence, the mean bioluminescence from wells containing 106 
purified metacyclic promastigotes of L. major WT, Δisp2/3, or Δisp2/3:ISP2/3. Asterisks indicate 
statistical significance between the groups at p < 0.05 (*) and p < 0.01 (**), as determined by 
one-way ANOVA with Tukey post test. 
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Figure 4-4 In vitro growth curves of promastigote cultures of L. major WT, Δisp2/3, 
Δisp2/3:ISP2/3 and the LUC2-expressing cell lines. Promastigote cultures were started at 105 
cells ml-1 and cell densities were determined daily for 7 d. Data shown on a logarithmic scale. ■, 
WT; ○, Δisp2/3; ▲, Δisp2/3:ISP2/3; ■, L. major+LUC2; ○, Δisp2/3+LUC2; ▲, 
Δisp2/3:ISP2/3+LUC2. 
4.2.3 Tracking parasite bioluminescence with the in vivo imaging 
system (IVIS) 
BLI of the three LUC2-expressing cell lines, L. major+LUC2, Δisp2/3+LUC2, and 
Δisp2/3:ISP2/3+LUC2 (from Figure 4-3), in the mouse model, enabled the 
parasite presence in localised cutaneous infections to be imaged in real-time 
over a period of 7 wk. This made it possible to observe and compare the 
dynamics of infection, in terms of parasite loads, at both early and late time-
points. Metacyclic promastigotes, 104, were inoculated into the ear dermis of 
C57BL/6 mice. For each time-point after parasite inoculation, mice were 
injected with the luciferase substrate, D-luciferin, into the peritoneal cavity to 
induce the bioluminescence from the LUC2-expressing parasites. Mice were 
anaesthetised then imaged in the IVIS using a CCD camera to detect and capture 
the photons emitted from the bioluminescent parasites between 10 and 15 min 
after luciferin injection. Based on preliminary kinetic studies, 10 to 15 min was 
the optimal time to capture the peak of the luciferase-specific signal from the 
ear. 
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Figure 4-5 shows representative images of one mouse per group over the course 
of infection. A region of interest (ROI) was created that covered the entire 
surface of the ear, in order to measure the total flux, the photons per second 
(photons sec-1) over the ROI. The same ROI was used to evaluate the 
bioluminescent signal in all mice at all time-points, and values given in white are 
the mean bioluminescent signal for each group, as plotted in Figure 4-6A. A 
pseudo-coloured image representing the bioluminescence was overlaid onto a 
photograph as an anatomical reference. Images from the control mice, which 
were mice inoculated with the parental cell lines, parasites lacking the luc2 
gene, L. major WT, Δisp2/3, and Δisp2/3:ISP2/3, show the background 
bioluminescence from the ear to be approximately 4.3x103 photons sec-1, which 
is the same as that exhibited in the naive ear of infected mice (Figure 4-5A). A 
representative image from a naive ear of an infected mouse at 4 wk is shown, as 
at this time-point ears infected with the LUC2-expressing parasites had a peak 
bioluminescent signal. One hour after parasite inoculation, there was a 
bioluminescent signal from the ears of mice inoculated with the LUC2-expressing 
parasites (Figure 4-5B), 1.5-fold higher for L. major+LUC2 and 
Δisp2/3:ISP2/3+LUC2 infections, and 1.2-fold higher for Δisp2/3+LUC2 infection, 
as compared to the signal from the control mice (Figure 4-6A). This initial signal 
decreased to levels seen in the control mice by 24 h and remained low until 1 wk 
post-infection for the L. major+LUC2 and Δisp2/3:ISP2/3+LUC2 infections, and 2 
wk post-infection for the Δisp2/3:ISP2/3+LUC2 infection, at which point the 
signal began to increase above that of the initial signal for all LUC2-expressing 
groups. This signal continued to increase up to 5 wk post-infection, at 1.04x105 
photons sec-1 for the L. major+LUC2 infection, but only up to 3 wk, at 4.12x105 
photons sec-1 for the Δisp2/3:ISP2/3+LUC2 infection showing, on average, a 17-
fold and 63-fold increase from the initial signals for these groups respectively. 
The signal from the ears of Δisp2/3+LUC2-infected mice stayed low over the 
course of infection, as compared with mice infected with the L. major+LUC2 and 
Δisp2/3:ISP2/3+LUC2 cell lines; the highest signal being at 3 wk post-infection, 
at 1.03x104 photons sec-1, only 2-fold higher than the initial signal for this group. 
After the respective peaks, the signals in all the groups began to decrease, with 
the signal from only the Δisp2/3+LUC2-infected mice returning to a level 
equivalent to the background signal by 7 wk post-infection. 
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At 7 wk post-infection, mice were culled, and the ears and superficial cervical 
dLNs were removed to determine the parasite burdens in these tissues (Figure 4-
6, B and C). In the ear samples, parasites could only be detected in the 
Δisp2/3:ISP2/3+LUC2 group, of which only 3 out of 5 ears had detectable 
parasites, with a mean of 103 parasites per ear (Figure 4-6B). Parasites could be 
detected in the dLNs of all groups, although there was no significant difference 
in the parasite numbers between the groups, which had means between 1x105 
and 2x105 parasites per dLN (Figure 4-6C). 
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Figure 4-5 In vivo bioluminescence imaging of LUC2-expressing cell lines at the site of 
inoculation. Purified metacyclic promastigotes (104 in 10 µl PBS) were intradermally inoculated 
into the ears of C57BL/6 mice (n=2 for L. major WT, Δisp2/3, and Δisp2/3:ISP2/3, and n=5 for 
LUC2-expressing L. major, Δisp2/3, and Δisp2/3:ISP2/3). Mice were imaged in the IVIS 10 to 15 
min after intraperitoneal D-luciferin injection. Representative images of one mouse per group 
over the course of infection for A) the control mice infected with L. major WT, Δisp2/3, and 
Δisp2/3:ISP2/3 parasites, including an image from a naive ear at 4 wk post-infection, and B) the 
mice infected with L. major+LUC2, Δisp2/3+LUC2, and Δisp2/3:ISP2/3+LUC2 cell lines. The 
colour scale indicates bioluminescent radiance in photons/second/cm2/steradian. The red oval 
indicates the region of interest (ROI) and the value in the red box indicates the total flux, given 
in photons per second (photons sec-1), over the ROI in the individual image shown. The same 
colour scale and ROI was applied to all images analysed. The value in white gives the mean total 
flux for the group at each time-point. 
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Figure 4-6 Quantification of bioluminescent signal from LUC2-expressing cell lines, and 
parasite burdens at the site of inoculation and in the draining lymph node. A) The mean total 
flux over the ROI of the ear, given in photons per second (photons sec-1), for each group of 
infected mice at each time-point over the course of 7 wk infection. ■, L. major WT; ○, Δisp2/3; 
▲, Δisp2/3:ISP2/3; ■, L. major+LUC2; ○, Δisp2/3+LUC2; ▲, Δisp2/3:ISP2/3+LUC2. Error bars 
represent S.E.M. Asterisks indicate statistical significance between the LUC2-expressing groups 
at p < 0.05 (*) and p < 0.01 (**), as measured by one-way ANOVA with a Tukey post test. Parasite 
loads in B) the ear and C) the dLN at 7 wk post-infection, as determined by LDA. Parasite loads 
from the individual samples are shown with the lines indicating the mean for the group. Dashed 
line indicates the lower limit of detection. Data are shown on a logarithmic scale.     
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4.2.4 Measurements of tissues and quantification of parasite loads 
To further evaluate any pathological features of infection and parasite burdens, 
the ears and dLNs, as well as the livers and spleens, were removed from 
C57BL/6 mice intradermally inoculated with 104 metacyclic promastigotes of L. 
major WT, Δisp2/3, or Δisp2/3:ISP2/3. The mean diameters of the dLNs were 
calculated by taking the average of three diameter measurements around the 
dLN with a vernier caliper. The masses of the livers and spleens were also 
evaluated. The ears, dLNs, livers, and spleens were then homogenised and 
limiting dilutions were performed. 
Lymph node diameter was measured at 2, 5, and 10 wk post-infection (Figure 4-
7A). At 2 wk post-infection, there was no significant difference in the dLN 
diameter of WT-, Δisp2/3-, and Δisp2/3:ISP2/3-infected mice, which ranged 
between 1.3 and 2.4 mm in diameter. By 5 wk post-infection, the dLN diameter 
of WT- and Δisp2/3-infected mice was 2-fold and 2.3-fold higher than 
measurements taken at 2 wk post-infection, respectively. Whereas the mean 
dLN diameter of Δisp2/3:ISP2/3-infected mice at 5 wk post-infection was only 
1.4 mm greater than that observed at 2 wk post-infection. The mean dLN 
diameter of Δisp2/3-infected mice, 3.7 mm, was significantly larger than 
Δisp2/3:ISP2/3-infected mice, 2.6 mm, at 5 wk post-infection. At 10 wk post-
infection, the mean dLN diameters for the groups were similar to those observed 
at 5 wk post-infection, although there was no significant difference between the 
parasite groups. 
LDAs were performed using ears infected for 2, 5, and 10 wk; however, at 2 wk 
post-infection, parasites could not be detected in the ears of mice infected with 
any of the parasite groups, WT, Δisp2/3, or Δisp2/3:ISP2/3. At 5 wk post-
infection, in the first experiment, parasites could not be detected in any of the 
ears infected with Δisp2/3 parasites (Figure 4-7B, first column), and in a second 
experiment, Δisp2/3 parasites could not be detected in 4 out of the 5 ears 
(Figure 4-7B, second column). In both these experiments, WT parasites could be 
detected in all, but one, of the ear samples (Figure 4-7B, first and second 
columns), with mean parasite loads of 2.1x104 and 6.4x103 parasites per ear in 
the two independent experiments respectively. At 10 wk post-infection, Δisp2/3 
parasites could, again, not be detected in the ears, and at this time-point, WT 
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parasites could only be detected in 3 out of the 5 ears, with a mean parasite 
load of less than 1000 (Figure 4-7B, third column). At both 5 and 10 wk post-
infection, the mean parasite loads in Δisp2/3:ISP2/3-infected ears were 
significantly higher than those of Δisp2/3- and WT-infected ears, at 1.9x106 and 
2.8x105 parasites per ear in the two independent experiments respectively 
(Figure 4-7B, second and third columns).  
Parasites were detected in the dLNs of mice infected with all of the parasite 
groups, WT, Δisp2/3, or Δisp2/3:ISP2/3, at 5 and 10 wk post-infection, and there 
was no significant difference in the parasite loads between these groups (Figure 
4-7C, second and third columns). At 5 wk post-infection, the mean parasite loads 
of WT infections in the dLNs were 2.3x104 and 8.6x104 parasites per dLN in the 
first and second experiments respectively (Figure 4-7C, first and second 
columns). In the first experiment, the mean parasite loads of WT infections in 
the ear and dLN were similar at 2.1x104 and 2.3x104 parasites respectively 
(Figure 4-7, B and C, first column), whereas in the second experiment, the mean 
parasite load in the dLN was approximately 13-fold higher than those at the site 
of infection, the ear, at this time-point (Figure 4-7, B and C, second column). In 
the first experiment at 5 wk post-infection, there was a significantly higher WT 
parasite load in the ear compared with Δisp2/3 infection, and this was also 
observed in the dLN (Figure 4-7, B and C, first column). However, in the second 
experiment at 5 wk post-infection, although there were significantly more 
Δisp2/3:ISP2/3 parasites in the ear compared with WT and Δisp2/3 parasites, 
there was no significant difference in the parasite loads between the parasite 
groups in the dLNs (Figure 4-7, B and C, second column). These differences may 
be due to biological variations between the animal groups used for each 
experiment. At 10 wk post-infection, there was, again, no significant difference 
in the parasite loads between the parasite groups in the dLNs; however, the 
mean parasite loads of Δisp2/3:ISP2/3 infections at 10 wk was 2.5x105 parasites 
per dLN, which was higher than that observed for WT and Δisp2/3 infections, 
which were 1.1x103 and 2.7x102 parasites per dLN respectively (Figure 4-7C, 
third column). Of note, the parasite loads for WT and Δisp2/3  infections at 10 
wk were lower than those observed at 5 wk, which is depicted in Figure 4-7D, in 
addition to two other LDAs performed at 12 and 14 wk post-infection comparing 
WT and Δisp2/3 infections in the dLN following an ear dermis inoculation of 
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these parasite cell lines. These data show that both L. major WT and Δisp2/3 
parasites persist in the dLN beyond 10 wk post-infection. 
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Figure 4-7 Parasite burdens during infection with L. major WT, Δisp2/3, and Δisp2/3:ISP2/3. 
Purified metacyclic promastigotes (104 in 10 µl PBS) were intradermally inoculated into the ears 
of C57BL/6 mice (n=5 for each time-point). The parasite loads of the ear and dLN in the first 
column at 5 wk were collected from the same mice, and the data represented in the second 
column, 5 wk, and third column, 10 wk, were collected from the same mice respectively. A) The 
dLNs were removed at 2, 5, and 10 wk post-infection, and the diameter was measured by vernier 
caliper. Parasite loads in the B) ear and the C) dLN at 5 and 10 wk post-infection were 
determined by LDA. D) Graph showing the parasite loads in the dLNs of mice infected with WT 
(■) or Δisp2/3 (●) parasites at 5 (C, second column), 10 (C, third column), 12, and 14 wk post-
infection from independent experiments. Dashed lines indicate the lower limit of detection. 
Asterisks indicate statistical significance between the groups at p < 0.05 (*) and p < 0.0001 (****), 
as measured by an unpaired t-test or a one-way ANOVA with a Tukey post test. 
Mass measurements and limiting dilutions of the livers and spleens were also 
performed at 2, 5, and 10 wk post-infection, to determine whether parasites 
from of any of the three cell lines had disseminated beyond the dLN. There were 
no significant differences in the masses of the livers and spleens of mice 
infected in the ear with L. major WT, Δisp2/3, or Δisp2/3:ISP2/3 parasites 
(Figure 4-8), except at 2 wk post-infection in which the liver mass from WT-
infected mice was higher than that of Δisp2/3-infected mice (Figure 4-8A, first 
column). No parasites were detected for any of the groups at any of the time-
points investigated. 
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Figure 4-8 Liver and spleen masses during infection with L. major WT, Δisp2/3, and 
Δisp2/3:ISP2/3. Purified metacyclic promastigotes (104 in 10 µl PBS) were intradermally 
inoculated into the ears of C57BL/6 mice (n=5 for each time-point). The A) livers and B) spleens 
were removed at 2, 5, and 10 wk post-infection, and the masses were measured. Asterisks 
indicate statistical significance between the groups at p < 0.05 (*), as measured by one-way 
ANOVA with a Tukey post test. 
4.3 Discussion 
The results of this chapter suggest that L. major ISP2 confers parasite survival at 
the site of inoculation in vivo. Eschenlauer et al. (2009) and Faria et al. (2011) 
previously demonstrated that L. major mutants deficient in ISP2/3, Δisp2/3, had 
reduced parasite burdens after an initial upregulation of internalisation, as 
compared with L. major WT infections, in macrophages from BALB/c and 
C57BL/6 mice respectively. To follow on from these previous in vitro 
experiments, it has been shown here, through BLI (Figure 4-5 and 4-6) and LDA 
B 
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(Figure 5-7B) techniques, that this phenotype can also be observed in vivo, 
further indicating an important role for ISP2 in the establishment and 
persistence of Leishmania infection. ISP2 has been shown to inhibit host serine 
peptidases of the S1A family, including NE and CG (Eschenlauer et al., 2009; 
Faria et al., 2011; Morrison et al., 2012), which are expressed by mammalian 
innate immune cells, including neutrophils, monocytes, and macrophages. S1A 
serine peptidases play many roles in the modulation of the immune response, 
including proteolytic modification of chemokines to regulate immune cell 
recruitment, and in the activation of immune cells through the cleavage of 
cytokines and cell surface receptors. Therefore, ISP2 may inhibit the activity of 
host SPs in vivo to modulate the innate immune responses facilitating L. major 
survival, which will be discussed in Chapter 5. 
The use of a reproducible L. major infection model is important in the study of 
putative L. major virulence factors, as the disease profile observed in response 
to L. major mutants deficient in, or overexpressing, the putative virulence 
factor may reveal its function in the modulation of host immune responses and 
hence indicate their potential as vaccine candidates. In this study, in which low 
dose parasite inocula were used, differences were observed in the lesion 
progression profiles (Figure 4-1 and 4-2) and parasite loads, reflected in the BLI 
(Figure 4-6) and LDAs (Figure 4-7), between L. major WT and Δisp2/3 infections; 
this indicates that the use of a low dose intradermal infection model for L. 
major is robust enough to detect differences caused by single L. major virulence 
gene mutations. Infection with L. major Δisp2/3:ISP2/3 parasites, which has 
been shown to slightly overexpress ISP2 (as shown is Chapter 3), resulted in 
significantly higher parasite loads at the site of infection, assessed by LDA at 5 
wk post-infection (Figure 4-7B) and BLI of a LUC2-expressing Δisp2/3:ISP2/3 cell 
line over the course of infection (Figure 4-6A), compared with L. major WT and 
Δisp2/3 infections, further confirming the importance of ISP2 for parasite 
survival. Interestingly, parasites of all three cell lines persisted in the dLNs 
(Figure 4-7C), which may reflect differences in the environment between the 
site of infection and the dLN, such as the differences in the presence of SPs, the 
activity of which ISP2 has been shown to inhibit. It is likely that the SP 
composition at the site of infection and the dLN will be different due to 
differences in the cellular compositions between these two locations, in that 
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there are more neutrophils, macrophages, and monocytes at the site of infection 
but not all of these migrate to the dLN (León et al., 2007). 
Lesion size is often taken as a measure of disease progression over the course of 
L. major infection (Späth et al., 2000; Jacobs et al., 2005). Faria et al. (2011) 
had previously performed footpad inoculations of C57BL/6 mice with L. major 
WT and Δisp2/3 parasites, reporting no significant differences between the 
lesion sizes of the two groups over 10 wk. This does not match the infection 
profiles reported in this study for both footpad and ear inoculation of L. major 
WT and Δisp2/3 parasites, in which the lesions of Δisp2/3-infected mice 
developed and resolved more rapidly than WT-infected mice (Figure 4-1 and 4-
2). The differences observed are most likely due to the parasite inocula, as Faria 
et al. (2011) used 2x106 stationary-phase promastigotes, whereas 104 metacyclic 
promastigotes were used in this study. Stationary-phase cultures are composed 
of procyclic and metacyclic promastigotes, as well as the other intermediate 
promastigote forms. Although there are no significant differences in the in vitro 
growth curves between L. major WT and Δisp2/3 promastigotes (Figure 4-4), the 
quantification of the composition of promastigote forms in the stationary-phase 
culture has not been conducted for these cell lines. In addition, it has already 
been shown that ISP2 is more highly expressed in infective metacyclic 
promastigotes and amastigotes compared to procyclic promastigotes 
(Eschenlauer et al., 2009); therefore, using the same number of metacyclic 
promastigotes allows for a better comparison of the in vivo infections between 
the parasite groups. 
A “silent” phase of parasite growth has been described in L. major infection 
models upon inoculation with a low parasite dose. Lira et al. (2000) inoculated 
100 L. major Friedlin metacyclic promastigotes into the footpads of C57BL/6 
mice and only observed lesion development at 6 to 8 wk post-infection, 
compared to a high dose of 106 metacyclic promastigotes, which caused footpad 
swelling at 1 wk post-infection, with a peak at 3 wk post-infection. The footpad 
lesion development caused by low dose inocula shown by Lira et al. (2000) more 
closely resembles the lesion development in this study in which 104 L. major 
Friedlin WT metacyclic promastigotes were inoculated into the footpad (Figure 
4-1), as lesion development was not evident until 5 wk post-infection. The 
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kinetics of the lesion development in the ear of C57BL/6 mice infected with L. 
major Friedlin WT parasites performed in this study (Figure 4-2) also closely 
resembles trends shown by Baldwin et al. (2003), who likewise used 104 L. major 
Friedlin metacyclic promastigotes in the ear model showing lesion formation 
around 3 wk and a peak lesion size at 5 to 6 wk, and Cangussú et al. (2009) who 
used 103 L. major Friedlin metacyclic promastigotes also showing lesion 
formation around 3 wk and a delayed peak lesion size at 7 wk. The lesion 
profiles reported in these papers suggest that the experimental model used in 
this investigation is reproducible for L. major Friedlin infection. Recently, 
Schuster et al. (2014) proposed a method to standardise the measurement of 
lesions in the ear, as the techniques varied in the scientific literature including 
thickness measured by dial or vernier caliper, diameter of the induration 
measured by vernier caliper, a scoring system based on diameter, and lesional 
volume. This report found that all these techniques failed to represent what is 
visually observed, particular in the early stages of erythema swelling and when 
lesions show signs of necrosis (Schuster et al., 2014). Lesion development 
should, therefore, be considered in qualitative terms, rather than as a 
quantitative measure of disease progression. The use of BLI can help improve the 
monitoring of lesion development, as not only does BLI reflect the parasite loads 
at the site of inoculation, the imaging system takes a photograph as an 
anatomical reference, which could act as a direct two-dimensional record of 
lesion development over time. 
Lesion size does not always correlate with parasite burden particularly when a 
low parasite dose is used (Lira et al., 2000), in fact, it is more coincident with 
the onset of immunity in terms of cellular infiltration (Belkaid et al., 2000). The 
absence of lesion formation during the first few weeks after a low dose 
inoculation of L. major suggests that host immune responses mediating cellular 
infiltration and parasite killing are avoided, as parasite loads peak after this 
period. Morphometric analysis of the number and type of cells composing the ear 
dermis over the course of a 103 L. major Friedlin metacyclic promastigote 
infection in C57BL/6 mice show an accumulation of leukocytes from 4.5 wk post-
infection coinciding with the start of lesion development (Cangussú et al., 2009). 
In this study, lesion development after infection with Δisp2/3 parasites is 
evident even after 2 or 3 wk of infection and appears to be higher than that of 
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WT infection (Figure 4-2), even though Δisp2/3 parasites could not be detected 
in LDAs at 5 wk post-infection (Figure 4-7B); these results suggest that contrary 
to what is observed for L. major WT infection, mechanisms regulating cellular 
infiltration and parasite killing may be upregulated, or no longer inhibited by 
ISP2, during Δisp2/3 infection. Furthermore, the dLNs of Δisp2/3-infected mice 
at 5 wk post-infection were significantly larger than those of Δisp2/3:ISP2/3-
infected mice (Figure 4-7A), which may indicate lymph node hypertrophy, which 
is the expansion of the lymph nodes to promote the increase of naive T cells into 
the lymph node in order to generate a protective antigen-specific immune 
response (Hsu & Scott, 2007; Carvalho et al., 2012). 
The parasite loads detected in the ear for L. major WT infections (Figure 4-7B) 
are consistent with those of Belkaid et al. (2000), who inoculated 100 L. major 
Friedlin metacyclic promastigotes into the ear dermis. They showed low parasite 
loads of less than 1000 parasites at 2 wk post-infection, with the peak parasite 
load at 4 wk, over 105 parasites, but lesions only becoming apparent at 5 wk 
(Belkaid et al., 2000). Parasite burdens in this study were determined by the LDA 
method; however, other techniques are available, such as qPCR of Leishmania 
transcripts, such as ssrRNA (de La Llave et al., 2011). The detection limit of the 
LDAs for the ear samples was over 102 parasites. The detection limit was 
calculated based on sample preparation, as the first few wells of the LDA plates 
consisted of dense material from the ear that prevented the detection of any 
extracellular parasites. This dense material, which probably consisted of high 
concentrations of toxic products, may have also prevented parasite growth, as 
even after a couple of weeks of incubation there were no parasites in these 
wells. LDAs only detect amastigotes that are able to differentiate and survive as 
promastigotes in culture in the presence of antibiotics. The LDA method is also 
subject to error due to loss of parasites in the tissue harvesting and 
homogenising steps. In addition, technical and biological variation can occur in 
these quantification methods, which makes the results difficult to reproduce, as 
demonstrated by the two 5 wk post-infection LDA experiments performed on the 
ears of L. major WT- and Δisp2/3-infected mice (Figure 4-7B, first and second 
columns). Contamination arose in some LDAs previously performed with ear 
samples, which prevented the parasite burdens from being calculated; this was 
eventually overcome by increasing the concentration of the antibiotic, 
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gentamicin, in the growth medium, although the gentamicin may also have had 
an effect on the parasite growth (Daneshvar et al., 2003). Parasites were not 
detected in any ear sample for any parasite-infected group, WT, Δisp2/3, or 
Δisp2/3:ISP2/3, at 2 wk post-infection. It is thought that only 10% of the 
metacyclic promastigotes inoculated into mice survive and transition into 
amastigotes, based on parasite loads determined by the abundance of L. major 
transcripts (Giraud et al., 2014). In studies that have monitored L. major 
parasite burdens in the site of infection over time after a low dose inoculation in 
resistant C57BL/6 mice, parasites have not been detected less than 3 or 4 wk 
post-infection at the site of inoculation assessed by LDA (Belkaid et al., 2000; 
Lira et al., 2000). However, the use of qPCR methods has detected a low 
abundance of the parasite transcripts over this early phase of infection (Giraud 
et al., 2014). Additionally, Baldwin et al. (2003) investigated the parasite 
burdens in the dLNs at 5, 10, and 15 wk post-infection, showing a decline over 
the course of infection, as was shown in this study for both L. major WT and 
Δisp2/3-infected mice. 
BLI of the three LUC2-expressing cell lines, L. major, Δisp2/3, and 
Δisp2/3:ISP2/3, in the mouse model enabled the infections to be followed over 
the long-term, in order to compare the dynamics of infection in the initial 
stages, as was previously evaluated by Faria et al. (2011), and at late time-
points. This is the first study to use the BLI system to compare the infection 
profiles of different parasite gene mutants. de La Llave et al. (2011) and Giraud 
et al. (2014) used firefly luciferase-expressing L. major IR173 to monitor disease 
progression in the ear dermis of C57BL/6 mice after inoculation with 104 
metacyclic promastigotes. Four phases were described; phase 1, from 0 to 4 
days, during which bioluminescence was similar to the background values; phase 
2, from 4 to 29 days, where the signal increased, peaking around 19 days; phase 
3, from 29 to 47 days, where the signal decreased to background levels but 
lesion development was still ongoing; and phase 4, from 47 to 118 days, in which 
there was no signal but the lesion was slowly resolving. A similar bioluminescent 
profile was observed for L. major Friedlin in this study. There were no 
significant differences in the bioluminescent signal from the LUC2-expressing 
parasites over the first week of infection (Figure 4-6A). In vitro luciferase 
reporter gene assays with 105 to 106 metacyclic promastigotes showed that LUC2 
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expression, as determined by bioluminescence, of the L. major+LUC2 cell line 
was significantly higher than that of the Δisp2/3+LUC2 or Δisp2/3:ISP2/3+LUC2 
cell lines (Figure 4-3). However, in vivo imaging of these cell lines 1 h after 
intradermal inoculation with 104 metacyclic promastigotes showed that the L. 
major+LUC2 and Δisp2/3:ISP2/3+LUC2 cell lines had mean signals of 6.28x103 
photons sec-1 and 6.51x103 photons sec-1 respectively, whereas the mean signal 
from the ears infected with the Δisp2/3+LUC2 cell line was 5.12x103 photons sec-
1, almost halfway between the background signal of ears infected with the 
parental cell lines, parasites not expressing luciferase, 4.3x103 photons sec-1, 
and the L. major+LUC2 and Δisp2/3:ISP2/3+LUC2 infected groups (Figure 4-6A). 
The difference between the bioluminescent signal of these cell lines in vitro and 
in vivo could be attributed to differences in the luciferase kinetics in vitro and 
in vivo, or it may indicate the parasite condition. Perhaps the cell lines are 
experiencing different metabolic stresses due to differences in internalisation, 
as Δisp2/3 parasites are internalised more efficiently by macrophages in vitro 
and Faria et al. (2011) also recovered macrophages with high parasite loads of 
intracellular Δisp2/3 parasites after a 3 h infection in the peritoneal cavity of 
C57BL/6 mice. Similarly Eschenlauer et al. (2009) showed high Δisp2/3 parasite 
burdens in the footpad of BALB/c mice after 24 h of infection. However, the 
parasite loads have not been assessed earlier than 3 h post-infection, 
particularly in this low dose intradermal infection model. By 1 wk post-infection 
the bioluminescent signal of the LUC2-expressing Δisp2/3:ISP2/3 cell line was 
already significantly higher than that of the L. major+LUC2 and Δisp2/3+LUC2 
infections. Changes in the kinetics of in vitro parasite growth are classically 
associated with changes in parasite virulence; however, the growth curves of the 
cell lines used in this study were similar to that of L. major WT parasites (Figure 
4-4). The signal from the ears infected with L. major+LUC2 also began to 
increase at 1 wk, but the signal from Δisp2/3:ISP2/3+LUC2 infections was higher 
than that of L. major+LUC2 infections over 5 wk, which is when the signal began 
to decline. The signal from the ears infected with the Δisp2/3+LUC2 cell line, 
however, remained low over the course of infection, which could indicate that 
the parasites had been reduced to numbers no longer detectable, or that the 
parasites were in a bad condition. These data in conjugation, with the parasite 
burdens at the site of inoculation, again indicate a role of ISP2 in in vivo 
survival. 
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BLI can be used to reflect parasite burden, as often the numbers of parasites at 
the site of infection can be detected by BLI imaging before a detectable lesion 
develops (de La Llave et al., 2011). As with lesion size and parasite burdens, 
however, the lesion size does not directly correlate with the bioluminescent 
signal, as de La Llave et al. (2011) showed a peak lesion size followed 10 d after 
the peak bioluminescent signal. The bioluminescent signal itself though can be 
directly correlated with parasite burden, although it is necessary to determine 
the relationship between each luciferase-expressing cell line and the 
bioluminescence before making assumptions as to the parasite loads in each 
tissue. In this study, clones of L. major+LUC2, Δisp2/3+LUC2, and Δisp2/3:ISP2/3 
were chosen, which were as closely matched for luciferase expression in vitro as 
possible, as it is not possible to obtain clones of different cell lines with exactly 
the same levels of expression. Even with the levels of luciferase expression being 
similar for the same lifecycle stages in vitro, differences in parasite growth and 
condition, particularly in vivo, mean that it is important to determine the 
relationship of the parasite burdens and bioluminescence for each luciferase-
expressing cell line. Reimão et al. (2013) and Myburgh et al. (2013) also directly 
imaged plates of serially diluted luciferase-expressing L. amazonensis and 
Trypanosoma brucei on the IVIS respectively, to determine the correlation 
between parasite number and photons detected. The BLI signal strength can vary 
depending of the Leishmania lifecycle stage and parasite condition, as well as 
the tissue location, due to light absorption and scattering, the kinetics of 
luciferin distribution, and the availability of co-factors, such as ATP (Thalhofer 
et al., 2010). The detection sensitivity has been shown to differ depending on in 
vivo or ex vivo measurements of tissues infected with luciferase-expressing 
parasites (Michel et al., 2011). Bioluminescence from different organs cannot be 
compared within the same animal, but for a given organ, the bioluminescence 
can reflect differences in the parasite loads between animals infected with the 
same cell line. In vivo imaging of luciferase-expressing cell lines also does not 
give any information on whether the parasites are intracellular or extracellular. 
Differences between the bioluminescent signals immediately after inoculation 
can, therefore, reflect the infection efficiency in each animal. Prior to 
infection, the levels of bioluminescence from purified metacyclic promastigotes 
of each of the three LUC2-expressing cell lines showed significant differences in 
in vitro luciferase reporter gene assays (Figure 4-4), although no data was 
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collected on the bioluminescence of amastigotes. Michel et al. (2011) 
demonstrated that the signal from luciferase-expressing L. infantum amastigotes 
is lower than that of exponentially growing promastigotes, which could be 
attributed to the fact that amastigotes generally display lower metabolic 
activity. Combined in vivo imaging and reverse transcription qPCR assays of L. 
major transcripts have been proposed to determine parasite burdens in vivo in 
relation to the bioluminescent signal (de La Llave et al., 2011; Giraud et al., 
2014). 
The ear dermis was chosen as the site of inoculation to resemble a “natural” 
infection and this was also a good choice for imaging LUC2-expressing parasites, 
as due to the thinness of the ear pinna, there is a lack of quenching of the light 
emission. However, signals from the dLN were not detected due to the deeper 
location and hence quenching from overlying tissues, blood, as well as the dark 
skin and hair pigment of the C57BL/6 mice. Firefly luciferase has a maximum 
emission of 562 nm. Parasites expressing red-shifted luciferase (PpyRE9H), which 
has a maximum emission of 617 nm, can be imaged in deeper tissues (McLatchie 
et al., 2013); this system is more sensitive, detecting fewer than 100 T. brucei. 
The enhanced sensitivity of red-shifted luciferase may be useful in the early 
stages of infection, when the signal is low for LUC2-expressing parasites, and 
also to capture dissemination to the dLN in C57BL/6 mice. 
Recently, Giraud et al. (2014) used the BLI model of infection with simultaneous 
analysis of inflammatory processes and immune responses in the site of infection 
and the dLN by determining the abundance of mouse transcripts for the T cell 
subsets, CD4, CD8, and Foxp3, as well as related cytokines, including IL-4, IL-10, 
IFN-γ, and IL-12p40, over the course of infection. High IL-4 transcript abundance 
was detected at the peak of BLI signal and parasite burden, whereas CD4, IFN-γ, 
and IL-12p40 transcript abundance corresponded with a decrease in BLI signal 
and parasite burden (Giraud et al., 2014). The resistance of a mouse model is 
based on the resolution of lesion size, the clearance of parasites from the site of 
infection and the dLN, and the development of a Th1 response. Giraud et al. 
(2014) have provided the first study linking these factors in a “natural” infection 
model using BLI imaging to provide a better understanding of the dynamics of 
lesion progression, parasite burden, and cellular infiltration. In the next chapter, 
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the innate immune responses, in terms of immune cell recruitment and 
activation, in response to L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 infections 
will be discussed, to explain the differences in disease profiles observed in this 
chapter. 
It has been shown that mice displaying progressive lesions following primary 
inoculation display an absence of cutaneous lesions upon re-inoculation (Courret 
et al., 2003). Persistence of L. major within the host after lesion resolution has 
been attributed to the role of IL-10 produced by CD4+CD25+ regulatory T cells 
(Belkaid et al., 2002). Due to the differences observed in the disease profiles of 
L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 infections, it may be of interest to 
investigate whether there is any effect on concomitant immunity. 
Taken together, the low dose intradermal C57BL/6 infection model for L. major 
Friedlin is characteristic of other L. major low dose infection models shown in 
other reports, indicating that this model is highly reproducible, in terms of 
lesion progression and parasite burdens. This model is also much more 
representative of a human infection, as opposed to the subcutaneous high dose 
model. This model has allowed the comparison of disease profiles upon infection 
with L. major WT and ISP2 gene mutants enabling the investigation into the role 
of the L. major virulence factor, ISP2, in parasite survival and growth. The 
results presented indicate the importance of ISP2 in the establishment and 
persistence of Leishmania infection in vivo. BLI has also become a powerful tool 
in assessing the efficacy of drugs, and in tracking the dissemination of various 
luciferase-expressing cell lines. This study has shown that the BLI method can be 
applied to sensitively evaluate the role of putative virulence factors in vivo. 
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5 Comparison of the cellular immune response 
dynamics during infection with L. major wild-type 
and ISP2 gene mutants in vivo 
5.1 Introduction 
5.1.1 Innate cell recruitment and activation during L. major 
infection in the mouse model 
Upon L. major inoculation into the skin, a strong local inflammatory immune 
response is initiated due to tissue damage caused by the inoculation method. 
Neutrophils are one of the earliest innate immune cell types that infiltrate the 
site of infection, occurring less than an hour after parasite inoculation, to form a 
“plug” of neutrophils in the broken epidermis (Peters et al., 2008). Neutrophils 
are recruited by sandfly- and Leishmania-derived factors (van Zandbergen et al., 
2002; Peters et al., 2008), as well as chemokines, such as CXCL1 (KC) and CXCL2 
(MIP-2), produced by epithelial cells, keratinocytes, fibroblasts, and neutrophils 
(Müller et al., 2001). Neutrophils phagocytose metacyclic promastigotes to serve 
as intermediate hosts for Leishmania (Laufs et al., 2002; Peters et al., 2008). By 
three days post-infection, inflammatory monocytes and macrophages become 
the predominant innate immune cells present at the site of infection (Ribeiro-
Gomes et al., 2012). Monocytes and macrophages are recruited by CCL3 (MIP-1α) 
and CCL4 (MIP-1β) secreted by neutrophils (van Zandbergen et al., 2004). 
Macrophages become the major host cell type harbouring intracellular 
Leishmania at the site of infection. Inflammatory monocytes differentiate into 
either monocyte-derived macrophages or monocyte-derived dendritic cells at 
the site of infection based on the presence of local growth factors and 
cytokines. DCs are proposed to be important in the generation of an adaptive 
immune response; DCs migrate from the site of infection to the dLNs to present 
antigen to naive T cells inducing an antigen-specific T cell response (León et al., 
2007). 
Neutrophils can contribute to inflammation through the process of degranulation 
or the formation of NETs, both of which release granule components into the 
extracellular environment. Neutrophils generate ROS, which oxidise molecules, 
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such as amino acids and nucleotides, and have cytoplasmic azurophilic granules 
consisting of antimicrobial factors, such as MPO, and proteolytic enzymes, 
including SPs. Macrophages and DCs are also able to phagocytose L. major. In 
addition, they produce toxic metabolites, such as NO, which is catalysed by iNOS 
(De Trez et al., 2009). 
5.1.2 Role of serine peptidases in the mammalian immune 
response 
Serine peptidases of neutrophils, often referred to as neutrophil serine proteases 
(NSPs), are stored in high concentrations of their active form in azurophilic 
granules. The NSPs can digest phagocytosed microorganisms through the fusion 
of azurophilic granules with phagolysosomes harbouring the microorganisms 
(Belaaouaj et al., 2000). Upon neutrophil activation, following exposure to 
inflammatory stimuli, the NSPs are secreted into the extracellular environment 
where they have key roles in the regulation of host immune responses. The NSPs 
are also released from apoptotic neutrophils, and are found bound to NETs. 
Neutrophil elastase (NE), cathepsin G (CG), and proteinase 3 (PR3) are the main 
NSPs; these are also found in monocytes. Mast cells, eosinophils, and basophils 
are also sources of NE and PR3, whilst NE has been found in association with CR3 
on the surface of macrophages (Cai & Wright, 1996). 
The primary function of these SPs, of the S1A trypsin-fold family of clan PA, is to 
specifically process cytokines and chemokines to either enhance or abolish their 
function or stability, such as their affinity for their receptor. Proteolytic 
modification by these SPs is typically achieved through limited N-terminal 
cleavage of the respective cytokine or chemokine (reviewed in Pham, 2008). 
There are around 50 chemokines, which are highly specific immunomodulators 
broadly categorised as homeostatic or inflammatory. Migration of immune cells 
to the site of inflammation is mediated by a concentration gradient of active 
chemokines, which is sensed through the use of cognate G protein-coupled 
receptors (GPCRs). The cleavage of cytokines and chemokines by NSPs can, 
therefore, either enhance or terminate the immune response. In addition, NSPs 
can promote or prevent the activation of specific cell receptors leading to the 
modulation of intracellular signalling cascades, which can impact upon the 
production and release of chemokines, and the activation of cell effector 
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processes (Ribeiro-Gomes et al., 2007; Benabid et al., 2012). Table 5-1 highlights 
targets of the NSPs, including cytokines, chemokines, growth factors, receptors, 
and adhesion molecules, which have already been identified and characterised. 
NSPs have also been implicated in the initiation of the adaptive immune 
response through the activation of lymphocytes, as well as the cleavage of 
extracellular matrix (ECM) components to facilitate leukocyte egress from blood 
vessels (reviewed in Pham, 2006). 
Table 5-1 The effects of neutrophil serine proteases (NSPs), neutrophil elastase (NE), 
cathepsin G (CG), and proteinase 3 (PR3), on host biological targets. Adapted from Wiedow & 
Meyer-Hoffert (2005) and Pham (2008) with permission. 
Target Regulated by 
Potential effect during an  
inflammatory response 
Cytokines 
IL-1β Pro-form activated by PR3 
Induces cell proliferation and 
differentiation 
IL-2 Inactivated by NE 
Inhibits differentiation of antigen-
specific T cells  
IL-6 
Inactivated by NE, CG, 
and PR3 
Wide variety of biological functions 
IL-8 (or CXCL8) Activated by PR3  Increases neutrophil chemotaxis 
IL-18 
Pro-form activated by PR3 
Inactivated by NE 
Induces release of IFN-γ from NK 
cells and Th1 cells 
IL-32  Activated by PR3 
Induces production and secretion of 
TNF-α, IL-6, IL-8, and CXCL2 
TNF-α 
Pro-form activated by NE, 
CG, and PR3 
Mature form degraded by 
NE and CG 
Regulates immune cells, including 
the production of cytokines, cell 
proliferation and differentiation, and 
apoptosis 
Chemokines 
Chemerin 
Pro-form activated by NE 
and CG 
Increases APC chemotaxis, such as 
macrophages and DCs 
CCL3 (or MIP-1α) 
Inactivated by NE, CG, 
and PR3 
Abrogates monocyte/macrophage 
chemotaxis  
CCL5 (or RANTES) Inactivated by CG 
Abrogates T cell, basophil, and 
eosinophil chemotaxis 
CCL15 (or MIP-1δ) Activated by CG 
Increases neutrophil and monocyte 
chemotaxis 
CXCL2 (or MIP2) Activated by CG Increases neutrophil chemotaxis 
CXCL5 (or ENA-78) Activated by CG Increases neutrophil chemotaxis 
CXCL8 (or IL-8)  
Activated by PR3 
Inactivated by NE and CG 
Affects neutrophil chemotaxis 
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CXCL12 (or SDF-1α) Inactivated by NE and CG Abrogates lymphocyte chemotaxis 
Growth factors 
TGF-β 
Soluble form released by 
NE 
Blocks activation of monocyte-
derived cells and lymphocytes 
Regulates differentiation of Treg and 
Th17 cells 
Receptors 
IL-2 receptor α Cleaved by NE and PR3 Inhibits cellular response to IL-2 
IL-6 receptor Cleaved by CG Inhibits cellular response to IL-6  
CXCR4 Cleaved by NE and CG 
Abrogates lymphocyte chemotaxis 
through CXCL12 binding 
CD2, CD4, and CD8 Cleaved by NE and CG Impairs T cell activation 
CD14  Cleaved by NE and CG Impairs LPS-induced cell activation 
CD23 
NE and CG release soluble 
fragments 
Stimulates ROS and pro-inflammatory 
cytokine production in monocytes 
CD43 (or 
sialophorin) 
Cleaved by NE 
Regulates monocyte and lymphocyte 
adhesion 
CD87 (or urokinase 
receptor) 
Cleaved by NE and CG Regulates cell migration 
CR1 (or CD35) Cleaved by NE Inhibits complement activation 
TLR4 Activated by NE 
Activates cell signalling through 
MyD88/IRAK/TRAF-6 pathway 
Upregulation of IL-6, IL-8, and TNF-α 
production  
TNF receptor Cleaved by NE Inhibits cellular response to TNF-α 
Protease-activated 
receptor 2 (PAR-2) 
Cleaved by NE, CG, and 
PR3 
Affects release of pro-inflammatory 
mediators, such as CCL3 and CXCL8, 
from epithelial cells 
GCSF receptor Cleaved by NE 
Inhibits cellular response to GCSF 
causing inhibition, proliferation, and 
differentiation of granulocytes and 
macrophages 
Formyl peptide 
receptor (FPR) 
Cleaved by CG 
Abrogates neutrophil and monocyte 
chemotaxis 
Progranulin Inactivated by NE 
Suppresses oxidative burst and 
release of proteases by neutrophils 
Adhesion molecules 
Intercellular 
adhesion molecule 1 
(ICAM-1) 
Cleaved by NE and CG 
Affects leukocyte transmigration 
Increases neutrophil infiltration 
Vascular cell 
adhesion protein 1 
(VCAM-1) 
Cleaved by NE and CG 
Affects monocyte and lymphocyte 
adhesion to vascular endothelium 
  Chapter 5 
107 
 
Antimicrobial peptides 
LL-37 Pro-form activated by PR3 Active against bacterial infection 
Excessive extracellular activity of NSPs can contribute to tissue damage; 
therefore, the activity of the NSPs is tightly controlled by natural inhibitors. The 
liver produces inhibitors, such as the serpins, AAT and ACT, which are 
distributed throughout the body in plasma. Serpins are irreversible inhibitors, 
which function by presenting their reactive site as a substrate for the protease, 
trapping the enzyme and distorting its catalytic site through a conformational 
change of the serpin (Huntington, 2011). There are also tissue-specific 
inhibitors, such as the chelonianins, elafin and SLPI. 
Other human SPs involved in immunity, which are in the same clan as the NSPs, 
are the granzymes, produced by NK cells and cytotoxic T cells, and chymase and 
tryptase of mast cells. These trypsin-like SPs have different substrate 
specificities to the elastase-like, NE and PR3. Granzymes mediate apoptosis of 
virus-infected and tumour cells, whereas chymase and tryptase are involved in 
the clearance of extracellular pathogens, degradation of ECM components, and 
blood coagulation. Based on the localisation and functions of the SPs in vivo, and 
previous in vitro studies on the roles of ISP2 (Faria et al., 2011), it is more likely 
that ISP2 inhibits the activity of the SPs produced by neutrophils and monocytes, 
which play prominent roles during L. major infection. In addition, Eschenlauer et 
al. (2009) and Faria et al. (2011) have previously shown that ISP2 is a strong 
inhibitor of NE activity. 
5.1.3 Serine peptidase-deficient mice 
The generation of mice deficient in the individual NSPs, NE encoded by the Elane 
gene, also known as the Ela2 gene, CG encoded by the Ctsg gene, and PR3 
encoded by the Prtn3 gene, or combinations of these NSPs, have enabled 
investigation into the contribution of these NSPs as antimicrobial molecules and 
their roles in the regulation of inflammation. In general, homozygous transgenic 
mice were generated through targeted gene disruption of the specific genes in 
embryonic stem cells, and germline transmission of the mutant gene loci was 
enabled through the generation and breeding of chimeric mice; NE-/- (Belaaouaj 
et al., 1998), CG-/- (MacIvor et al., 1999), NE-/-PR3-/- (Kessenbrock et al., 2008), 
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and NE-/-CG-/- mice (Tkalcevic et al., 2000) have so far been generated. In these 
transgenic mice, the NSPs are no longer expressed from bone marrow-derived 
cells. 
NSPs have direct microbicidal properties against bacteria through the disruption 
of bacterial membranes (Belaaouaj et al., 2000). NE-deficient mice are more 
susceptible to Gram-negative bacterial infections, such as Eschericia coli and 
Klebsiella pneumonia (Belaaouaj et al., 1998), whereas CG-deficient mice are 
more susceptible to infections with the Gram-positive, Staphylococcus aureus 
(Reeves et al., 2002). 
Mice deficient in both NE and CG, or NE alone, have been shown to have a 
defect in neutrophil recruitment in response to zymosan, with decreases in the 
production of CXCL1, CXCL2, TNF-α, and IL-1β (Adkison et al., 2002; Young et 
al., 2004). In mice deficient in both NE and PR3, there is an accumulation of 
progranulin, due to an inability to degrade this anti-inflammatory factor, which 
functions in the suppression of the oxidative burst; this potentially inhibits 
neutrophil activation and can lead to a decrease in recruitment of immune cells 
(Kessenbrock et al., 2008). 
The role of host NSPs in the modulation of immune responses during parasitic 
infections has not been fully assessed, particularly with the use of these NSP-
deficient mice. 
5.1.4 In vivo methods to assess innate cell infiltration and 
activation 
Gross et al. (2009) established a method of imaging MPO activity in vivo using 
the redox-sensitive compound, luminol. Luminol-induced bioluminescence 
enables quantitative longitudinal monitoring of MPO activity of activated 
phagocytes. MPO constitutes about 5% of the protein in azurophilic granules of 
neutrophils and approximately 1% of the protein in monocytes. MPO is also found 
in macrophages and other polymorphonuclear leukocytes, such as eosinophils, 
basophils, and mast cells. Upon phagocyte activation, large quantities of active 
MPO are secreted into the phagosomes to catalyse a reaction between hydrogen 
peroxide, H2O2, generated during the phagosomal oxidative burst, with chloride 
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ions, Cl-, to produce antimicrobial hypochlorous acid, HOCl. HOCl oxidises 
various molecules including DNA, proteins, and lipids. Luminol is a small 
uncharged molecule that can penetrate the plasma membrane and phagosomal 
membrane to enable quantification of MPO activity in these innate cell types in 
vivo. Bioluminescence is specific to MPO activity, as the signal is abolished in 
Mpo-/- mice and upon treatment with 4-ABAH, a  potent inhibitor of MPO activity 
(Gross et al., 2009; Zhang et al., 2013). The exact interaction with luminol is 
currently unknown; whether HOCl directly or indirectly oxidises luminol, or 
whether products from other reactions catalysed by MPO, such as the oxidation 
of NO, oxidise luminol to produce light. This luminol-based in vivo imaging 
technique has been used in animal models for acute inflammation, such as acute 
dermatitis, arthritis, and tumours (Gross et al., 2009; Zhang et al., 2013), but, 
as yet, has not been utilised to monitor the dynamics of phagocyte activation in 
models of infectious disease, including Leishmania. 
5.1.5 Aims 
In the previous chapter, the disease progression of L. major WT and the ISP2 
gene mutants was examined in vivo, revealing reduced parasite loads of an L. 
major ISP2/3-deficient mutant, Δisp2/3, at the site of inoculation compared 
with WT infection. In this chapter, the role of ISP2 on the modulation of host 
immune responses at the site of inoculation, and in the dLN, in the low dose 
intradermal C57BL/6 infection model, discussed in Chapter 4, with L. major 
Friedlin WT and the ISP2 gene mutants will be assessed in vivo. Flow cytometric 
analysis and novel in vivo BLI techniques will be used to evaluate innate cell 
infiltration and activation over the course of infection; this type of analysis has 
not previously been performed in the study of putative virulence factors in vivo. 
The sequence of local inflammatory events during infection with L. major WT, 
Δisp2/3, a cell line re-expressing ISP2/3, Δisp2/3:ISP2/3, or a cell line 
overexpressing ISP2, WT [pXG-ISP2], may indicate a role for ISP2 in the 
modulation of immune responses during infection with Leishmania. In addition, 
transgenic mice deficient in NE, Ela-/-, will be used to assess the role of this host 
NSP in the generation of immune responses to L. major WT and the ISP2 gene 
mutants in vivo. 
The aims of this chapter are to: 
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 Analyse the recruitment of the innate cell populations at the site of 
inoculation over the course of infection by flow cytometry 
 Monitor phagocyte activation at the site of inoculation over the course of 
infection through BLI 
 Assess the activation state of effector cells, in terms of the iNOS response and 
DC maturation through the expression of co-stimulatory markers 
 Determine the cytokine microenvironment at the site of inoculation and in the 
dLN with regards to the levels of IFN-γ 
 Evaluate the role of NE in these immune responses through the use of Ela-/- 
mice 
5.2 Results 
5.2.1 Innate immune cell dynamics at the site of intradermal L. 
major inoculation 
The cellular innate immune response at the site of infection was examined 
following intradermal inoculation with 104 L. major WT or Δisp2/3 metacyclic 
promastigotes into the ears of C57BL/6 mice. Innate cell subsets within the ear 
were analysed by flow cytometry from 1 d to 5 wk post-infection. The gating 
strategy excluded dead cells through staining with a fixable viability dye, in 
which dead cells were irreversibly labelled. Cells of the myeloid lineage were 
then identified and gated based on CD11b expression, which is expressed on the 
surface of many leukocytes, such as monocytes, macrophages, NK cells, specific 
subsets of DCs, neutrophils, and other granulocytes (Larson & Springer, 1990; 
Ribeiro-Gomes et al., 2012). The percentage of these cells within the live cell 
population in the ear increased from 1 to 5 wk post-infection for those infected 
with WT parasites, and 1 to 4 wk post-infection for Δisp2/3 parasites (Figure 5-
1A). The total cell numbers within the ear were assessed by manual cell counts 
on a haemocytometer showing that the cell number was higher in ears infected 
with WT or Δisp2/3 parasites than the naive ears at almost every time-point 
studied (Figure 5-1B), suggesting cellular infiltration to the infected site. There 
were increases in the total cell number from 2 wk post-infection for both WT 
  Chapter 5 
111 
 
and Δisp2/3 infections, which became higher than in the initial phase of 
infection, less than 1 wk post-infection; however, the only significant difference 
was at 2 d post-infection, in which the total cell number was higher in Δisp2/3 
infection than WT infection (Figure 5-1B). 
 
Figure 5-1 Myeloid cell composition at the site of inoculation during infection with L. major 
WT and Δisp2/3. Purified metacyclic promastigotes (104 in 10 µl PBS) were intradermally 
inoculated into the ears of C57BL/6 mice (n=5 for each group at each time-point). A) Changes in 
the percentages of CD11b+ cells within the live cell population assessed by flow cytometry. B) 
Total cells in the ear dermis assessed by cell counts on a haemocytometer. ■, WT; ○, Δisp2/3. 
Results are expressed as means per group at each time-point after infection, a representative of 
two independent experiments. Error bars represent S.E.M. Dashed lines represent A) the mean 
percentage of CD11b+ cells within the live cell population of a naive ear and B) the mean total 
cells in a naive ear. Asterisks indicate statistical significance between WT and Δisp2/3 at p < 
0.01 (**), as measured by an unpaired t-test. 
A 
B 
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The CD11b+ innate cell subsets were further classified based on their surface 
antigen profiles, to investigate neutrophils, macrophages, DCs, monocytes, and 
the monocyte-derived macrophages and DCs (moDCs) (Table 5-2). The gating 
strategy used in this investigation was based on that proposed by Ribeiro-Gomes 
et al. (2012), as it encompassed all the innate immune cells that are thought to 
be important during Leishmania infection, and the recruitment of which may be 
affected by the inhibition of SP activity (Table 5-1). This gating strategy also 
allowed  the reproducibility of the intradermal L. major infection models used in 
this study and that of Ribeiro-Gomes et al. (2012) to be shown, in terms of 
innate immune cell recruitment at the site of inoculation, and enabled 
comparisons of the innate immune cell dynamics to site of inoculation with L. 
major WT parasites to that of the ISP2 gene mutants. An example of the gating 
strategy for the innate immune cell subsets of the ear dermis is given in Figure 
5-2. 
Table 5-2 Cell surface markers of CD11b+ myeloid innate cell subsets. 
Cell type 
Region in 
Figure 5-2 
Ly6C Ly6G CD11c MHCII 
Neutrophils 2 Intermediate Positive   
Resident dermal 
macrophages 
5 Negative Negative Negative Positive 
Resident dermal 
dendritic cells 
6 Negative Negative Positive Positive 
Inflammatory 
monocytes 
7 High Negative Negative Negative 
Monocyte-derived 
macrophages 
8 High Negative Negative Positive 
Monocyte-derived 
dendritic cells 
9 High Negative Positive Positive 
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Figure 5-2 Gating strategy to determine innate immune cell subsets in the ear dermis. 
Subpopulations of CD11b+ myeloid cells (region 1) were gated on Ly6C and Ly6G expression; 
regions 3 and 4 were further gated on CD11c and MHCII expression. The subpopulation of CD11b+ 
myeloid cells were defined as follows: Ly6CintLy6G+ neutrophils (region 2); Ly6C-Ly6G-CD11c-
MHCII+ resident macrophages (region 5); Ly6C-Ly6G-CD11c+MHCII+ resident dendritic cells (region 
6); Ly6ChiLy6G- inflammatory monocytes (region 7); Ly6ChiLy6G-CD11c-MHCII+ monocyte-derived 
macrophages (region 8); and Ly6ChiLy6G-CD11c+MHCII+ monocyte-derived dendritic cells (region 
9). 
The graphs shown in Figure 5-3 indicate the percentage of each cell type within 
the CD11b+ population (Figure 5-3, top panels) and the total number of each cell 
type, as calculated through manual cell counts (Figure 5-3, bottom panels), 
plotted as means per group at each time-point. To demonstrate how the innate 
cell populations in L. major WT- and Δisp2/3-infected ears differed from the 
naive ear, presented on the graphs are the mean percentages and numbers of 
each cell type in the naive ear, which were used as a control at each time-point. 
The CD11b+ cells of naive ears were comprised of large percentages and numbers 
of resident dermal macrophages and DCs (Figure 5-3, C to F), but low 
percentages and numbers of monocytes and monocyte-derived cells (Figure 5-3, 
G to L). Mice were also injected in the ear with PBS, in order to distinguish 
parasite-specific immune responses from tissue damage-induced inflammation; 
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however, at the time-points studied, there was no difference in the innate cell 
populations between PBS-injected and naive ears. This has been shown by other 
groups, who only report a difference in neutrophil recruitment between sham 
injected and naive ears at 1 h post-infection (Ribeiro-Gomes et al., 2012). 
Neutrophils constituted the largest percentage of the CD11b+ population at 1 d 
in both WT and Δisp2/3 infections (Figure 5-3A), which was also reflected in 
higher numbers of neutrophils (Figure 5-3B). The neutrophils then decreased to 
levels equivalent to those of a naive ear until 2 wk post-infection, at which a 
second wave of neutrophils was observed, which peaked at 4 wk in both WT and 
Δisp2/3 infections (Figure 5-3, A and B). The percentages of dermal 
macrophages and DCs within the CD11b+ population showed a peak at 4 d (Figure 
5-3, C and E), at which the neutrophils were at a baseline level. After this point, 
the percentages of dermal macrophages and DCs were lower than that of a naive 
ear, which likely reflects a substantial infiltration of other CD11b+ cell subsets. 
The numbers of dermal macrophages and DCs did not differ significantly to that 
of a naive ear from 1 wk, except at 5 wk, where the numbers of macrophages 
were significantly higher than the naive ear for WT and Δisp2/3 infections 
(Figure 5-3D). 
There was a peak in the percentage of inflammatory monocytes in both WT and 
Δisp2/3 infections at 2 d (Figure 5-3G), followed by peaks in the percentages of 
monocyte-derived macrophages and moDCs at 4 d (Figure 5-3, I and K). A second 
wave of these monocyte cell types was observed after a decrease to levels seen 
in naive ears at 1 wk; these second waves peaked at 2 wk for Δisp2/3 infections, 
but 3 wk for WT infections, as proportion of the CD11b+ population (Figure 5-3, 
G, I, and K). The decrease in the percentages of these monocyte cell types after 
their peaks may be due to the considerable increase in the percentage of 
neutrophils within the CD11b+ population, as the total numbers of the 
monocytes, monocyte-derived macrophages, and moDCs continued to increase 
up to 5 wk for both WT and Δisp2/3 infections (Figure 5-3, H, J, and L). There 
was a significantly higher percentage and total number of monocyte-derived 
macrophages and moDCs, and higher percentage of inflammatory monocytes at 2 
wk post-infection for Δisp2/3 infection compared with WT infection (Figure 5-3, 
G to L). 
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The percentage of CD11b+ cells within the live cell populations of the dLNs were 
also assessed from 1 to 5 wk after intradermal inoculation with L. major WT or 
Δisp2/3 metacyclic promastigotes. Figure 5-4 shows a significantly higher 
percentage of CD11b+ cells in the dLNs of Δisp2/3-infected mice at 2 wk post-
infection than WT-infected mice. 
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Figure 5-3 Dynamics of the innate immune cell populations at the site of inoculation during infection with L. major WT and Δisp2/3. Purified metacyclic 
promastigotes (104 in 10 µl PBS) were intradermally inoculated into the ears of C57BL/6 mice (n=5 for each time-point). Changes in the percentages of each cell 
type within the CD11b+ population (top panels) and changes in the total number of each cell type (bottom panels) per ear during infection with L. major WT (■) or 
Δisp2/3 (○). Innate immune cell types are defined as given in Table 5-2 and Figure 5-2; neutrophils (A and B), dermal macrophages (C and D), dermal dendritic 
cells (E and F), inflammatory monocytes (G and H), monocyte-derived macrophages (I and J), and monocyte-derived dendritic cells (K and L). Results are 
expressed as means per group (n=5) at each time-point after infection, a representative of two independent experiments. Error bars represent S.E.M. Dashed lines 
represents the mean percentage of each cell type within the CD11b+ population (top panels) and the mean numbers of each cell type (bottom panels) in a naive 
ear. Asterisks indicate statistical significance between WT and Δisp2/3 at p < 0.05 (*) and p < 0.01 (**), as measured by an unpaired t-test. 
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Figure 5-4 Myeloid cell composition of the draining lymph node after intradermal inoculation 
with L. major WT or Δisp2/3. Purified metacyclic promastigotes (104 in 10 µl PBS) were 
intradermally inoculated into the ears of C57BL/6 mice (n=5 for each time-point). The 
percentage of CD11b+ within the live cell population of the dLN was assessed during infection 
with  L. major WT (black bars) or Δisp2/3 (grey bars). Single cell suspensions from the dLNs were 
stained with the pan-myeloid cell marker, CD11b. Bars represent the means per group at each 
time-point after infection. Error bars represent S.E.M. Dashed lines represents the mean 
percentage of CD11b+ cells within the live cell population in naive dLNs. Asterisks indicate 
statistical significance between WT and Δisp2/3 at p < 0.05 (*), as measured by an unpaired t-
test. 
5.2.2 Imaging myeloperoxidase (MPO) activity of activated 
phagocytes during L. major infection 
Luminol was used to non-invasively monitor MPO activity during the course of 
infection with L. major WT and ISP2 gene mutants in vivo. L. major WT, Δisp2/3, 
and an ISP2 overexpressor, WT [pXG-ISP2], were inoculated into the ear dermis 
of C57BL/6 mice at a dose of 104 metacyclic promastigotes. For controls, ears 
were injected with an equivalent volume of PBS, or the needle only; naive ears 
were also imaged to provide the background signal for the BLI. For each time-
point after parasite inoculation, mice were intraperitoneally injected with 
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luminol to generate an MPO-specific bioluminescent signal. Mice were 
anaesthetised then imaged in the IVIS using a CCD camera to detect and capture 
the photons emitted between 10 and 15 min after luminol injection. Figure 5-5A 
shows representative images of one mouse for each of the control groups, and 
Figure 5-5B shows representative images of one mouse per group infected with 
either L. major WT, Δisp2/3, or WT [pXG-ISP2] parasites over the course of 
infection. 
Figure 5-5C shows the average MPO-specific bioluminescent signal from the ears 
of each mouse group at each time-point studied. There was a low MPO-specific 
bioluminescent signal from the ears infected with all three L. major cell lines at 
1 h post-infection, which was significantly different from the background signal 
from the naive ear, but not from the PBS and needle only controls. The 
bioluminescent signal from the PBS and needle only controls at 1 h was between 
that from the parasite groups and the naive ears, from which they were not 
significantly different. There was a slight increase in the signal from the PBS and 
needle only controls at 4 h, but the signal from these groups decreased to that 
of a naive ear by 24 h, which was on average 4.1x103 photons sec-1 over the 
course of infection. The signal from the PBS and needle only control groups 
remained around 4.7x103 photons sec-1 over the next 13 wk, which was not 
significantly different from that of the naive ear. The signal from the parasite-
infected ears also decreased to the level of the background signal by 48 h. 
At 2 wk post-infection, there was an increase in the bioluminescent signal from 
ears infected with WT and Δisp2/3 parasites, which continued to increase at 3 
wk, and was maintained around the same level until 11 wk for WT infection and 
9 wk for Δisp2/3 infection. Over 3 to 6 wk, the average bioluminescent signal 
from Δisp2/3-infected ears appeared to be higher than that from WT-infected 
ears. This may indicate differences in the activation status of the phagocytes; as 
the only differences in innate immune cell recruitment were higher numbers of 
monocyte-derived cells at 2 wk in Δisp2/3 infection compared with WT 
infection, as evidenced by flow cytometry (Figure 5-3). At 9 wk, the signal from 
Δisp2/3-infected ears began to decrease and by 13 wk the signal was almost 
equivalent to the background signal, whereas the decrease in signal from WT-
infected mice from 11 wk was not as pronounced. This stage may show the 
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resolution of the disease with fewer phagocytes present, as these time-points 
were not assessed by flow cytometry. The signal from WT [pXG-ISP2]-infected 
ears was much more delayed, not beginning to increase until 4 wk, and reaching 
the peak around 12 wk. The overexpression of ISP2 may, therefore, lead to 
inhibition of innate cell recruitment to the site of infection. The respective 
peaks in bioluminescent signal for each of the parasite groups during this second 
wave was approximately 6 to 7-fold higher than their initial signal at 1 h.  
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Figure 5-5 In vivo bioluminescence imaging of MPO activity of activated phagocytes at the 
site of inoculation during infection with L. major WT and ISP2 gene mutants. C57BL/6 mice 
were inoculated in the ear with 104 L. major WT, Δisp2/3, WT [pXG-ISP2] metacyclic 
promastigotes (n=5 for each group). Mice were imaged in the IVIS 10 to 15 min after 
intraperitoneal luminol injection. Representative images of one mouse per group over the course 
of infection for A) the controls, which were the naive ears, ears injected with the needle only, 
or ears injected with 10 µl PBS (n=4 for each group), and B) ears infected with L. major WT, 
Δisp2/3, and WT [pXG-ISP2]. The colour scale indicates bioluminescent radiance in 
photons/second/cm2/steradian. The red oval indicates the region of interest (ROI) and the value 
in the red box indicates the total flux, given in photons per second (photons sec-1), over the ROI 
in the individual image shown. The same colour scale and ROI was applied to all images 
analysed. The value in white gives the mean total flux for the group at each time-point. C) The 
mean total flux for the group at each time-point over the course of 13 wk infection. ■, WT; ○, 
Δisp2/3; ▼, WT [pXG-ISP2]; ♦, PBS; ◊, injection only; ×, naive. Data are shown on a logarithmic 
scale. Error bars represent S.E.M. Asterisks indicate statistical significance between the parasite 
groups at p < 0.05 (*) and p < 0.001 (***), as measured by one-way ANOVA with a Tukey post test. 
MPO is known to be contained within the granules of neutrophils and monocytes 
(Tay et al., 1998), but whether MPO is present in macrophages of mice is still 
unclear, as certain tissue macrophages in humans have been shown to be MPO-
positive (Daugherty et al., 1994; Nagra et al., 1997). Therefore, flow cytometry 
was performed, using intracellular staining with an anti-MPO antibody, to 
analyse the MPO protein content in the cell types analysed in this investigation 
(Table 5-2). This information of MPO protein content could provide a better 
indication of which innate cell types contributed to the differences observed in 
the bioluminescent signal of MPO activity detected using luminol between L. 
major WT and the ISP2 gene mutants in vivo (Figure 5-5). 
C 
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Mice were intradermally inoculated with metacyclic promastigotes of L. major 
WT, Δisp2/3, or Δisp2/3:ISP2/3, which stably expresses ISP2, rather than WT 
[pXG-ISP2]; the ears were processed and analysed 2 wk post-infection, the time-
point at which differences were observed in the innate immune cell populations 
in the ear after infection with WT or Δisp2/3 parasites (Figure 5-3). The graphs 
showing the percentage of CD11b+ cells within the total live cell population 
(Figure 5-6A) and the percentage of each innate cell type within the CD11b+ 
population (Figure 5-6, B to E) were analysed as in Figure 5-1 to 5-3. However, 
Figure 5-6C represents all Ly6Chi cells, which incorporates the inflammatory 
monocytes, monocyte-derived macrophages, and moDCs, as too few cells were 
analysed to make reliable distinctions between these cell types. The 
percentages of each of these innate cell types in response to WT and Δisp2/3 
infection at 2 wk was similar to that seen earlier (Figure 5-1 and 5-3). The use of 
the Δisp2/3:ISP2/3 cell line corroborated the differences observed previously in 
the Ly6Chi monocyte and monocyte-derived cell populations in the WT and 
Δisp2/3 infections at this time-point (Figure 5-3, G, I, and K, and Figure 5-6C); 
the cell populations in response to WT and Δisp2/3:ISP2/3 infections were not 
significantly different, but between infections with Δisp2/3 and Δisp2/3:ISP2/3, 
which slightly overexpresses ISP2 (Figure 3-1), were significantly different. 
However, there was also a significantly higher percentage of neutrophils in the 
Δisp2/3 infection compared with Δisp2/3:ISP2/3 infection (Figure 5-6B), whereas 
no significant difference was observed between Δisp2/3 and WT infections 
(Figure 5-3A and Figure 5-6B). 
Figure 5-6F shows that there was significantly more MPO+ staining within the 
CD11b+ population of ears infected with Δisp2/3 parasites, than Δisp2/3:ISP2/3 
and WT parasites, although this difference was not significantly different. 
Intracellular staining of MPO showed that almost all neutrophils were MPO+, 97%, 
and approximately 48% of Ly6Chi cells were MPO+, regardless of the ear samples 
analysed, i.e. parasite-infected, PBS-injected, or naive. Resident macrophages 
and DCs had negligible MPO staining at 0.25% and 4.7% respectively. This 
indicates that MPO can be used as an additional stain to distinguish between 
these innate cell types in mice. Due to the levels of MPO staining within each of 
these cells types and the percentage of each of these cell types within the 
CD11b+ population, MPO+ neutrophils (Figure 5-6G) and MPO+ Ly6Chi cells (Figure 
Chapter 5 
128 
 
5-6H) were significantly higher in Δisp2/3 infection compared with WT and 
Δisp2/3:ISP2/3 infections. This suggests that either of these cell types could 
contribute to the MPO-specific bioluminescent signal in vivo when these 
phagocytes are activated. 
 
Figure 5-6 MPO protein content of innate immune cells in the ear dermis of C57BL/6 mice at 
2 wk post-infection with L. major WT and ISP2 gene mutants. Purified metacyclic 
promastigotes (104 in 10 µl PBS) of L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 were intradermally 
inoculated into the ears of C57BL/6 mice (n=5). Innate immune cell populations of the ear were 
analysed by flow cytometry as shown in Figure 5-2. The intracellular MPO staining was then 
assessed for each cell population in each of the groups; data are presented as the percentage of 
each MPO+ cell type within the CD11b+ population for each group. Percentages of A) CD11b+ cells 
within the live cell population, and B) neutrophils, C) Ly6Chi cells, D) dermal macrophages, and 
E) dermal dendritic cells, F) total MPO+ cells, G) MPO+ neutrophils, and H) MPO+ Ly6Chi cells 
within the CD11b+ population. Asterisks indicate statistical significance between groups at p < 
0.05 (*), p < 0.01 (**) and p < 0.001 (***), as measured by one-way ANOVA with a Tukey post test. 
5.2.3 Quantification of the iNOS response, IFN-γ production, and 
DC maturation 
As there were differences between the innate cell recruitment and activation 
during infection with L. major WT and the ISP2 gene mutants, the expression of 
iNOS within these innate cell types was investigated. iNOS, also known as NOS2, 
produces the toxic metabolite, NO, which is known to control L. major infection 
(Stenger et al., 1994; Vouldoukis et al., 1995; De Trez et al., 2009; Petritus et 
al., 2012). The differences observed in the innate immune cell recruitment and 
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activation at the site of infection occurred during the second wave of innate cell 
infiltration, starting at 2 wk post-infection; therefore, the focus of the 
subsequent investigations were during this stage of infection. 
Mice were intradermally inoculated with L. major WT, Δisp2/3, or 
Δisp2/3:ISP2/3 metacyclic promastigotes, the ears were processed and analysed 
at 2 and 5 wk post-infection. There was prominent iNOS expression in the 
parasite-infected ears at both 2 (Figure 5-7, A and B) and 5 wk post-infection 
(Figure 5-7C). There was a significantly higher percentage of iNOS+ cells in 
Δisp2/3-infected ears compared with those infected with WT and Δisp2/3:ISP2/3 
parasites at 2 wk, but by 5 wk, there was no significant difference between the 
groups. The higher iNOS expression in Δisp2/3-infected ears at 2 wk was due to 
an increase in iNOS expression in the resident macrophages, resident DCs, 
inflammatory monocytes, and monocyte-derived macrophages (Figure 5-7, E to 
H). The level of iNOS expression within the moDCs was high in response to all the 
parasite groups (Figure 5-7I), suggestive of the iNOS-producing moDCs that have 
been described in L. major infection (De Trez et al., 2009). Conversely, the level 
of iNOS expression within the neutrophils was low (Figure 5-6D). 
Chapter 5 
130 
 
 
Figure 5-7 Inducible nitric oxide synthase (iNOS/NOS2) expression at the site of inoculation 
at 2 wk post-infection with L. major WT and ISP2 gene mutants. Purified metacyclic 
promastigotes (104 in 10 µl PBS) of L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 were intradermally 
inoculated into the ears of C57BL/6 mice (n=5). Innate immune cell populations of the ear were 
analysed by flow cytometry as shown in Figure 5-2; data are presented as the percentage of 
iNOS/NOS2+ cells within each cell type for each group. A) Histogram to show the iNOS+ cells 
within the CD11b+ population at 2 wk post-infection. Shaded area represents the cells from a 
naive ear. Blue line, WT; grey line, Δisp2/3; yellow line, Δisp2/3:ISP2/3. Percentage of iNOS+ 
cells within the CD11b+ population at B) 2 wk and C) 5 wk post-infection. Percentage of iNOS+ D) 
neutrophils, E) resident macrophages, F) resident dendritic cells, G) inflammatory monocytes, H) 
monocyte-derived macrophages, and I) monocyte-derived dendritic cells, as assessed by flow 
cytometry. Asterisks indicate statistical significance between groups at p < 0.05 (*), p < 0.01 (**), 
and p < 0.0001 (****), as measured by one-way ANOVA with a Tukey post test. 
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IFN-γ secreted by Th1 cells stimulates the expression of iNOS, which produces 
NO. High levels of IFN-γ can be an indication of the polarisation of the adaptive 
immune response towards a Th1 response, which is associated with the control 
of Leishmania infection (Locksley et al., 1991; Park et al., 2000; De Trez et al., 
2009). The concentration of IFN-γ at the site of inoculation and in dLN of mice 
infected with L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 parasites, at 2 wk post-
infection was assessed by ELISA (Figure 5-8, A and B respectively). At the site of 
inoculation, the concentration of IFN-γ in Δisp2/3-infected ears was significantly 
higher than that of WT- and Δisp2/3:ISP2/3-infected ears (Figure 5-8A). Although 
the mean concentration of IFN-γ in the dLNs of Δisp2/3-infected mice appeared 
higher than that of WT and Δisp2/3:ISP2/3 infections, there was no significant 
difference between the WT, Δisp2/3, and Δisp2/3:ISP2/3 infections (Figure 5-
8B). 
 
Figure 5-8 IFN-γ concentration at 2 wk post-infection with L. major WT and ISP2 gene 
mutants. Purified metacyclic promastigotes (104 in 10 µl PBS) of L. major WT, Δisp2/3, and 
Δisp2/3:ISP2/3 were intradermally inoculated into the ears of C57BL/6 mice (n=5). ELISAs were 
performed using supernatants isolated from the A) ears and B) dLNs. Mean with error bars 
representing S.E.M. Asterisks indicate statistical significance between groups at p < 0.01 (**), as 
measured by one-way ANOVA with a Tukey post test. 
A B 
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DCs are proposed to be important in the generation of an adaptive immune 
response during Leishmania infection; DCs migrate from the site of infection to 
the dLNs to present antigen to naive T cells in order to induce an antigen-
specific T cell response (León et al., 2007). To assess the activation of the DC 
populations, the resident DCs and the moDCs, flow cytometry was performed to 
determine the surface expression of CD86 and CD80. CD86 and CD80 are co-
stimulatory molecules that work in tandem to prime a T cell response through T 
cell activation (Moser, 2001). CD86 is a marker of early DC maturation, whereas 
CD80 is a marker of mature DCs (Zheng et al., 2004). CD80 and CD86 have also 
been reported to activate the Th1 and Th2 developmental pathways respectively 
(Kuchroo et al., 1995), which has been shown to play a role during L. major 
infection (Brown et al., 1996). Mice were intradermally inoculated with L. major 
WT or Δisp2/3 parasites, the ears were processed and analysed at 2 wk post-
infection. There was a significantly higher percentage of moDCs in response to 
Δisp2/3 infection compared with WT infection (Figure 5-9A), as seen previously 
(Figure 5-3K). However, there was also a significantly higher percentage of 
resident DCs in WT infection compared with Δisp2/3 infection, although there 
was no significant difference from the naive ear (Figure 5-9B). 
There was no difference in the surface staining of CD86 on moDCs (Figure 5-9C) 
and resident DCs (Figure 5-9D) from parasite-infected or naive ears. There was, 
however, a significant increase in CD80 expression on moDCs from Δisp2/3-
infected ears compared with those from WT-infected and naive ears (Figure 5-
9E). In addition, there appeared to be an increase in CD80 expression on 
resident DCs from Δisp2/3-infected ears, although this was not significantly 
different from WT-infected or naive ears (Figure 5-9F). 
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Figure 5-9 Dendritic cell co-stimulatory molecule expression at 2 wk post-infection with L. 
major WT and Δisp2/3. Purified metacyclic promastigotes (104 in 10 µl PBS) of L. major WT and 
Δisp2/3 were intradermally inoculated into the ears of C57BL/6 mice (n=5). Innate immune cell 
populations of the ear were analysed by flow cytometry as shown in Figure 5-2. Percentage of A) 
monocyte-derived dendritic cells and B) resident dendritic cells within the CD11b+ population at 
2 wk post-infection. Percentage of CD86+ C) monocyte-derived dendritic cells and D) resident 
dendritic cells. Percentage of CD80+ E) monocyte-derived dendritic cells and F) resident 
dendritic cells. Asterisks indicate statistical significance between groups at p < 0.05 (*), p < 0.01 
(**), and p < 0.001 (***), as measured by one-way ANOVA with a Tukey post test. 
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5.2.4 The role of neutrophil elastase (NE) during Leishmania 
infection in vivo 
Mice deficient in NE, Ela-/-, were used to investigate the role of this host NSP in 
the generation of immune responses to L. major WT and the ISP2 gene mutants 
in vivo. 
5.2.4.1 Genotyping of transgenic Ela-/- mice 
Ela-/- mice used in this study were previously generated through the disruption of 
the endogenous NE gene with a targeting vector containing neomycin 
phosphotransferase cDNA driven by the phosphoglycerate kinase promoter (PGK-
neo) (Belaaouaj et al., 1998). Ela-/-mice are currently maintained in a C57BL/6 
genetic background. 
PCR was performed on DNA purified from the ear tissue of C57BL/6 and Ela-/- 
mice to check the presence of the NE gene in C57BL/6 mice (Figure 5-10A, lanes 
1 and 2), and the neomycin marker in Ela-/- mice (Figure 5-10A, lanes 7 and 8). 
Samples from lanes 1, 2, 7, and 8, were re-run in Figure 5-10B, because no band, 
representing the wild-type NE gene in C57BL/6 mice, was observed in lane 2 of 
Figure 5-10A. Figure 5-10B shows that this band (lane 2) is much fainter and may 
not have been detected or loaded correctly in Figure 5-10A. DNA from C57BL/6 
mice was negative for the neomycin marker (Figure 5-10A, lanes 3 and 4). 
Multiple bands were observed in PCR with the NE primers against DNA from Ela-/- 
mice, although there were no bands present the same size as the wild-type NE 
gene (Figure 5-10A, 5 and 6); the presence of multiple bands is due to the 
disruption of the NE gene. 
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Figure 5-10 Genotyping of transgenic neutrophil elastase deficient, Ela-/-, mice through PCR 
analysis. A) Two independent DNA samples from C57BL/6 mice with primers for the wild-type 
neutrophil elastase gene (lanes 1 and 2) and the neomycin marker (lanes 3 and 4). Two 
independent DNA samples from Ela-/- mice with primers for the wild-type neutrophil elastase 
gene (lanes 5 and 6) and the neomycin marker (lanes 7 and 8). B) Samples from lanes 1, 2, 7, and 
8 of Figure 5-10A, were run on a separate gel, lanes 1, 2, 3, and 4 respectively, to check the 
loading of lane 2 of A. 
5.2.4.2 Lesion measurements over the course of L. major infection in Ela-/- 
mice 
Lesion size was evaluated in the ears of Ela-/- mice following intradermal 
inoculation of 104 L. major WT, Δisp2/3, or WT [pXG-ISP2] metacyclic 
promastigotes (Figure 5-11). Ear thickness did not change in ears injected with 
PBS or the needle only, or in the naive ears, which were, on average, 0.25 mm 
over the course of infection. WT- and Δisp2/3-infected ears showed a similar 
lesion profile, in which ear thickness began to increase at 2 wk post-infection, 
peaking and gradually decreasing from 4 wk onwards. WT [pXG-ISP2]-infected 
ears showed a much more delayed lesion progression, which did not begin to 
increase until 5 wk post-infection and continued to increase up to 11 wk post-
infection. 
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Figure 5-11 Lesion development in the ears of Ela-/- mice infected with L. major WT and ISP2 
gene mutants. The ears of Ela-/- mice were infected with 104 L. major WT (n=4), Δisp2/3 (n=4), 
or WT [pXG-ISP2] (n=3) metacyclic promastigotes. Ear thickness was measured weekly using a 
dial caliper. Average ear thickness over 13 wk of infection. ■, WT; ○, Δisp2/3; ▼, WT [pXG-
ISP2]. Error bars represent S.E.M. Asterisks indicate statistical significance between groups at p < 
0.05 (*), as measured by one-way ANOVA with Tukey post-test. 
5.2.4.3 Imaging myeloperoxidase (MPO) activity of activated phagocytes in 
Ela-/- mice 
To determine whether NE plays a role in regulating phagocyte activation during 
infection with L. major WT and the ISP2 gene mutants, luminol was used to non-
invasively monitor MPO activity at the site of inoculation over the course of 
infection, as described earlier. L. major WT, Δisp2/3, and WT [pXG-ISP2] 
parasites were inoculated into the ear dermis of Ela-/- mice at a dose of 104 
metacyclic promastigotes. Controls were performed as in the C57BL/6 mice, ears 
were injected with an equivalent volume of PBS or the needle only. The 
bioluminescent signal from the control ears was low over the course of the 
experiment (Figure 5-12B). Naive ears were also imaged to provide the 
background signal for the BLI. Figure 5-12A shows representative images of one 
mouse per group infected with either L. major WT, Δisp2/3, or WT [pXG-ISP2] 
parasites over the course of infection. 
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As in the C57BL/6 mice, there was a low MPO-specific bioluminescent signal 
from the ears infected with all three L. major cell lines at 1 h post-infection, 
although this was not significantly different from the background signal of the 
naive ear, or from the PBS and needle only controls (Figure 5-12B). The signal 
from the controls and the parasite-infected ears decreased to that of a naive ear 
by 24 h, which was on average 4.7x103 photons sec-1 over the course of 
infection. There was no significant difference in the MPO-specific 
bioluminescent signal between the parasite groups over the first 48 h. 
At 2 wk post-infection, there was an increase in the bioluminescent signal from 
ears infected with WT and Δisp2/3 parasites, which continued to increase until 6 
wk for WT infection and 5 wk for Δisp2/3 infection. From 1 wk post-infection, 
the average bioluminescent signal from WT-infected ears appeared to be higher 
than that from Δisp2/3-infected ears. The peaks in bioluminescent signal for WT- 
and Δisp2/3-infected ears during this second wave was approximately 4.7 and 
2.7-fold higher than their initial signal at 1 h, respectively. The signal from WT 
[pXG-ISP2]-infected ears did not reach a peak during the course of this 
experiment; the signal began to increase at 3 wk post-infection and continued to 
increase over the next 10 wk. The increase in lesion formation (Figure 5-11) and 
the continuous increase in MPO-specific bioluminescence in the WT [pXG-ISP2]-
infected ears suggest that the infection is more persistent than the WT and 
Δisp2/3 infections. 
LDAs were performed on the dLNs of the mice infected with L. major WT, 
Δisp2/3, and WT [pXG-ISP2] parasites at 13 wk post-infection (Figure 5-12C). 
Parasite burdens in the dLNs of WT [pXG-ISP2]-infected mice were significantly 
higher than those of Δisp2/3 infection, and WT parasite burdens also seemed 
higher than those of Δisp2/3 infection, although this was not significantly 
different. 
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Figure 5-12 In vivo bioluminescence imaging of MPO activity of activated phagocytes at the 
site of inoculation during infection with L. major WT and ISP2 gene mutants in Ela-/- mice. 
Ela-/- mice were inoculated in the ear with 104 L. major WT (n=4), Δisp2/3 (n=4), WT [pXG-ISP2] 
(n=3) metacyclic promastigotes. Mice were imaged in the IVIS 10 to 15 min after intraperitoneal 
luminol injection. A) Representative images of one mouse per group over the course of infection 
for ears infected with L. major WT, Δisp2/3, and WT [pXG-ISP2]. The colour scale indicates 
bioluminescent radiance in photons/second/cm2/steradian. The red oval indicates the region of 
interest (ROI) and the value in the red box indicates the total flux, given in photons per second 
(photons sec-1), over the ROI in the individual image shown. The same colour scale and ROI was 
applied to all images analysed, including the controls. The value in white gives the mean total 
flux for the group at each time-point. B) The mean total flux for the group at each time-point 
over the course of 13 wk infection. ■, WT; ○, Δisp2/3; ▼, WT [pXG-ISP2]; ♦, PBS; ◊, injection 
only; ×, naive. C) Parasite burdens in the dLNs of Ela-/- mice determined by LDA at 13 wk post-
infection. Data are shown on a logarithmic scale. Error bars represent S.E.M. Asterisks indicate 
statistical significance between the parasite groups at p < 0.05 (*) and p < 0.01 (**), as measured 
by one-way ANOVA with a Tukey post test. 
B 
C 
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5.2.4.4 Innate immune cell infiltration and activation at the site of 
inoculation at 2 wk post-infection in Ela-/- mice 
In C57BL/6 mice, the major differences observed in the innate cell recruitment 
and activation between L. major WT and Δisp2/3 intradermal infections 
occurred at 2 wk. Therefore, to assess the role of NE in these responses, the 
cellular immune response at the site of inoculation was examined in Ela-/- mice 
at 2 wk post-infection following intradermal inoculation with 104 L. major WT, 
Δisp2/3, or Δisp2/3:ISP2/3 metacyclic promastigotes. Innate cell populations, 
given in Table 5-2, were analysed by flow cytometry as shown in Figure 5-2. 
The percentage of CD11b+ cells within the live cell population in Δisp2/3-
infected ears was significantly higher than that of WT- and Δisp2/3:ISP2/3-
infected ears (Figure 5-13A). As in the C57BL/6 mice, there were significantly 
higher percentages of inflammatory monocytes, monocyte-derived macrophages, 
and moDCs in Δisp2/3-infected ears compared with WT- and Δisp2/3:ISP2/3-
infected ears (Figure 5-13, C to E), and this was reflected in higher numbers of 
these cells (Figure 5-13, G to I), although there was only a significant difference 
in the moDCs. There was also a significantly higher percentage of neutrophils 
(Figure 5-13B), which was not observed in the C57BL/6 mice (Figure 5-3A), but 
there were no significant differences in the numbers of neutrophils between the 
groups (Figure 5-13F). 
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Figure 5-13 Composition of the cellular infiltrate at the site of inoculation at 2 wk post-
infection with L. major WT and ISP2 gene mutants in Ela-/- mice. Purified metacyclic 
promastigotes (104 in 10 µl PBS) of L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 were intradermally 
inoculated into the ears of Ela-/- mice. A) Percentage of CD11b+ cells within the live cell 
population, assessed by flow cytometry. Percentages of each cell type within the CD11b+ 
population (top panel) and changes in the total number of each cell type (bottom panel) per ear. 
Innate immune cell types are defined as given in Table 5-2 and Figure 5-2; Ly6CintLy6G+ 
neutrophils (B and F), Ly6ChiLy6G- inflammatory monocytes (C and G), Ly6ChiLy6G-CD11c-MHCII- 
monocyte-derived macrophages (D and H), and Ly6ChiLy6G-CD11c+MHCII+ monocyte-derived 
dendritic cells (E and I). Results are expressed as means per group (n=5). Error bars represent 
S.E.M. Asterisks indicate statistical significance between groups at p < 0.05 (*), p < 0.01 (**), and 
p < 0.001 (***), as measured by one way ANOVA with Tukey post test. 
Ear dermal cells were additionally stained to evaluate the expression of the co-
stimulatory molecules, CD80 and CD86, on the DC populations in the Ela-/- mice 
infected with L. major WT, Δisp2/3, and Δisp2/3:ISP2/3 parasites for 2 wk. As in 
the C57BL/6 mice, there was no difference in the surface staining of CD86 on 
moDCs (Figure 5-14A) and resident DCs (Figure 5-14B) from the parasite-infected 
or naive ears. There was, however, a significant increase in CD80 expression on 
moDCs (Figure 5-14C) and resident DCs (Figure 5-14D) from Δisp2/3-infected ears 
compared with those from naive ears and those infected with WT and 
Δisp2/3:ISP2/3 parasites. 
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Figure 5-14 Dendritic cell co-stimulatory molecule expression at 2 wk post-infection with L. 
major WT and ISP2 gene mutants in Ela-/- mice. Percentage of CD86+ A) monocyte-derived 
dendritic cells and B) resident dendritic cells. Percentage of CD80+ C) monocyte-derived 
dendritic cells and D) resident dendritic cells. Asterisks indicate statistical significance between 
groups at p < 0.01 (**) and p < 0.0001 (****), as measured by one-way ANOVA with a Tukey post 
test. 
5.2.4.5 Quantification of parasite loads in Ela-/- mice 
To determine whether parasite survival of L. major WT and the ISP2 gene 
mutants was affected in the Ela-/- mice, LDAs were performed at 5 wk post-
infection. There were no significant differences in the parasite burdens in the 
ears or dLNs infected with L. major WT, Δisp2/3, or Δisp2/3:ISP2/3 parasites 
(Figure 5-15). However, parasites could only be detected in one Δisp2/3-infected 
ear and two WT-infected ears, compared with Δisp2/3:ISP2/3-infected ears, in 
which parasites could be detected in four out of five of the samples (Figure 5-
15A). 
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Figure 5-15 Parasite burdens at 5 wk post-infection with L. major WT and ISP2 gene mutants 
in Ela-/- mice. Purified metacyclic promastigotes (104 in 10 µl PBS) were intradermally inoculated 
into the ears of Ela-/- mice (n=5). The parasite loads in the A) ear and B) dLN at 5 wk were 
determined by LDA. Parasite loads from the individual samples are shown with the lines 
indicating the mean for the group. Dashed line indicates the lower limit of detection. 
There were also no significant differences in the diameters of the dLNs, or the 
masses of the livers and spleens at 5 wk post-infection in Ela-/- mice infected 
with L. major WT, Δisp2/3, or Δisp2/3:ISP2/3 parasites (Figure 5-16). 
 
Figure 5-16 Lymph node diameters, and liver and spleen masses, at 5 wk post-infection with 
L. major WT and ISP2 gene mutants in Ela-/- mice. Purified metacyclic promastigotes (104 in 10 
µl PBS) were intradermally inoculated into the ears of Ela-/- mice (n=5). A) The dLNs were 
removed and the diameters were measured by vernier caliper. B) Livers and C) spleens were also 
removed and the masses were measured. 
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5.3 Discussion 
The results of this chapter indicate that L. major ISP2 may modulate host 
immune responses, with regards to innate immune cell infiltration and 
activation, during the second wave of innate cell recruitment to the site of 
infection which occurs around 2 wk post-infection. Ears infected with an L. 
major ISP2/3-deficient mutant, Δisp2/3, showed an increase in inflammatory 
monocytes, monocyte-derived macrophages, and moDCs at 2 wk post-infection, 
compared with those infected with L. major WT parasites or an ISP2/3 re-
expressing cell line, Δisp2/3:ISP2/3 (Figure 5-3, G to L, and 5-6C). At 2 wk, the 
iNOS response, which generates NO, the toxic metabolite responsible for the 
majority of Leishmania killing in vivo (Stenger et al., 1994; De Trez et al., 2009), 
was significantly higher in Δisp2/3-infected ears compared with WT- and 
Δisp2/3:ISP2/3-infected ears (Figure 5-7B). This was due to an upregulation of 
iNOS expression within the inflammatory monocytes and monocyte-derived 
macrophages, as well as the resident macrophages and DCs (Figure 5-7, E to H). 
At this same time-point, the production of IFN-γ, which stimulates iNOS-
generated NO production, was higher in Δisp2/3 infections compared with WT 
and Δisp2/3:ISP2/3 infections (Figure 5-8). The expression of DC co-stimulatory 
molecules, which are upregulated during the DC maturation process, was also 
investigated. CD80, a marker of mature DCs, was upregulated on moDCs and 
resident DCs in Δisp2/3 infections at 2 wk post-infection (Figure 5-9, E and F), 
which also suggests these DCs may be more posed to prime antigen-specific T 
cells. This could feedback to induce the iNOS response of the other innate cells 
present at the site of infection through the action of IFN-γ produced by Th1 
cells. In vivo imaging also suggested that the activation of neutrophils and 
inflammatory monocytes from 2 wk post-infection may be higher in Δisp2/3 
infection than WT infection, as determined by monitoring MPO-specific 
bioluminescence at the site of infection (Figure 5-5). The differences in the 
innate immune response at the site of infection in response to L. major WT and 
Δisp2/3 parasites suggest the effector mechanisms of the innate immune cells in 
the ear dermis are more primed towards the killing of L. major Δisp2/3 
parasites, and the DCs more primed towards inducing an adaptive T cell 
response. 
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It was hypothesised that ISP2 would act upon the early innate immune response 
due to previous in vitro studies of the role of ISP2 in the uptake and killing of L. 
major by macrophages (Eschenlauer et al., 2009; Faria et al., 2011), and that 
the proposed SP targets are primarily produced by innate immune cells, 
including neutrophils, macrophages, and monocytes. However, there were no 
significant differences in the early recruitment or activation of innate cells, at 
time-points of less than one week, between WT and Δisp2/3 infections (Figure 5-
3 and 5-5). The concentration and function of SPs in the dermis of a naive ear 
prior to L. major inoculation is unknown, in that there may be few targets for 
ISP2 meaning there may be little to no observed effect on immune modulation at 
these early time-points. The inhibitory effect of L. major ISP2 may only become 
apparent when the balance between SPs and ISP2 is affected; as may occur after 
the peaks of neutrophil and monocyte infiltration at 1 and 2 d post-infection 
respectively, and the subsequent exposure of L. major to the SPs, of which 
neutrophils and monocytes are major sources; or when the L. major infection 
becomes fully established, through intracellular replication in the host cells, 
leading to higher concentrations of ISP2. It could also be that ISP2 inhibits the 
activity of SPs from these cell types throughout infection, preventing the 
proteolytic modification of cytokines and chemokines, which thus affects the 
recruitment and activation of immune cells during the second wave of innate 
immune cell infiltration observed (Thalhofer et al., 2011; Ribeiro-Gomes et al., 
2012). 
5.3.1 Innate cell recruitment and functions during Leishmania 
infection 
In this study, flow cytometry was used to assess the inflammatory response at 
the site of inoculation with L. major WT and the ISP2 gene mutants. The cell 
surface markers used in this investigation were chosen to observe innate immune 
cell types that are important in Leishmania infection, as a source of SPs, have 
already shown to have an interaction with ISP2 in vitro (Faria et al., 2011), and 
the recruitment of which may be affected by the inhibition of SP activity (Table 
5-1). The gating strategy was based on that by Ribeiro-Gomes et al. (2012), 
which gated resident macrophages and DCs as Ly6C-, and monocytes and 
monocyte-derived cells as Ly6C+, and differentiated macrophages and DC subsets 
by CD11c expression (Table 5-2 and Figure 5-2). Similar gating strategies with 
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these cell markers have been used to investigate these innate immune cell 
populations, although they additionally report intermediate expression of some 
markers, relating to cell maturation (León et al., 2007). 
The ear dermis is composed of large numbers of dermal macrophages and DCs 
but relatively few neutrophils and inflammatory monocytes within the CD11b+ 
population (Dupasquier et al., 2004; Peters et al., 2008; Ribeiro-Gomes et al., 
2012), as was shown in this study (Figure 5-3). Thalhofer et al. (2011) 
investigated the inflammatory cells using the pan-leukocyte marker, CD45, over 
7 d following intradermal ear inoculation of 106 metacyclic L. infantum chagasi 
promastigotes into BALB/c mice. Neutrophils peaked between 6 and 24 h, 
whereas macrophages peaked at 3 d. Similarly, Ribeiro-Gomes et al. (2012) 
investigated CD11b+ myeloid cell populations over 14 d following intradermal ear 
inoculation of 2x105 metacyclic L. major promastigotes into C57BL/6 mice. In 
their investigation, there was a slow increase in the total CD11b+ cells in ears 
over the first week of infection with a massive expansion over the second week. 
Neutrophils were detected at 1 h, peaked at 12 h, which then decreased 
between 1 and 4 d. In this study, a peak in the neutrophil infiltration is observed 
at 24 h, which then drops to levels observed in a naive ear, while resident 
macrophages and DCs peaked at 4 d (Figure 5-3, A to F). Sham injections without 
parasites only induced a neutrophil response at 1 h, likely due to the tissue 
damage (Ribeiro-Gomes et al., 2012); in this study the earliest time-point 
assessed was 1 d (Figure 5-3), at which time there were no differences in the 
cell populations in ears injected with PBS compared to the naive ears. At 
subsequent time-points, recruitment is dependent upon the infectious status of 
the inoculum (Peters et al., 2008). Ribeiro-Gomes et al. (2012) observed an 
increase in inflammatory monocytes beginning at 12 h and peaking at 24 h, with 
a second wave of infiltration beginning at 7 d. Whereas resident macrophages 
and DCs remained relatively unchanged until 7 d. The percentage of moDCs in 
this study represented a very small proportion of the CD11b+ population but 
expanded upon Leishmania infection (Figure 5-3, G and H); this level is not 
unusual, as moDCs are often detected in low numbers (León et al., 2007; 
Ribeiro-Gomes et al., 2012). These observations show that regardless of the 
parasite inoculation dose in the ear dermis, the sequence of innate immune cell 
Chapter 5 
148 
 
recruitment to Leishmania infection remains the same, including the timing of 
the peaks of infiltration for each of the innate immune cell types. 
The maintenance of neutrophils at the site of infection has been shown to be 
affected by the delivery method; in that neutrophil recruitment at early time-
points is similar whether parasites are delivered by needle inoculation or sandfly 
bite, however, neutrophil recruitment to sandfly bite is more prolonged (Peters 
et al., 2008). The initial recruitment of neutrophils appears to be independent 
of parasite-specific signals, as a similar response is seen in the absence of 
parasites (Peters et al., 2008), but the prolonged effect is likely due to the 
parasite-derived factors. There were no differences in the recruitment of 
neutrophils over the first week of infection with L. major WT or Δisp2/3 
parasites suggesting that ISP2 does not have an effect on neutrophil recruitment 
(Figure 5-3, A and B). However, the use of flow cytometry to detect differences 
in the innate cell populations is subject to error due to the loss of cells during 
sample preparation, particularly during the ear digestion and homogenisation 
steps; this is especially problematic during the initial stages of infection when 
the total number of CD11b+ cells is not significantly higher than that of a naive 
ear (Figure 5-1). It is possible to pool biological replicates in order to retain 
more cells and acquire more events in flow cytometry; however, due to 
variations between biological samples this is not recommended, as it could skew 
the data making it difficult to identify differences in the innate cell populations 
between experimental groups. In this study, biological replicates were used for 
each group at each time-point, running at least one million total events per 
sample in order to gate cell subsets accurately, and two independent technical 
replicates were performed to give more confidence that any differences 
observed between the innate immune cell populations between the L. major WT 
and Δisp2/3 infections were genuine and statistically significant. 
5.3.1.1 The second wave of innate cell recruitment 
A second wave of innate cell infiltration has been described in the case of 
neutrophils, monocytes, and monocyte-derived cells at 7 d in response to 
Leishmania infection, in which their cell numbers exceed the peak numbers 
observed during the first wave of infiltration (Thalhofer et al., 2011; Ribeiro-
Gomes et al., 2012). However, in both these reports the innate cell dynamics at 
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the site of infection were only investigated up to 2 wk post-infection. A second 
wave of neutrophil infiltration even occurs in transient neutrophil depletion 
suggesting that other cells at the site of infection, or the parasites themselves, 
induce neutrophil recruitment at this stage of infection (Thalhofer et al., 2011). 
A second wave of neutrophils was observed for both WT and Δisp2/3 infections, 
which persisted for, at least, up to 4 wk post-infection (Figure 5-3, A and B), as 
well as a prolonged monocyte, monocyte-derived macrophage, and moDC 
response during this stage of infection (Figure 5-3, G to L). The prolonged 
infiltration of these innate immune cells has not previously been reported for 
Leishmania infection, as investigations into the presence of innate cells at the 
site of inoculation typically cease at 2 wk post-infection. It is around 1 to 2 wk 
post-infection that the adaptive immune response is generated, after migration 
of APCs to the dLN to present antigen to T cells, T cell activation and clonal 
expansion, recruitment to the site of infection, and secretion of cytokines. 
At this stage of infection, it is likely that mediators from the adaptive immune 
response will contribute to the neutrophil and monocyte infiltration, as at 1 wk 
post-infection, all the CD11b+ innate cell subsets investigated in this study had 
levels equivalent to that of a naive ear (Figure 5-3). IL-17 cytokines, such as IL-
17A and IL-17F, are able to promote the recruitment of neutrophils and 
monocytes, mediating the persistence of an inflammatory lesion. IL-17 is 
released by γδ T cells, CD4+ T cells, NK cells, as well as neutrophils. Mice 
deficient in IL-17 have significantly lower neutrophils in the skin compared to 
control mice from 4 wk post-infection with L. major onwards (Lopez Kostka et 
al., 2009). In addition, IFN-γ, secreted by Th1 cells, has been reported to 
promote monocyte recruitment (Gonzalez-Lombana et al., 2013). At this time-
point, inflammatory cells are perhaps more apt to encounter infected cells, and 
they may be more “primed” for activation or exert different effects on the 
immune response. 
There were fewer monocytes, monocyte-derived macrophages, and moDCs 
observed at 2 wk in WT infection than in Δisp2/3 infection (Figure 5-3, G to L); 
ISP2 may modulate the recruitment of these cell types to the site of inoculation, 
through the inhibition of SP activity. NSPs, such as NE, can proteolytically modify 
cytokines and chemokines to regulate immune responses (Table 5-1); in addition, 
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NSPs can also interact with cell receptors to modulate intracellular signalling 
cascades, which can affect the production and release of cytokines and 
chemokines from cells (Ribeiro-Gomes et al., 2007). Inhibition of NSP activity 
could lead to reduced parasite killing as fewer effector cells present, which 
means lower iNOS responses in the entire tissue, in addition, there would be 
fewer APCs, such as the moDCs, to prime an adaptive T cell response. 
At 2 wk post-infection, there was a higher concentration of IFN-γ at the site of 
Δisp2/3 infection compared with that in WT and Δisp2/3:ISP2/3 infections 
(Figure 5-8). This could indicate that an adaptive Th1 immune response has been 
induced earlier in the Δisp2/3 infection than in the WT infection, meaning ISP2 
could potentially delay the formation of an adaptive immune response through 
modulation of the innate cellular responses. The T cell response is thought to be 
defined during the first three days of L. major infection due to interaction of T 
cells with APCs but antigen-specific T cells are only present at the site of 
inoculation by 1 wk, the numbers of which peak at 3 wk post-infection (Pagán et 
al., 2013). The T cell response may have a feedback loop affecting the 
recruitment and activation of the second wave of innate cell infiltration as the 
presence of IFN-γ could account for the higher number of monocytes (Figure 5-3, 
G and H) (Gonzalez-Lombana et al., 2013), and the higher iNOS expression in the 
innate immune cells at the site of  Δisp2/3 infection compared with those of WT 
and Δisp2/3:ISP2/3 infections at this time-point (Figure 5-7). A similar proposal 
has been suggested for L. major virulence factors, phosphoglycans (PGs), as L. 
major lacking PGs, lpg2- parasites, induce higher IL-12 production from DCs and 
are unable to induce early IL-4 and IL-10 production from lymphocytes in BALB/c 
mice (Liu et al., 2009). To investigate whether the timing, magnitude, and 
polarisation of the T cell response is affected during infection with L. major WT 
and the ISP2 gene mutants, it would be essential to further elucidate the 
cytokine microenvironment over the course of infection, in terms of IL-2, IL-12, 
and IFN-γ, which are indicative of a Th1 response, and IL-4 and IL-13, which are 
indicative of a Th2 response, as well as immuno-regulatory cytokines, IL-10 and 
TGF-β. 
DCs are now thought to be the major cell type that harbours Leishmania in the 
dLN, and are the cell type responsible for the orchestration of an adaptive 
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immune response through antigen presentation and IL-12 production (von Stebut 
et al., 1998; Ritter et al., 2004; León et al., 2007). There were higher numbers 
of moDCs at the site of inoculation in Δisp2/3 infection at 2 wk compared with 
WT infection (Figure 5-3, K and L), with an increase in CD11b+ cells in the dLN at 
this same time-point (Figure 5-4). It would be of interest to define the innate 
cell subsets in the dLN over the course of infection, to determine whether there 
are any differences in the migration of innate immune cell types between the 
site of inoculation and the dLN in WT and Δisp2/3 infection. 
5.3.1.2 Monocytes and monocyte-derived dendritic cells 
Monocytes are recruited to the site of L. major infection and differentiate into 
moDCs, which are thought to be important in the induction of Th1 responses 
during L. major infection (León et al., 2007). Mouse CD11b+Ly6ChiCCR2+ 
monocytes are similar to human CD14hi monocytes, which constitute almost 90% 
of the circulating blood monocyte population and are the monocytes that are 
recruited to inflamed tissue (Geissmann et al., 2003). DCs are a highly 
heterogenous population, defined by their specialised functions and the 
differential expression of specific cell surface markers, reflecting differences in 
their cellular origin. A DC population expressing CD11b+CD11c+Ly6C+MHCII+ and 
high levels of iNOS, termed inflammatory or moDCs, have been proposed to have 
important roles in the control of L. major infection, the presence of which is 
dependent upon a Th1 microenvironment involving IL-12 and IFN-γ (De Trez et 
al., 2009). These DCs have a similar phenotype to the TNF-iNOS-producing 
dendritic cells (Tip-DCs) reported in other models (Serbina et al., 2003), 
although only a small percentage are TNF-producing (De Trez et al., 2009). 
Petritus et al. (2012) compared the recruitment of monocytes and moDCs to L. 
major and L. mexicana infections. Intradermal inoculations were performed in 
the ears in C57BL/6 with 105 metacyclic promastigotes. Fewer monocytes were 
recruited, and moDCs produced less iNOS and migrated less efficiently to the 
dLN in L. mexicana infection, which was proposed to lead to insufficient priming 
of a Th1 response. By using a blocking antibody against the IL-10 receptor, 
Petritus et al. (2012) also showed an increase in monocyte and moDC 
recruitment to the site of L. mexicana infection at 2 wk post-infection. IL-10 
may decrease the expression of CCL2 (MCP1), which is an important chemokine 
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for monocyte and DC chemotaxis, as has been reported in T. brucei infection 
(Bosschaerts et al., 2010); or the immuno-regulatory role of IL-10 may dampen 
Th1 responses leading to lower iNOS and IFN-γ. L. major also causes aggregation 
and activation of platelets, leading to the release of platelet-derived growth 
factor (PDGF), which stimulates endothelial cells, fibroblasts, and macrophages 
to produce CCL2 (Goncalves et al., 2011). 
MoDCs are the major producers of iNOS during L. major infection (De Trez et al., 
2009), approximately 20% of the moDCs in L. major infection have been shown 
to be iNOS+ at 2 wk post-infection, compared to 3% in L. mexicana infection 
(Petritus et al., 2012). In this study, up to 60% of the moDCs were iNOS+ in L. 
major WT, Δisp2/3, and Δisp2/3:ISP2/3 infections (Figure 5-7I). Although there 
were no differences in the iNOS expression in this cell population between the 
infections with WT and the ISP2 gene mutants, there were more moDCs in 
Δisp2/3 infection at 2 wk post-infection, suggesting that recruitment was 
affected rather than the effector mechanisms of this cell type.  
MoDCs migrate to the dLN to stimulate antigen-specific Th1 responses, leading 
to the production of IFN-γ from Th1 cells, and are also proposed to be the major 
producers of IL-12 during L. major infection (León et al., 2007). MoDCs are 
detected in the dLN at 3 d after infection with L. major, which coincides with 
the expansion of the antigen-specific T cells (Pagán et al., 2013), the numbers of 
moDCs decrease markedly at 1 wk, then increase again at 2 wk, and continue to 
increase up to 4 wk post-infection (León et al., 2007). Petritus et al. (2012) 
investigated the migration of moDCs from the ear to the dLN at 2 wk post-
infection through FITC painting of the ear; they showed a significantly higher 
number of moDCs in the dLNs in L. major infection compared with L. mexicana 
infection. MoDCs had low levels of CD86 expression in both WT and Δisp2/3 
infection (Figure 5-9C), which has also described by León et al. (2007). During 
Δisp2/3 infection, moDCs did, however, show an upregulation in the DC co-
stimulatory molecule, CD80, at 2 wk post-infection (Figure 5-9E), which suggests 
that these cells are more primed to induce an antigen-specific T cell response. 
Bosschaerts et al. (2010) have proposed that the maturation of DCs to functional 
Tip-DCs, expressing CD80 and CD86, in T. brucei infection is dependent upon 
IFN-γ and MyD88 signalling, which is downstream of TLR4. There was also a 
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corresponding increase in CD11b+ cells in the dLNs of Δisp2/3-infected mice at 2 
wk post-infection (Figure 5-4), although the cell subsets were not determined. L. 
major-activated DCs also induce lymph node hypertrophy to promote T cell 
recruitment to the dLN and enhance the protective responses (Carvalho et al., 
2012), in the previous chapter the mean diameter of the dLN in Δisp2/3 
infection was significantly higher than in WT and Δisp2/3:ISP2/3 infection at 5 
wk (Figure 4-7A). 
The presence of moDCs during L. major infection is further complicated by the 
timing of differentiation from the bone-marrow monocytes. León et al. (2007) 
identified two subsets in the popliteal dLNs; lymph node moDCs, which 
differentiated from monocytes that had migrated to the lymph node first; and 
dermal moDCs, which had differentiated from monocytes at the site of infection, 
served as hosts for L. major, and presented antigen to T cells to generate a Th1 
response. 
In vitro studies have shown that TLR activation, including TLR4, triggers the 
differentiation of monocytes into macrophages and DCs (Krutzik et al., 2005), 
which likely occurs through MyD88 signalling (De Trez et al., 2004). ISP2 has 
been shown to inhibit the activity of NE, preventing the activation of TLR4 
signalling cascades in macrophages (Faria et al., 2011). The increase in 
monocyte-derived macrophages and moDCs in Δisp2/3 infection may be due to 
TLR4-induced differentiation of monocytes in the absence of ISP2. L. major ISP2 
may block moDC differentiation, as it has been shown that Salmonella 
typhimurium and bacterial LPS is able to block this conversion (Rotta et al., 
2003), as well as L. amazonensis promastigotes (Favali et al., 2007). The 
differentiation of monocytes into moDCs could be examined in vitro based on 
surface co-stimulatory molecule expression, such as CD40, CD80, and CD86, 
after co-culture with L. major WT and the ISP2 gene mutants (Favali et al., 
2007; Markikou-Ouni et al., 2012), in the presence or absence of TLR4 blocking 
antibodies. 
5.3.1.3 Neutrophil-dendritic cell interactions 
C57BL/6 mice depleted of neutrophils have significantly reduced L. major 
parasite loads at an intradermal site of inoculation after 1 wk post-infection 
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(Peters et al., 2008). The use of neutrophil-depleted mice has shown that 
infected DCs from these mice have higher expression levels of CD86 and CD40, 
and are more efficient than infected DCs from C57BL/6 mice in activating 
Leishmania-primed T cells to secrete IFN-γ (Ribeiro-Gomes et al., 2012). In 
addition, neutrophil-depleted mice showed a greater expansion of Leishmania-
specific CD4+ T cells (Ribeiro-Gomes et al., 2012). Neutrophils are the first host 
cell type for Leishmania and are major sources of SPs. Without the neutrophil 
contribution of SPs at the site of infection, there may be reduced cleavage of 
cytokine, chemokine, and cell receptor targets, which may affect DC 
maturation. In this study, moDCs from Δisp2/3 infection showed greater 
expression of CD86 compared with those from WT infection. 
Neutrophil granule proteins have been shown to induce monocyte recruitment 
and DC maturation through TLR4-dependent pathways, including human 
alarmins, such as β-defensins (Biragyn et al., 2002), human LL-37 and the murine 
homologue CRAMP (Kurosaka et al., 2005; Soehnlein et al., 2008; Chen et al., 
2014), lactoferrin (de la Rosa et al., 2008), and azurocidin (Chertov et al., 
1997), an inactive SP homologue, which is unable to cleave peptide bonds 
(Watorek, 2003). Finally, neutrophil binding to immature DCs via interactions of 
Mac-1 of neutrophils and DC-SIGN of DCs leads to the delivery of activation 
signals and antigenic molecules, causing DC maturation with increased 
expression of CD40, CD80, and CD86 (van Gisbergen et al, 2005). DC engulfment 
of apoptotic neutrophils has been shown to inhibit DC production of pro-
inflammatory cytokines, expression of co-stimulatory molecules, and their 
ability to stimulate T cell proliferation (Sauter et al., 2000). However, the roles 
of neutrophil granule proteins in the pathology or protection of Leishmania 
infection have not been fully assessed. 
5.3.1.4 The iNOS response 
Mice deficient in iNOS have much more severe pathology during L. major 
infection, during which the lesions become necrotic (Diefenbach et al., 1998). L. 
major infection can also be reactivated in chronically infected healthy C57BL/6 
mice following iNOS inhibitor treatment (Stenger et al., 1996). iNOS and the 
generation of NO is, therefore, essential for Leishmania clearance in vivo 
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(Stenger et al., 1994; Vouldoukis et al., 1995; De Trez et al., 2009; Petritus et 
al., 2012). 
De Trez et al. (2009) performed intracellular staining for iNOS on the dLNs of 
C57BL/6 mice following subcutaneous footpad inoculation of 106 promastigotes. 
Their analysis showed that at the peak of iNOS expression, at 4 wk post-
infection, only 0.4% of the total cells analysed were positive for iNOS; however, 
they did not investigate iNOS expression at the site of infection. They showed 
that up to 90% of iNOS-producing cells in the dLN were moDCs, whereas 
granulocytes represented only 10 to 15% of iNOS+ cells. In this study, 
approximately 15% of the CD11b+ cells at the site of L. major WT infection were 
iNOS+ at 2 wk (Figure 5-7B). However, during Δisp2/3 infection, the iNOS 
expression in CD11b+ cells was upregulated to approximately 25% due to an 
increase in iNOS expression in inflammatory monocytes, monocyte-derived 
macrophages, resident macrophages, and resident DCs (Figure 5-7, E to H). In 
this study, the iNOS response in the dLN was not assessed, but if the iNOS 
response in the dLN is lower than at site of infection, as the data from De Trez 
et al. (2009) would suggest, which is attributed to differences in the innate 
immune cell populations present (León et al., 2007), this could account for the 
differences in parasite burdens between the ear and the dLN in the WT and 
Δisp2/3 infections (Figure 4-7, B and C). 
5.3.2 In vivo imaging of the innate immune responses 
In vivo optical imaging reagents and substrates allow quantification of molecular 
and cellular responses in animal models. Luminol has previously only been used 
to assess the respiratory burst during Leishmania infections in vitro (al Tuwaijri 
et al., 1990; Vuotto et al., 2000). Luminol has since been shown to be specific 
for MPO activity, although the exact interaction by which bioluminescence is 
induced however, is still unknown (Gross et al., 2009; Tseng & Kung, 2012). 
Neutrophils highly express MPO, inflammatory monocytes have intermediate 
expression of MPO, and DCs do not express MPO (Ribeiro-Gomes et al., 2012). 
Circulating monocytes lose MPO activity as they infiltrate and differentiate into 
macrophages in tissue (Kumar et al., 2004); however, certain tissue 
macrophages in humans have been shown to be MPO-positive (Daugherty et al., 
1994; Nagra et al., 1997). Tseng & Kung (2012) showed using purified neutrophils 
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and monocytes that both these cell type contribute to the MPO-specific 
bioluminescent signal induced by luminol. To check the MPO status of the innate 
immune cells analysed in this study, flow cytometry was performed with an anti-
MPO antibody, which showed that all neutrophils were MPO+, and Ly6Chi cells, 
which constitute monocytes, monocyte-derived macrophages, and moDCs, were 
approximately 48% positive for MPO staining, whereas the MPO staining in 
resident macrophages and DCs was negligible (Figure 5-6). 
In vivo imaging of the MPO-specific bioluminescent signal during infection with 
L. major WT, Δisp2/3, or the ISP2 overexpressing cell line, WT [pXG-ISP2], in 
C57BL/6 mice showed that ears infected with Δisp2/3 parasites appeared to 
have a slightly higher MPO-specific bioluminescent signal than WT-infected ears 
(Figure 5-5); this may have been the maximal signal, limited by the amount of 
luminol substrate present. It also appeared that WT-infected Ela-/- mice had a 
higher MPO-specific bioluminescent signal than Δisp2/3-infected mice (Figure 5-
12, A and B), which was unexpected based on the observation in C57BL/6 mice, 
however, these differences were not significantly different. The signals were 
much more delayed in WT [pXG-ISP2] infection in both C57BL/6 and Ela-/- mice, 
which suggests an inhibition of phagocyte recruitment or activation; it could be 
that the overexpression of ISP2 enables the inhibition of other SP targets, such 
as CG and PR3. Flow cytometry was not performed with ears infected with WT 
[pXG-ISP2] parasites, as the episomal expression of ISP2 was not always 
consistent, likely due to variation in plasmid copy number (Chakkalath et al., 
2000). However, data from ears infected with Δisp2/3:ISP2/3 parasites, which 
slightly overexpress ISP2 (Figure 3-1), sometimes showed a more significant 
decrease in innate cell recruitment than that of WT- and Δisp2/3-infected ears 
(Figure 5-6, B and C). 
Upon its release from neutrophils, MPO becomes inactive in the tissue 
microenvironment meaning that there is both enzymatically active and inactive 
MPO present at the site of inflammation. MPO has a direct effect on tissue 
damage but it is also taken up by resident macrophages expressing macrophage 
mannose receptors (MMRs) (Shepherd & Hoidal, 1990). MPO and MMR interaction 
leads to the release of ROS along with other pro-inflammatory cytokines, 
including TNF-α, IL-1, IL-6, IL-8, and GCSF, from macrophages (Lefkowitz et al., 
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1997, 2000). As there were obvious differences in the MPO-specific 
bioluminescent signals from mice infected with WT [pXG-ISP2] parasites 
compared with those infected with WT and Δisp2/3 parasites, it would be 
interesting to do histological analysis over the course of these infections to 
determine if there are any signs of tissue damage, such as fibrinoid necrosis, 
particularly in the WT [pXG-ISP2] infection where the signal continued to 
increase beyond 8 wk of infection, the time at which the Δisp2/3 infection 
appeared to be resolving. 
The light emitted in the luminol reaction is in the blue spectrum with a peak of 
425 nm, which means it is easily scattered and absorbed by the tissues, and 
therefore can only be used to observe phagocyte activation at superficial surface 
foci, such as the mouse ear. Zhang et al. (2013) have developed a method in 
which the blue light emitted by luminol excites nanoparticles to emit light in the 
near-infrared range in a process termed chemiluminescence resonance energy 
transfer (CRET). Luminol-R is an administration of luminol with non-conjugated 
800 nm-emitting quantum dots, improving the detectability of the luminescent 
signal for MPO activity in deep tissues. This could enable the detection of 
activated phagocyte migration from the site of infection to the dLN. 
Lucigenin allows in vivo imaging of late phase and chronic inflammation, which 
detects the superoxide anion, O2
-, dependent on generation by phagocyte NADPH 
oxidase activity in macrophages (Tseng & Kung, 2012). This type of in vivo 
imaging could provide additional data on the activation of, in particular, 
monocyte-derived macrophages during infection with L. major WT and the ISP2 
gene mutants, as differences were observed in the recruitment of this innate 
immune cell type (Figure 5-3, I and J). 
Kossodo et al. (2011) have developed a near-infrared activatable fluorescence 
imaging agent specific to NE activity, known as Neutrophil Elastase 680 FAST, in 
order to detect and quantify NE activity in vivo. The agent is two near infrared 
fluorophores linked to either end of a peptide sequence, PMAVVQSVP, which is 
highly selective for mouse NE over mouse CG, as well as human MMP-9, and 
cathepsin B (Kalupov et al., 2009; Kossodo et al., 2011); although mouse PR3 
also activates the imaging agent at a much lower rate (Kalupov et al., 2009). 
Upon peptide cleavage, the fluorophores are no longer self-quenched and 
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become fluorescent with a maximum emission at 690 nm. It would be interesting 
to use this imaging agent during infection with L. major WT and the ISP2 gene 
mutants, as it may enable the quantification of ISP2 inhibition in vivo. 
5.3.3 Redundancy and synergistic effects of NSPs 
Modification of chemokines by NSPs controls a temporal pattern of immune cell 
trafficking to the site of inflammation, which could account for the differences 
seen between WT and Δisp2/3 infections at the later stages in C57BL/6 mice. 
Neutrophil elastase-deficient mice, Ela-/-, were used to assess the role of this 
host SP in the generation of immune responses to L. major WT and the ISP2 gene 
mutants. Few studies have been conducted to investigate the roles of NSPs in 
vivo, particularly during infectious disease. However, the data for innate 
immune cell infiltration and DC co-stimulatory molecule expression between 
infection with L. major WT and Δisp2/3 parasites at 2 wk in Ela-/- mice was 
similar to that observed in C57BL/6 mice (Figure 5-12 and 5-13). 
The NSPs, NE, CG, and PR3, have a broad and overlapping range of targets 
(Table 5-1). The lack of difference between data from C57BL/6 and Ela-/- mice at 
2 wk post-infection could indicate potential redundancy of the NSPs, in that CG 
or PR3 could compensate for the loss of NE (Kessenbrock et al., 2008). NE and 
PR3, in particular, have similar substrate specificities. Only one time-point was 
investigated in the Ela-/- mice for the innate immune cell recruitment, at the 
time-point which corresponded to the differences observed in C57BL/6 mice. It 
is possible that there may have been earlier effects that were not detected. 
As shown in Table 5-1, NSPs have been shown to modify a large number of 
targets, and more are perhaps yet to be identified. ISP2 may also inhibit the 
activity of other SP targets in vivo, such CG, PR3, or the newly identified, NSP4 
(Perera et al., 2012). NSP4 has been shown to have elastase activity, with 39% 
identity to NE and PR3. Low amounts of NSP4 have been found in the azurophilic 
granules of human neutrophils and, like the other NSPs, is converted to a 
catalytically active protease by cleavage of an N-terminal pro-dipeptide of the 
inactive zymogen by the lysosomal cysteine protease, dipeptidyl peptidase I 
(DPPI, or cathepsin C). NSP4 is also inhibited by AAT (Perera et al., 2012, 2013). 
NSP4 also has a homologue in mice, termed Prss-57. In Prss-57-deficient mice, 
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there was a marginal increase in the levels of TNF-α and CCL2 in response to LPS 
injection (Tang et al., 2010); however, the exact targets of NSP4 are still to be 
determined. 
In vitro ISP2 has been shown to inhibit the activity of NE, which prevents the 
activation of a TLR4-NE signalling cascade in macrophages (Faria et al., 2011). It 
is unknown how NE activates TLR4 (Ribeiro-Gomes et al., 2007); whether NE 
directly engages TLR4, or cleaves another receptor which activates TLR4 
signalling. TLR4 signalling cascades, however, can lead to the upregulation of 
cytokine and chemokine production and secretion, such as IL-8 (Ribeiro-Gomes 
et al., 2007; Benabid et al., 2012). NSPs may, therefore, work synergistically, for 
example, in the case of neutrophil recruitment, they could mediate the 
production and secretion of IL-8 by engaging TLRs or protease-activated 
receptors (PARs), or enhancing the activity of IL-8 through proteolytic 
modification, this would recruit more neutrophils, which are then activated to 
release NSPs. As neutrophils are the first cells to arrive at sites of inflammation 
and are a major source of NSPs, their presence at the site of inflammation could 
potentially influence subsequent waves of cell recruitment, and the inhibition of 
NSPs by ISP2 is therefore likely to have a multitude of effects in vivo. 
Monocyte and monocyte-derived cell recruitment was higher in Δisp2/3 infection 
at 2 wk compared with WT infection. The key chemokines involved in monocyte 
chemotaxis to the site of infection are CCL2, CCL3, CCL5, CCL7, and CCL12 (Shi 
& Pamer, 2011). As yet, only CCL3 and CCL5 have been shown to be processed 
by NSPs (Table 5-1). Neutrophils also release CCL3 to recruit monocytes and DCs 
during the early stage of infection in C57BL/6 mice (Charmoy et al., 2010). 
5.3.3.1 MPO and NSPs 
There are contrasting views on the interaction of MPO and NSPs; the conversion 
of H2O2 to HOCl may protect NSPs from inactivation (Reeves et al., 2002), or 
MPO may mediates direct oxidative inactivation of NSPs (Hirche et al., 2005). 
HOCl does, however, inactivate AAT, the physiological inhibitor of all three 
NSPs. In vivo imaging showed that there was a slightly higher MPO-specific 
bioluminescent signal in the ears of Δisp2/3-infected C57BL/6 mice, the 
presence of the MPO reaction products may, therefore, contribute the 
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inactivation of SP inhibitors leading to a protease-inhibitor imbalance, which 
augments the protective responses and the clearance of Δisp2/3 parasites. 
5.3.4 Future directions 
As there were differences in cellular recruitment, it would be of interest to 
determine if there are any specific changes in the chemokine levels during 
infection with L. major WT and the ISP2 gene mutants. This could be achieved 
through tissue qPCR or luminex-based methods to determine the levels of a 
range of chemokines. Using both methods may also indicate differences in 
proteolytic modification of the chemokines. Earlier time-points could be studied; 
although there has been no difference in innate cell recruitment before 1 wk 
post-infection there may be other differences, such as the cytokine and 
chemokine levels, which may guide the subsequent responses. It may also be 
important to determine the pattern of Th1/Th2 cytokine expression during WT 
and Δisp2/3 infection, such as IL-2, IL-4, IL-12, and IL-13, as mentioned earlier, 
as the development of the Th1 response may differ between WT and Δisp2/3 
infection, which could feedback to the innate cell infiltration and activation. 
NSPs become enzymatically active during transport to the granules through the 
cleavage of an N-terminal pro-dipeptide by DPPI. In mice deficient in DPPI, NSPs 
have very little enzymatic activity, as well as decreased infiltration to sites of 
inflammation and decreased local production of cytokines (Adkison et al., 2002). 
Comparisons of infections with L. major WT and the ISP2 gene mutants in these 
transgenic mice may show whether NSPs are the only targets of ISP2 and 
elucidate an interaction of ISP2 with the NSPs in vivo, although identification of 
the precise mechanism may be difficult due to the numerous targets of the NSPs. 
In C57BL/6 CCR2 deficient mice, in which the CCR2 receptor is not expressed on 
monocytes, monocytes accumulate in the bone marrow unable to respond to its 
chemokine partners, which include CCL2, CCL7, and CCL12, resulting in 
susceptibility to L. major infection (Sato et al., 2000; Quinones et al., 2007). In 
C57BL/6 mice and Ela-/- mice, there was an increase in monocyte recruitment to 
Δisp2/3 infections, the use of CCR2-/- mice may indicate a dependency on the 
chemokines mentioned, to explain the differences observed in monocyte 
recruitment between WT and Δisp2/3 infections. 
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Using fluorescently-labelled cell lines, it would be of interest to determine 
whether L. major WT and the ISP2 gene mutants reside within the same innate 
immune cell types and whether there is any difference in the migration of these 
cell types between the site of infection and the dLN. Although macrophages are 
the major host cell type for Leishmania, neutrophils, monocytes, DCs, and 
fibroblasts can also harbour intracellular Leishmania; L. infantum chagasi, 
however, does not reside in DCs (Thalhofer et al., 2011). Parasites deficient in 
ISP2/3 are internalised more efficiently by macrophages; the internalisation of 
Δisp2/3 parasites by other innate cells is currently under investigation. It could 
be that Δisp2/3 parasites are internalised more efficiently by neutrophils, which 
may affect the dynamics of the adaptive immune response. Thalhofer et al. 
(2011) showed that there were more parasite-containing cells in the dLNs of 
control BALB/c mice than in neutrophil-depleted mice, and that this 
corresponded with significantly lower numbers of leukocytes containing 
intracellular parasites in the skin of neutrophil-depleted mice in the first few 
hours of infection. It may only be possible to detect fluorescently labelled 
parasites inoculated at high doses, as Ribeiro-Gomes et al. (2012) recovered 
fewer than 103 red fluorescent protein (RFP)-positive cells at 1 and 4 h after 
intradermal inoculation of 105 metacyclic L. major promastigotes. Ribeiro-Gomes 
et al. (2012) did however, describe two waves of RFP+ recruitment at 1 d and 7 
to 14 d, with monocyte-derived macrophages and moDCs harbouring RFP-
expressing parasites during the second phase primarily. León et al. (2007) also 
reported a difference in the migration of non-infected and infected moDCs; 
more than 90% of the moDCs in the skin were infected, whereas less than 10% 
were infected in the dLN at 4 wk post-infection. This was supported by 
differential expression of the lymph node homing receptor CCR7 on the infected 
and non-infected moDCs (León et al., 2007). 
5.3.5 Concluding remarks 
In summary, the data reported in this chapter indicate that L. major ISP2 is 
capable of modulating host immune responses locally in vivo. Flow cytometric 
analysis of innate immune cell infiltration at the site of intradermal L. major WT 
infection has revealed the same sequence of innate cell recruitment to the site 
of infection described by other groups, regardless of the initial parasite 
inoculation dose, showing that innate cell recruitment is highly conserved in 
Chapter 5 
162 
 
Leishmania infection. The use of this method has enabled the discovery of 
differences in the recruitment and activation of the moDCs during the second 
wave of innate cell infiltration to the site of infection with an L. major mutant 
deficient in ISP2/3, Δisp2/3. Through the use of luminol, it has also been 
possible for the first time to image activated phagocytes in response to an 
infectious disease in vivo, taken further, it has been used to compare the 
phagocyte activation during infection with L. major WT and mutant deficient in, 
or overexpressing, a putative virulence factor, ISP2. 
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6 General Discussion 
Leishmania are known to modulate host immune responses to facilitate their 
survival; however, few Leishmania virulence factors, which mediate these 
interactions, have been characterised, particularly with regards to their effect 
on immune responses in vivo. It is important to understand how parasites 
manipulate immune responses that facilitate parasite survival and disease 
initiation and persistence, and deduce which immune responses lead to 
pathology and protection, as this can provide insights into strategies for disease 
intervention. 
L. major has three ecotin-like peptide inhibitors of serine peptidases, which 
have been designated ISP1, ISP2, and ISP3 (Eschenlauer et al., 2009). In vitro 
studies have already shown that L. major ISP2 acts as a Leishmania virulence 
factor that inhibits the mammalian host serine peptidase, neutrophil elastase 
(NE) preventing the activation of a TLR4-NE signalling cascade (Faria et al., 
2011). Inhibition of this signalling cascade in macrophages leads to the 
modulation of phagocytosis and reactive oxygen species production, which 
facilitates L. major intracellular survival (Faria et al., 2011). The potential for 
ISP2 to modulate host immune responses through the inhibition of host serine 
peptidase activity was an attractive line of investigation, as TLR4-NE signalling 
cascades have been shown to trigger pro-inflammatory responses in both mouse 
models and human cells, such as the production and release of TNF-α (Ribeiro-
Gomes et al., 2007; Benabid et al., 2012), IL-6 (Benabid et al., 2012), and IL-8 
(Walsh et al., 2001; Devaney et al., 2003; Benabid et al., 2012), a 
chemoattractant and activator of neutrophils. Hence, the presence or absence 
of L. major ISP2 could have greater effects in vivo on cellular recruitment and 
activation, and consequently on the long-term disease progression. In addition, 
serine peptidases of innate immune cells, which include NE, cathepsin G, and 
proteinase 3, are able to proteolytically modify cytokines and chemokines to 
regulate inflammatory responses, independent of TLR4 interaction (Pham, 2008). 
Therefore, the overall aim of this study was to investigate the effects of ISP2 in 
the wider context of the immune responses and disease progression in vivo. To 
achieve this, comparisons of the lesion development, parasite survival, and 
innate immune cell activation and recruitment were made between in vivo 
  Chapter 6 
164 
 
infections with L. major WT and ISP2 gene mutants, particularly a cell line 
deficient in ISP2/3, Δisp2/3 (Eschenlauer et al., 2009). 
Faria et al. (2011) have previously shown reduced intracellular loads of L. major 
Δisp2/3 parasites in macrophages, compared with those of L. major WT 
parasites, after in vivo infections of less than one day. In this study, parasite 
burdens at the site of inoculation and in the draining lymph nodes were 
assessed. There were consistently lower parasite burdens of Δisp2/3 parasites at 
the site of inoculation than those of WT parasites and a cell line re-expressing 
ISP2/3, Δisp2/3:ISP2/3, at later stages of in vivo infection, beyond 5 wk. This 
showed that there was not an increase in parasite loads from the early time-
points studied by Faria et al. (2011), indicating that L. major requires ISP2 for 
the initiation and persistence of disease. In addition, the parasite burdens of 
Δisp2/3:ISP2/3 parasites, which slightly overexpresses ISP2, were consistently 
higher than those of WT and Δisp2/3 parasites at the site of inoculation, which 
suggests that the levels of ISP2 expression may affect parasite burdens. 
Interestingly, although parasite burdens at the site of inoculation were obviously 
different between the different cell lines, the parasite burdens within the 
draining lymph node were not significantly different, as was also observed by 
Faria et al. (2011) at 10 wk post-infection. Parasite burdens in the livers and 
spleens were also determined to discover whether ISP2 had any effect on disease 
tropism; however, no parasites were detected for any of the cell lines at any of 
the time-points examined. It would be of interest to determine whether this in 
the case in the susceptible BALB/c model, which is a typical VL model for L. 
donovani and L. infantum infections (Nieto et al., 2011; Loría-Cervera & 
Andrade-Narváez, 2014). Interestingly, neutrophils from BALB/c mice release 2 
to 3-fold less NE than those of C57BL/6 mice (Ribeiro-Gomes et al., 2007); the 
balance between NE and ISP2 in BALB/c mice could, therefore, contribute to the 
greater pathology caused by L. major in BALB/c mice. ISP2 has been identified in 
various species of Leishmania, including L. mexicana, which causes LCL and DCL, 
L. braziliensis, which causes LCL and MCL, and L. infantum, which causes LCL, 
MCL, and VL (Peacock et al., 2007). It is currently being investigated whether 
there is any sequence variation or any gene copy variation of the ISP2 gene 
between Leishmania species, which could contribute to differences in gene 
expression and may impact upon disease tropism (Rogers et al., 2011). This may 
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be of particular interest in the case of PKDL, in which skin lesions are heavily 
parasitised (Mukhopadhyay et al., 2014), as was observed in the Δisp2/3:ISP2/3 
infections. 
The major findings in terms of the innate immune responses to the L. major WT, 
Δisp2/3, and Δisp2/3:ISP2/3 cell lines in vivo were an increase in inflammatory 
monocytes, monocyte-derived macrophages, and monocyte-derived DCs at the 
site of inoculation, coupled with an increase in iNOS expression, IFN-γ 
production, and DC maturation marker expression at 2 wk post-infection in the 
Δisp2/3 infections (Figure 6-1). Taken together, these data suggest that the 
immune response is more primed towards clearance of the Δisp2/3 parasites. 
Monocyte-derived DCs induce protective antigen-specific Th1 responses (León et 
al., 2007; De Trez et al., 2009; Petritus et al., 2012), which are the primary 
source of IFN-γ. IFN-γ stimulates the expression of iNOS in macrophages and 
DCs, which catalyses the production of NO, a molecule that is important for 
effective parasite killing (De Trez et al., 2009; Petritus et al., 2012). The 
modulation of these responses by ISP2 in vivo still requires exploration, but the 
increase in monocytes and monocyte-derived cells at 2 wk post-infection, in the 
case of Δisp2/3 infection, could be due to an increase in cytokine and 
chemokine production through a TLR4-NE signalling cascade. This is a line of 
investigation currently being pursued; preliminary results indicate that Δisp2/3 
parasites induce cytokine release, including TNF-α, IL-6, CXCL1, and CXCL2 from 
C57BL/6 macrophages in vitro (Faria et al., unpublished). However, more 
cytokines and chemokines are to be tested, particularly chemokines that induce 
monocyte chemotaxis, such as CCL2, CCL3, CCL5, CCL7, and CCL12. 
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Figure 6-1 Immune responses at the site of L. major WT and Δisp2/3 infection at 2 wk. At 2 
wk post-infection, a second wave of innate immune cell infiltration to the site of L. major WT 
and Δisp2/3 infection was observed through flow cytometric techniques. There were equivalent 
numbers of neutrophils in both L. major WT and Δisp2/3 infection. However, there were more 
inflammatory monocytes, monocyte-derived macrophages and monocyte-derived dendritic cells 
at the site of L. major Δisp2/3 infection compared with L. major WT infection. Monocyte-derived 
dendritic cells also showed an upregulation in the co-stimulatory surface molecule, CD80. In 
addition, there was an increase in the concentration of IFN-γ and the expression of inducible 
nitric oxide synthase (iNOS) to L. major Δisp2/3 infection. Through the use of bioluminescence 
imaging techniques and limiting dilution assays (LDAs), the parasite burdens appeared to be 
lower in L. major Δisp2/3 infection compared with that of L. major WT infection. Although it is 
not known, which cells the parasites were residing in. These results suggest that at 2 wk post-
infection, the immune response was more primed toward parasite clearance in the case of L. 
major Δisp2/3 infection.  
TLR4 has two associated adaptor proteins; MyD88 and TRIF. TLR4 signalling is 
commonly divided into pathways, which occur through the adaptor proteins 
MyD88 and TRIF (Figure 6-2). The MyD88-dependent pathway leads to NF-κB and 
AP-1 activation, and TRIF-dependent pathways can lead to the activation of 
IRF3, as well as NF-κB and AP-1 (Ulrichts & Tavernier, 2008). NF-κB activation 
generally leads to the production of pro-inflammatory cytokines, such as TNF-α 
and IL-6, whilst IRF3 leads to the production of IFN-β, the expression of IFN-
inducible genes, such as CXCL10, and the maturation of DCs. The nuclear levels 
of the NF-κB subunit p65 and IRF3 were reduced in Δisp2/3-infected 
macrophages compared with those of WT-infected macrophages, but there was 
an increase in TNF-α and IFN-β expression (Faria et al., 2014). From these 
observations, Faria et al. (2014) proposed that L. major ISP2 inhibits the activity 
of PKR, which can be phosphorylated by MyD88 and TRIF (reviewed in García et 
al., 2006), through the inhibition of the TLR4-NE signalling cascade. PKR is an 
antiviral protein, which is able to inhibit protein synthesis through the 
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phosphorylation of the eukaryotic translation intiation factor eIF-2α, but is also a 
translational regulator of NF-κB, AP-1, IRF-1, STATs, ATF3 and 4, JNK, p38, and 
p53 (reviewed in Williams, 2001). Although the role of PKR in antiviral immunity 
is well characterised, the characterisation of PKR in parasitic infections is 
limited (Pereira et al., 2010; Ogolla et al., 2013). However, from the 
investigation by Faria et al. (2014), the increase in IFN-β through this signalling 
pathway could account for the increases in iNOS expression observed in the 
Δisp2/3 infection (Diefenbach et al., 1998; Oliveira et al., 2014); therefore, it 
would be of interest to determine whether the levels of IFN-β also differ 
between WT and Δisp2/3 infections in vivo. 
 
Figure 6-2 Potential effects of the prevention of TLR4 signalling cascades on immune 
responses in vivo. The L. major virulence factor, ISP2, has been shown to inhibit the activity of 
the serine peptidase neutrophil elastase (NE). This prevents the activation of a Toll-like receptor 
4 (TLR4)-NE signalling cascade, which can downregulate phagocytosis and inhibit the production 
of reactive oxygen species (ROS) in macrophages. TLR4 signalling is commonly divided into 
pathways, which occur through the adaptor proteins MyD88 and TRIF. The MyD88-dependent 
pathway leads to activation of the transcription factors, NF-κB and AP-1, and TRIF-dependent 
pathway typically leads to the activation of IRF3. NF-κB and AP-1 activation generally leads to 
the production of pro-inflammatory cytokines, such as TNF-α and IL-6, whilst IRF3 leads to the 
production of IFN-β, which, like IFN-γ is able to stimulate the expression of inducible nitric oxide 
synthase (iNOS). IRF3 can induce the expression of IFN-inducible genes, such as CXCL10, which is 
a chemoattractant for monocytes, dendritic cells, and T cells. IRF3 has also been shown to be 
involved in the differentiation of monocytes into macrophages and dendritic cells, and the 
maturation of dendritic cells through the upregulation of CD80 and CD86 expression. There was 
an increase in monocyte recruitment, iNOS, and expression of the dendritic cell co-stimulatory 
molecule, CD80, in L. major Δisp2/3 infection compared with L. major WT infection. These 
differences may be due to the inhibition of NE activity by L. major ISP2, which prevents the 
activation of the TLR4-NE signalling cascades, thus affecting the expression of cytokines, 
chemokines, and/or IFN-inducible genes. However, the downstream signalling cascades and 
effects in host cells need to be further characterised during interaction with L. major WT and 
ISP2 gene mutant parasites. 
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Increases in monocyte and monocyte-derived DC recruitment to the site of 
inoculation with Δisp2/3 parasites compared with WT parasites could lead to the 
other differences observed between these infections, as the monocyte-derived 
DCs may then prime a Th1 response causing the differences in the iNOS and IFN-
γ at this time-point. It is not unusual to observe differences in innate cell 
recruitment occurring later in infection. Fromm et al. (2012) showed that in 
TNF-deficient mice, a difference in monocyte-derived DC recruitment to the 
draining lymph node was only observed after 2 wk post-infection, compared to 
the C57BL/6 mice. 
ISP2 could also affect cytokine and chemokine processing through the inhibition 
of serine peptidase activity. This could have consequences on the recruitment of 
immune cells to the site of inoculation, and the differentiation, proliferation, 
and activation of immune cells (Wiedow & Meyer-Hoffert, 2005; Pham, 2008), 
which can then have consequences on the production of cytokines and 
chemokines, and the activation of effector mechanisms important for parasite 
clearance. To investigate whether there is an effect on cytokine and chemokine 
processing, simultaneous tissue qPCR and luminex-based methods could provide 
information on the cytokine/chemokine levels during infection with L. major WT 
and the ISP2 gene mutants, and may give an indication of cytokine/chemokine 
processing, particularly if inactivated cytokine/chemokine proteins are 
efficiently degraded. 
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Figure 6-3 Potential effects of inhibiting serine peptidase activity by L. major ISP2 during in 
vivo infection. Differences were observed in the innate cell response to the site of L. major WT 
infection compared with L. major Δisp2/3 infection. ISP2 has been shown to inhibit the activity 
of serine peptidases of the S1A family. S1A serine peptidases, neutrophil elastase (NE), cathepsin 
G (CG), and proteinase 3 (PR3), play important roles in the processing of cytokines and 
chemokines, which can either enhance or reduce their activity. Shown above are examples of 
the serine peptidase targets that have already been characterised and the effect that cleavage 
of these targets has on the inflammatory response. L. major ISP2 may inhibit the activity of 
these serine peptidases in vivo, which could explain the differences observed in cellular response 
to the site of inoculation between L. major WT and Δisp2/3 infections. The monocyte response 
to L. major WT infection was lower than that observed in L. major Δisp2/3 infection, which may 
be due to ISP2 preventing the enhancement of cytokine and chemokine activity, such as 
chemerin and CCL15, achieved through cleavage by serine peptidase. Additionally, processing of 
IL-18 has been shown to induce IFN-γ release from Th1 and NK cells; there was a higher 
concentration of IFN-γ at the site of L. major Δisp2/3 infection compared to L. major WT 
infection. The production and processing of cytokines and chemokines needs to be further 
investigated during infection with L. major WT and the ISP2 gene mutants to fully understand 
how the inhibition of serine peptidases in vivo may cause the differences observed in this study. 
Adapted from Eyles et al. (2006) with permission. 
ISP2 is expressed in all Leishmania lifecycle stages, with particularly high levels 
in the infective metacyclic and amastigote stages (Eschenlauer et al., 2009). In 
this study all in vivo inoculations were performed with metacyclic 
promastigotes, as would be transmitted during a sandfly bite (Kimblin et al., 
2008; Rogers et al., 2010). Leishmania metacyclic promastigotes and 
amastigotes interact differently with immune cells, in that amastigotes do not 
necessarily pass through neutrophils as observed for metacyclic promastigotes 
(Wenzel et al., 2012). Therefore, the interactions of L. major ISP2 of the 
metacyclic promastigotes and amastigotes will differ, as promastigotes will 
likely interact with serine peptidases produced by neutrophils in the first few 
hours before they are internalised, whereas amastigotes will interact with serine 
peptidases from neutrophils, monocytes, and macrophages, later in infection, 
when the parasites are released from cells into the extracellular environment. 
Hence, to determine whether there are stage-specific effects of ISP2 on the 
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immune responses, it could be of interest to perform infections with purified 
amastigotes of L. major WT and the ISP2 gene mutants to observe whether 
recruitment of the monocytes and monocyte-derived cells is induced earlier than 
2 wk post-infection. The interaction of L. major WT and the ISP2 gene mutants 
with other innate cell types in vitro, neutrophils and DCs in particular, is also 
currently under investigation, with focus on parasite internalisation, ROS and NO 
production, and cytokine secretion (Faria et al., unpublished). 
In this study, a low dose intradermal infection model was used to determine 
differences in disease progression and innate immune responses between L. 
major WT and cell lines deficient in the putative virulence factor, ISP2. This 
model proved to be sensitive enough to detect differences in parasite burdens, 
as assessed by limiting dilution assays, and innate immune cell populations, as 
assessed by flow cytometry. Luciferase-expressing cell lines also enabled an 
investigation into whether parasite survival was affected by the presence or 
absence of ISP2 through non-invasive longitudinal in vivo imaging in the mouse 
model. In addition, bioluminescence imaging was similarly used for longitudinal 
in vivo imaging of phagocyte activation, through the detection of 
myeloperoxidase activity (Gross et al., 2009), in response to infection with L. 
major WT and the ISP2 gene mutants. This is the first time that these in vivo 
imaging techniques have been used to determine the effects of putative parasite 
virulence factors on disease progression and phagocyte activation in real-time. 
In vivo imaging techniques are also important for the reduction of animals used 
in experimental procedures, as many animals are often required to perform 
limiting dilution assays with an appropriate number of biological replicates. In 
this study, these imaging experiments were performed independently, but there 
is potential for these techniques to be performed simultaneously, as the 
emission spectra are sufficiently separate, with peak emissions from the firefly 
luciferase and luminol reactions at 562 nm and 425 nm respectively. This is, of 
course, dependent upon the filters available on the in vivo imaging system (IVIS) 
used, as well as the depth of imaging required. There are other luciferase 
reporters with higher emission peaks available, such as red-shifted luciferase 
(McLatchie et al., 2013), which has a peak emission of 617 nm, as well as 
luminol-R, which is an administration of luminol with non-conjugated 800 nm-
emitting quantum dots (Zhang et al., 2013). Dual imaging of parasite 
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dissemination and phagocyte activation could provide information on disease 
tropism through the use of different Leishmania species, as well as the effects of 
neutrophil depletion on disease pathology, with have been reported to have 
different effects dependent upon the Leishmania species, the mouse strain, and 
the site of infection (Lima et al., 1998; Tacchini-Cottier et al., 2000; Ribeiro-
Gomes et al., 2004; McFarlane et al., 2008; Peters et al., 2008; Novais et al., 
2009; Charmoy et al., 2010; Sousa et al., 2014). This technique could also be 
used in transgenic mice to determine the effects of certain cytokines, 
chemokines, and receptors on Leishmania infection, such as TNF-α and CCR2, 
which have been shown to have effects on monocyte recruitment in Leishmania 
infection (Sato et al., 2000; Quinones et al., 2007; Fromm et al., 2012). 
In summary, ISP2 has been shown to be an important virulence factor in L. 
major; some of the effects of which have now been characterised in vitro and in 
vivo. In addition, a new infection model and imaging techniques have been 
proposed to enable the characterisation and comparison of Leishmania wild-type 
infections with those of cell lines deficient in, or overexpressing, putative 
virulence factors, for longitudinal studies of parasite survival and dissemination 
in concert with innate immune responses. 
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